JP2007504273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504273A5 JP2007504273A5 JP2006529506A JP2006529506A JP2007504273A5 JP 2007504273 A5 JP2007504273 A5 JP 2007504273A5 JP 2006529506 A JP2006529506 A JP 2006529506A JP 2006529506 A JP2006529506 A JP 2006529506A JP 2007504273 A5 JP2007504273 A5 JP 2007504273A5
- Authority
- JP
- Japan
- Prior art keywords
- sdf
- adhesions
- inhibitor
- adhesion
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 115
- 239000003814 drug Substances 0.000 claims description 96
- 229940079593 drug Drugs 0.000 claims description 85
- 239000003112 inhibitor Substances 0.000 claims description 81
- 108091034117 Oligonucleotide Proteins 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 66
- 229920000855 Fucoidan Polymers 0.000 claims description 65
- 230000003176 fibrotic effect Effects 0.000 claims description 62
- 241001465754 Metazoa Species 0.000 claims description 48
- -1 dextran sulfate Chemical compound 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 21
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 19
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 19
- 235000000346 sugar Nutrition 0.000 claims description 18
- 210000001015 abdomen Anatomy 0.000 claims description 17
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 17
- 229960002930 sirolimus Drugs 0.000 claims description 17
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 238000001802 infusion Methods 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 12
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 12
- 239000004098 Tetracycline Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 12
- 235000019364 tetracycline Nutrition 0.000 claims description 12
- 150000003522 tetracyclines Chemical class 0.000 claims description 12
- 229960002180 tetracycline Drugs 0.000 claims description 11
- 229930101283 tetracycline Natural products 0.000 claims description 11
- 108090000994 Catalytic RNA Proteins 0.000 claims description 10
- 102000053642 Catalytic RNA Human genes 0.000 claims description 10
- 239000003146 anticoagulant agent Substances 0.000 claims description 10
- 108091092562 ribozyme Proteins 0.000 claims description 10
- 239000000679 carrageenan Substances 0.000 claims description 9
- 229920001525 carrageenan Polymers 0.000 claims description 9
- 229940113118 carrageenan Drugs 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 230000002503 metabolic effect Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 7
- 229940100198 alkylating agent Drugs 0.000 claims description 7
- 239000002168 alkylating agent Substances 0.000 claims description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 7
- 238000013270 controlled release Methods 0.000 claims description 7
- 239000003246 corticosteroid Substances 0.000 claims description 7
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 7
- 229960000633 dextran sulfate Drugs 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 7
- 230000003902 lesion Effects 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 6
- 108010061435 Enalapril Proteins 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229940111134 coxibs Drugs 0.000 claims description 6
- 229960002086 dextran Drugs 0.000 claims description 6
- 229960003668 docetaxel Drugs 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 6
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 6
- 229930002330 retinoic acid Natural products 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229940123934 Reductase inhibitor Drugs 0.000 claims description 5
- 108010023197 Streptokinase Proteins 0.000 claims description 5
- 229940123237 Taxane Drugs 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 229960005202 streptokinase Drugs 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 239000005541 ACE inhibitor Substances 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 4
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 4
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 4
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 claims description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 4
- 229960000830 captopril Drugs 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 4
- 229960000681 leflunomide Drugs 0.000 claims description 4
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims description 4
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 4
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- GMGIWEZSKCNYSW-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;dihydrate Chemical compound O.O.C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 GMGIWEZSKCNYSW-UHFFFAOYSA-N 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 3
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 claims description 3
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 3
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 229960004676 antithrombotic agent Drugs 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 229960001425 deferoxamine mesylate Drugs 0.000 claims description 3
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 3
- 229960001842 estramustine Drugs 0.000 claims description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 3
- 229960000350 mitotane Drugs 0.000 claims description 3
- 229960001476 pentoxifylline Drugs 0.000 claims description 3
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 claims description 3
- 229940127126 plasminogen activator Drugs 0.000 claims description 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- 150000005671 trienes Chemical class 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 claims description 2
- 229960004982 vinblastine sulfate Drugs 0.000 claims description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 1
- SYKWLIJQEHRDNH-CKRMAKSASA-N glutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-CKRMAKSASA-N 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 101
- 239000010408 film Substances 0.000 description 72
- 241000700159 Rattus Species 0.000 description 44
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 39
- 238000009472 formulation Methods 0.000 description 39
- 239000000243 solution Substances 0.000 description 39
- 241000283973 Oryctolagus cuniculus Species 0.000 description 37
- 208000031737 Tissue Adhesions Diseases 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 36
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 35
- 229920002674 hyaluronan Polymers 0.000 description 34
- 229960003160 hyaluronic acid Drugs 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 31
- 235000013601 eggs Nutrition 0.000 description 29
- 238000011282 treatment Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 239000000499 gel Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 238000001356 surgical procedure Methods 0.000 description 20
- 229920001661 Chitosan Polymers 0.000 description 19
- 229940045110 chitosan Drugs 0.000 description 19
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 230000000692 anti-sense effect Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 12
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 12
- 210000004534 cecum Anatomy 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 11
- 229920001610 polycaprolactone Polymers 0.000 description 11
- 239000004632 polycaprolactone Substances 0.000 description 11
- 229940010747 sodium hyaluronate Drugs 0.000 description 11
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 108010012236 Chemokines Proteins 0.000 description 10
- 102000019034 Chemokines Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000006072 paste Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 239000002777 nucleoside Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- 241000195480 Fucus Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 108090000854 Oxidoreductases Proteins 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000000783 alginic acid Substances 0.000 description 6
- 229960001126 alginic acid Drugs 0.000 description 6
- 150000004781 alginic acids Chemical class 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000032798 delamination Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- 239000008156 Ringer's lactate solution Substances 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 210000003815 abdominal wall Anatomy 0.000 description 5
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 5
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000004700 cellular uptake Effects 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 229940104302 cytosine Drugs 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 210000004303 peritoneum Anatomy 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108091032955 Bacterial small RNA Proteins 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 101710203526 Integrase Proteins 0.000 description 4
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 241000199919 Phaeophyceae Species 0.000 description 4
- 206010060932 Postoperative adhesion Diseases 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 241000015177 Saccharina japonica Species 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000001772 anti-angiogenic effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229960005188 collagen Drugs 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 4
- 229960000309 enalapril maleate Drugs 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003232 mucoadhesive effect Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 229960001860 salicylate Drugs 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- FZKWRPSUNUOXKJ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrate Chemical compound O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O FZKWRPSUNUOXKJ-CVHRZJFOSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 206010073306 Exposure to radiation Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 description 3
- 208000002847 Surgical Wound Diseases 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000005289 controlled pore glass Substances 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960000616 diflunisal Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000003207 proteasome inhibitor Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229960002871 tenoxicam Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 108010061299 CXCR4 Receptors Proteins 0.000 description 2
- 102000012000 CXCR4 Receptors Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 2
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000195522 Fucales Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 241001466453 Laminaria Species 0.000 description 2
- 241001466452 Laminariaceae Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010058674 Pelvic Infection Diseases 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 241001261506 Undaria pinnatifida Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 210000000994 inner shell membrane Anatomy 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000000745 ion overload Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 229940013798 meclofenamate Drugs 0.000 description 2
- 229940103185 mefenamate Drugs 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical group CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229960000965 nimesulide Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical group C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000000998 shell membrane Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- KOWKJMXQYLJEIS-ZRURSIFKSA-N (2r,3r,4s,5r)-2-(2-aminopropyl)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(CC(N)C)O[C@H](CO)[C@@H](O)[C@H]1O KOWKJMXQYLJEIS-ZRURSIFKSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical group C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- MLRVZFYXUZQSRU-UHFFFAOYSA-N 1-chlorohexane Chemical compound CCCCCCCl MLRVZFYXUZQSRU-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical class OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 description 1
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical group C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Chemical group C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000908889 Adenocystis utricularis Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000908922 Chorda filum Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000980780 Cladosiphon okamuranus Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 241000251800 Cystoseira abies-marina Species 0.000 description 1
- AEMOLEFTQBMNLQ-PKKLWIBTSA-N D-Alluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-PKKLWIBTSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000946389 Ecklonia kurome Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000004452 Fucus evanescens Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000212297 Pelvetia Species 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 241000983742 Saccharina Species 0.000 description 1
- 241001017619 Saccharina cichorioides Species 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241001191185 Sarga Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- 241000258128 Strongylocentrotus purpuratus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- RLXCFCYWFYXTON-JTTSDREOSA-N [(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] N-hexylcarbamate Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC(=O)NCCCCCC)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RLXCFCYWFYXTON-JTTSDREOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229940112133 busulfex Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical compound O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- FDKXTQMXEQVLRF-UHFFFAOYSA-N dacarbazine Chemical compound CN(C)N=NC=1NC=NC=1C(N)=O FDKXTQMXEQVLRF-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- GTZOYNFRVVHLDZ-UHFFFAOYSA-N dodecane-1,1-diol Chemical group CCCCCCCCCCCC(O)O GTZOYNFRVVHLDZ-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010042430 galactose receptor Proteins 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical group CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 102000043525 human CXCL12 Human genes 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- IVVMYMCCLPZNRL-UHFFFAOYSA-N hydrazinylphosphonic acid Chemical class NNP(O)(O)=O IVVMYMCCLPZNRL-UHFFFAOYSA-N 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 231100000735 select agent Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 101150039622 so gene Proteins 0.000 description 1
- QHJLLDJTVQAFAN-UHFFFAOYSA-M sodium meclofenamate monohydrate Chemical compound O.[Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl QHJLLDJTVQAFAN-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- IVFLPPKNEWVNFG-UHFFFAOYSA-N tetracene-1-carboxamide Chemical compound C1=CC=C2C=C(C=C3C(C(=O)N)=CC=CC3=C3)C3=CC2=C1 IVFLPPKNEWVNFG-UHFFFAOYSA-N 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000002266 vitamin A derivatives Chemical group 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Description
æ¬çºæã¯ãæ®éæè¡åŸãçäœã®ïŒã€ã®éšåã®éã§åœ¢æãããäžçš®ã®å·è·¡ïŒè¡åŸççïŒã§ããçš®ã
ã®ç·ç¶æ§ççã«é¢ããã
ãã®ã»ãã®åºé¡ã«å¯Ÿããã¯ãã¹ãªãã¡ã¬ã³ã¹
ãã®ã»ãã®åºé¡ã«å¯Ÿããã¯ãã¹ãªãã¡ã¬ã³ã¹
æ¬åºé¡ã¯ãïŒïŒïŒïŒå¹ŽïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãïŒïŒïŒïŒå¹ŽïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒãïŒïŒïŒå·ãïŒïŒïŒïŒå¹ŽïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒãïŒïŒïŒå·ãïŒïŒïŒïŒå¹ŽïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒãïŒïŒïŒå·ãïŒïŒïŒïŒå¹ŽïŒïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒãïŒïŒïŒå·ãïŒïŒïŒïŒå¹ŽïŒïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒãïŒïŒïŒå·ãïŒïŒïŒïŒå¹ŽïŒïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãïŒïŒïŒïŒå¹ŽïŒïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒãïŒïŒïŒå·ãåã³ïŒïŒïŒïŒå¹ŽïŒïŒæïŒïŒæ¥ã«åºé¡ãããç±³åœä»®ç¹èš±åºé¡ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ã®åªå
æš©ã䞻匵ãããåç
§ãæ¬åºé¡ã«åºçŸããŠãããããšã«ãããããããã®æ瀺ãšé瀺ã«ã€ããŠããããåã³æ¬æ现æžã§è¿°ã¹ããããã®ã»ãã®åç
§ã®ãã¹ãŠãå
šäœãšããŠåç
§ã«ãã£ãŠæ¬æ现æžã«çµã¿å
¥ããã
ç·ç¶æ§ççã¯ãæ®éæè¡åŸãçäœã®ïŒã€ã®éšåã®éã§åœ¢æãããäžçš®ã®å·è·¡ïŒè¡åŸççïŒã§ãããç·ç¶æ§ççã¯æ·±å»ãªåé¡ãåŒãèµ·ãããããããšãã°ã女æ§ã®çæ®åšïŒåµå·£ããã¡ããŒããªç®¡ïŒã«é¢äžããç·ç¶æ§ççã¯ãäžåŠãæ§äº€çŒççåã³é節ãªéªšç€ã®çã¿ãåŒãèµ·ãããããè
žç®¡ã«çããç·ç¶æ§ççã¯ãè
žéå¡çåã¯è
žç®¡é®æãèµ·ããããããããšãã°ãå¿èãè骚ã®åšèŸºåã³æã®ãããªãã®ã»ãã®éšäœã«ãç·ç¶æ§ççã圢æããããæè¡ã«å ããŠãããšãã°ãåå®®å
èçãææãååŠçæ³ãæŸå°ç·ç
§å°ãå€å·åã³çã«ãã£ãŠãç·ç¶æ§ççã¯çãããã
æ¬ææžã§ã¯ãçš®ã
ã®ç·ç¶æ§ççãèå¯ãããããšãã°ãæè¡ççãè¡åŸççãæè¡åŸã®ççã骚ç€ææçã«ããççãæ©æ¢°çãªå€å·ã«ããççãæŸå°ç·ã«ããççãæŸå°ç·æ²»çã«ããççãå€å·ã«ããççãåã³å€æ¥ç©è³ªã«ããççã®ãããªçšèªã¯ãã¹ãŠãé¡äŒŒããã¡ã«ããºã ã«ããäºãã®çµç¹ãžã®ççãèšãããã¹ãŠçšèªãç·ç¶æ§ççã«å
å«ãããã
ç·ç¶æ§ççã®åœ¢æã¯ãæ£åžžã§ã¯çäœã§åé¢ããŠããçµç¹ãçžäºã«å¢æ®ããè€éãªéçšã§ãããæè¡ççïŒè¡åŸççãšããŠãç¥ãããïŒã¯ããããªããã°çµç¹ã®æ£åžžãªåµå·æ²»çã®åå¿ããæå·ã«çºå±ããè
¹éšã®æè¡æ£è
ãã¹ãŠã®ïŒåã®ïŒãè¶
ããŠçããããšãå ±åãããŠããïŒéç¹èš±æç®ïŒïŒããããç·ç¶æ§ççã®çµæ«ã¯çš®ã
ã§ãããå€ç§çéšäœåã¯ãããšãã°ãé¢äžããç
å€éšäœã®ãããªãã®ã»ãã®éšäœã«äŸåãããåé¡ã«ã¯ãæ
¢æ§çãªçŒçãè
žç®¡ã®éå¡ãåã³å¿èæè¡åŸã§ã¯æ»äº¡ã®ãªã¹ã¯ã®å¢å ããå«ãŸããå¯èœæ§ãããïŒéç¹èš±æç®ïŒ; éç¹èš±æç®ïŒ; éç¹èš±æç®ïŒïŒãçæ®å¹Žéœ¢ã®å¥³æ§ã§ã¯ãåå®®ããã¡ããŒããªç®¡åã¯åµå·£ã«é¢äžããç·ç¶æ§ççãå
šäžåŠççäŸã®ãããïŒïŒïŒ
ã®åå ã§ãããšæšå®ãããŠããïŒéç¹èš±æç®ïŒ; éç¹èš±æç®ïŒïŒã
ç·ç¶æ§ççã®åœ¢æã®éçšã«ã¯åœåããã£ããªã³ãããã¯ãŒã¯ã®æš¹ç«åã³æ£åžžçµç¹ã®ä¿®åŸ©ãé¢äžãããæ£åžžã®ä¿®åŸ©éçšã¯ãäžç®ã®ä¿®åŸ©ãšäžŠãã§ãã£ããªã³æº¶è§£ãå¯èœã«ãããããããªãããç·ç¶æ§ççã«åœ¢æã§ã¯ãç·ç¶èœçŽ°èããããã¯ãŒã¯å
ã§å¢æ®ããè¡ç®¡åœ¢æãçããã«ã€ããŠãã£ããªã³ãããªã¯ã¹ãæçããçµæçã«çŽïŒãïŒæ¥ä»¥å
ã«çµç¹åãããç·ç¶æ§ççãæš¹ç«ãããïŒéç¹èš±æç®ïŒ; éç¹èš±æç®ïŒïŒãççéçšã«ã¯ãå€å·çµç¹ã§ã®å¥œäžçã®æŽ»æ§åããã£ããªã³ã®æ²çåã³é£æ¥çµç¹ã®çµåããã¯ããã¡ãŒãžã®äŸµè¥²ããã®é åãžã®ç·ç¶èœçŽ°èã®å¢æ®ãã³ã©ãŒã²ã³ã®æ²çãè¡ç®¡åœ¢æåã³æ°žç¶çãªç·ç¶æ§çççµç¹ã®æš¹ç«ãå«ãŸããã
å€ç§çççãé²ãããã«æ§ã
ãªè©Šã¿ãè¡ãããŠããããããã«ã¯ãå€ç§çå€å·ã䌎ãçååŠçåã³çŽ°èåŠçäºè±¡ã«åœ±é¿ãåãŒãããšãæšçãšããå»è¬çã¢ãããŒãã䞊ã³ã«åãããçµç¹ãåé¢ããããã®ããªã¢æ³ãå«ãŸãããããšãã°ãè
¹è
å
æŽæµããããªã³å溶液ãåè¡ä¿é²å€ã®äœ¿çšãæè¡æ³ã®æ¹å€ãããšãã°ãé¡åŸ®é¡çæè¡æ³åã¯è
¹è
é¡æè¡æ³ãæè¡çšæè¢ããã®ã¿ã«ã¯ã®é€å»ãããã«å°ããªçž«å糞ã®äœ¿çšãåã³æŒ¿èè¡šé¢ã®äžŠçœ®ãã§ããéãæå¶ããããšãç®çãšããç©ççããªã¢ïŒãã£ã«ã ãã²ã«ãåã¯æº¶æ¶²ïŒã®äœ¿çšãè©Šã¿ãããŠãããçŸåšãäºé²çæ²»çæ³ã«ã¯ããã£ããªã³æ²çã®äºé²ãææã®äœæžïŒã¹ããã€ãåã³éã¹ããã€ãæççå€ïŒåã³ãã£ããªã³æ²çã®é€å»ãå«ãŸããã
è¡åŸã®ç·ç¶æ§ççãé²ãããã®ä»å
¥çè©Šã¿ã«ã¯ãæ°Žåæµ®ææ³åã¯ããªã¢è£
眮ãå«ãŸãããæ°Žåæµ®æã«ã¯ãèåšãé¢ããŠããè©Šã¿ã§ãããã¹ãã©ã³ïŒéç¹èš±æç®ïŒïŒåã¯ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ïŒéç¹èš±æç®ïŒïŒïŒã®ãããªããªããŒã倧éã«å€ç§ç空éã«ç¹æ»Žããããšãå«ãŸãããé
žåå€æ§ã»ã«ããŒã¹ïŒããšãã°ãã€ã³ã¿ãŒã·ãŒãTMïŒãããªããã©ãã«ãªããšãã¬ã³ïŒãŽã¢ããã¯ã¹æè¡çšèïŒããäœãããåæããªã¢èåã³ä¿®é£Ÿãã¢ã«ãã³é
žïŒã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ïŒïŒšïŒ¡ïŒïŒ£ïŒïŒ£ïŒã®çµã¿åããïŒã»ãã©ãã£ã«ã TMïŒããäœãããå®å
šã«åžåå¯èœãªèã¯ãåç©åã³ããã§è¡åŸã®çç圢æã軜æžããã®ã«äœ¿çšãããŠããïŒéç¹èš±æç®ïŒïŒ; éç¹èš±æç®ïŒïŒ; éç¹èš±æç®ïŒïŒïŒããããïŒïŒ£ïŒïŒ£èã®æåã¯ãç·ç¶æ§ççã圢æãããéãè
¹èã®åµå·ä¿®åŸ©ã®éãçµç¹ã®åé¢ãæäŸãããããã®èœåã«ç±æ¥ããŠããããèã¯ãé©çšåŸïŒãïŒæ¥éãè¡åŸã®çç圢æã®æéçµéã«çžåœããæéãæå·ããçµç¹äžã§éæãªç²æ§ã®è¢«èã圢æããããšãèªããããïŒéç¹èš±æç®ïŒïŒïŒãæ®å¿µãªããããããã®æ¹æ³ã§ã¯éãããæåããèŠãããŠããªãã
Ellis, H., Surg. Gynecol. Obstet., 133:497, 1971 diZerega, G. S., Prog. Clin. Biol. Res., 381:1-18, 1993 diZerega, G. S., Fertil. Steril., 61:219-235, 1994 Dobell, A. R., Jain, A. K., Ann. Thorac. Surg., 37:273-278, 1984 Holtz, G., Fertl. Steril., 41:497-507, 1984 Webel M.A. and Majvo, G., Am. J. Surg., 126:345-353, 1973 Buckman, R. F. et al., J. Surg. Res., 21:67-78, 1976 Raferty, A. T., J. Anat., 129:659-664, 1979 Adhesion Study Group, Fertil. Steril., 40:612-619, 1983 Elkins, T. E., et al., Fertil. Steril., 41:926-928, 1984 Burns, J. W. et al., Eur. J. Surg. Suppl., 577:40-48, 1997 Burns, J. W. et al., Fertil. Steril., 66:814-821, 1996 Becker, J. M. et al., J. Am. Coll. Surg., 183:297-306, 199 6 Ellis, H., Br. J. Surg., 50:10-16, 1963
Ellis, H., Surg. Gynecol. Obstet., 133:497, 1971 diZerega, G. S., Prog. Clin. Biol. Res., 381:1-18, 1993 diZerega, G. S., Fertil. Steril., 61:219-235, 1994 Dobell, A. R., Jain, A. K., Ann. Thorac. Surg., 37:273-278, 1984 Holtz, G., Fertl. Steril., 41:497-507, 1984 Webel M.A. and Majvo, G., Am. J. Surg., 126:345-353, 1973 Buckman, R. F. et al., J. Surg. Res., 21:67-78, 1976 Raferty, A. T., J. Anat., 129:659-664, 1979 Adhesion Study Group, Fertil. Steril., 40:612-619, 1983 Elkins, T. E., et al., Fertil. Steril., 41:926-928, 1984 Burns, J. W. et al., Eur. J. Surg. Suppl., 577:40-48, 1997 Burns, J. W. et al., Fertil. Steril., 66:814-821, 1996 Becker, J. M. et al., J. Am. Coll. Surg., 183:297-306, 199 6 Ellis, H., Br. J. Surg., 50:10-16, 1963
æããã«ã奜ãŸããã¯ããã«å¹ççã«å°ãªãå¯äœçšã§ãç·ç¶æ§ççã®åœ¢æãæå¶ãããåã¯ãããªãã°æ²»çããåã³ïŒåã¯äºé²ããååç©ãçµæç©ãæ¹æ³çïŒééæ³ãå«ãïŒã«å¯Ÿãããæªã 察åŠãããŠããªãããŒãºããããæ¬ååç©ãçµæç©ãæ¹æ³çã¯ããããã®å©ç¹ã®ïŒä»¥äžãæäŸããã
æ¬çºæã¯ãå€ç§çççãæ²»çããããã®ãæ¬æ现æžã§èå¯ãããïŒä»¥äžã®ç·ç¶æ§ççæå¶å€ãå«ãçµæç©åã³æ¹æ³çãå«ããç·ç¶æ§ççæå¶å€ã¯ãéåžžãäœãå¯äœçšãæäŸããªãããç·ç¶æ§ççã«å¯ŸããŠååãªæ²»çå¹æãæäŸãããããã«ãçš®ã
ã®ç°ãªã£ãç·ç¶æ§ççæå¶å€ãèå¯ããã®ã§ããã®ã»ãã®çŸæ£åã¯çç¶ãç
ãã§ããå¯èœæ§ãããæ£è
ã«ãããå¯äœçšãæžããããã«ãåã³ïŒåã¯æçãªå¥åº·ã«è¯ãå¹æåã¯æ²»çå¹æãæäŸããããã«ãç·ç¶æ§ççãæå¶ãããšå
±ã«ãçåã¯é¢ç¯çåã¯è
«ãåã¯æ¬æ现æžã®ïŒä»¥äžã®ç·ç¶æ§ççæå¶å€ã§æ²»çããããšãã§ããçš®ã
ã®ãã®ã»ãã®çŸæ£åã¯çç¶ãæ²»çããçµæç©ãšããŠãäœçšå€ã®çš®ã
ã®çµã¿åãããææã®ããã«éžæããããšãã§ãããæ¬æ现æžã®çµæç©ã¯ãç·ç¶æ§ççãšé¡äŒŒã®çç©åŠãå
±æããã±ãã€ãã®ãããªç·ç¶æ§å¢æ®åã³ãã®ç¶æ
ã®æ²»çã«ãæçšã§ãããåŸã£ãŠãæ¬æ现æžã«ãããèå¯ã¯ãã®ãããªç·ç¶æ§å¢æ®ã«ãåæ§ã«é©çšãããã
åŽé¢ã®ïŒã€ã§ã¯ãæ¬çºæã¯ãç·ç¶æ§ççãæå¶ããäœçšå€ãéžæããããšãåã³ç·ç¶æ§ççãæããããšãçãããéšäœã«æ²»çäžæå¹éã®äœçšå€ãæäžããããšãå«ããåç©ã«ãããŠç·ç¶æ§ççãæå¶ããæ¹æ³ãæäŸãããäœçšå€ã¯ãïŒä»¥äžã®ã¢ã«ã®ã³é
žãããã·ãµã€ã¯ãªã³ãã³ã«ããŸã³ããšã¹ãã©ã ã¹ãã³ãã¡ã¬ãžããŒã¹ãã³ãã¯é
žãã¡ã¯ããã§ãã¡ãŒãããã«ããã³é
žãããã¹ãã©ã³ç¡«é
žãã³ã©ãŒã²ã³ããããœããããã¬ã€ã³é
žãšãã©ããªã«ã®ãããªãšãã©ããªã«ãããã¡ãã³ãã·ã ãã¹ã¿ãã³ã®ãããªã¹ã¿ãã³ãã«ããããªã«ããããµã³ããããµã€ã¯ãªã³ãã¡ãœãã¬ããŒããã·ã¹ãã©ãã³ãã€ããããã§ã³ããšãªã¹ããã€ã·ã³ãããã©ãµã€ã¯ãªã³ãæâïŒã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããïŒïŒ¡ïŒ³ïŒ¯ïŒã®ãããªïŒ³ïŒ€ïŒŠâïŒé»å®³å€ãæâïŒå°ååãæâïŒïœïœïŒ²ïŒ®ïŒ¡ãæâïŒãªãŸããŒã ãæâïŒã¢ãã¿ããŒãâïŒã®å°ååé»å®³å€ãæïœïŒ³ïŒ€ïŒŠâïŒïŒïŒ°ïŒ¢ïŒ³ïŒŠã®ãããªæâïŒæäœãã©ããã€ã·ã³ãããããã·ãããã«ã»ã«ããŒã¹ããã¹ã«ãã¡ã³ãã·ã¯ããã¹ãã¡ããããã«ã«ããžã³ãããããã·ããŠã¬ã¢ãããã¿ã³ããã»ã¿ãã»ã«ãç¡«é
žãã³ãã©ã¹ãã³ãïŒïŒ§ïŒïŒïŒããã¡ã¹ã«ãããžã¯ããã§ããã¯ããããã·ã«ã ãã€ã³ãã¡ã¿ã·ã³ãã¢ã»ãã«ãµãªãã«é
žããžãã«ã·ãã«ããã¿ã¡ã¿ãŸã³ããããµã¡ã¿ãŸã³ãããã§ãããµãã³ã¡ã·ã¬ãŒããã¬ããã€ã³é
žããããªã³ããã³ããã·ãã£ãªã³ãã¹ãã¬ãããããŒãŒãâβãïŒïŒ°âïŒãããã¹ãããŒã¹ãããã¹ãã©ã³ïŒŽïŒïŒããã³ãã³ãã±ã«ã»ãã³äºæ°Žåç©ãã«ãã§ã€ã³ãã¬ãã«ããããã€ãªã¿âã«ã©ã®ãŒãã³åã¯ã©ã ãâã«ã©ã®ãŒãã³ã®ãããªã«ã©ã®ãŒãã³ãããããã·ãããã«ã»ã«ããŒã¹ãã¹ã¿ããªãŒã¹ãã³ã³ããã€ãã³ç¡«é
žïŒ¡ãå«ãããšãã§ããã
äœçšå€ã¯ãŸããæè
«çå€ãæççå€ãã€ãªã³ãã¬ãŒãå€ãããªãšã³ãã¯ãã©ã€ãæçç©è³ªãïŒâããããã·âïŒâã¡ãã«ã°ã«ããªã«âïœïŒ¡éå
é
µçŽ é»å®³å€ãã¬ããã€ããæè¡æ å€ãæååºå€ããã©ã¹ãããŒã²ã³æŽ»æ§åå€ããµã€ãã«ã€ã³ããããªã¯ã¹ã¡ã¿ããããã€ããŒãŒé»å®³å€ãããã©ãµã€ã¯ãªã³ãé»å®³å€ãããã¹ãã©ã³ç³ãåã¯ã«ã©ã®ãŒãã³ãã¢ã«ãã«åå€ã代è¬æå¶å€ããªããã¯ã¬ã¢ãŒãŒéå
é
µçŽ é»å®³å€ã现èå·å®³æ§æçç©è³ªãã¿ããµã³ããã³ã«ã»ã¢ã«ã«ãã€ããåã¯ãããã¢ãŒãŒé»å®³å€ãâïŒé»å®³å€ããã§ãã¡ãŒãããªãã·ã«ã ãã¢ã»ãã«é
žèªå°äœããµãªãã«é
žèªå°äœãåã¯ã³ã«ãã³ã¹ããã€ãã§ããããšãã§ããã
ä»ã«èšèŒããããã«ãæ¬æ现æžã«ãããçš®ã
ã®åŽé¢åã³å®æœæ
æ§ã¯ãç¹åŸŽçã§ããããšãã§ããææã®æ§åŒã«ãããŠæ··åããåã³äžèŽããåã³çµã¿åããããåã³é åºãå€ããããããåŸã£ãŠãäžèšã®åã³ããã®ç¹å®ã®äœçšå€åã³ä»¥äžã®äœçšå€çã¯ãåäžæ®µèœã«äžç·ã«çŸããªããŠãé©å®ãçµã¿åãããããšãã§ããã
å®æœæ
æ§ã®äžéšã§ã¯ã察象åã¯æ£è
ã¯ããããã€ãããã³ããŠãããŠã·ãåã¯ãã®ã»ãã®åºä¹³é¡ãåã¯ããªãç¬è«é¡åã¯ãã®ã»ãã®åç©ã®ãããªåç©ã§ãããæ²»çéšäœã¯ãå€ç§çéšäœã骚ç€ææçéšäœãæ©æ¢°çå·å®³éšäœãæŸå°ç·æŽé²éšäœãå€æ¥ç©è³ªã®ååšã«åãããéšäœåã¯ãã®ã»ãã®ææã®éšäœã§ããããšãã§ãããéšäœã¯ãå
šäœãšããŠã®åç©ãåã¯è
¹éšãåè¢ãè骚ãå¿èãçæ®åšãæ¶ååšãåŒåžç³»ãèžè
ãåã¯è¡ç®¡ç³»ã尿路系ã®å
éšåã¯ææã®ãã®ã»ãã®ç³»åã¯äœçœ®ã®ãããªç¹å®ã®éšäœã§ããããšãã§ããã
ããªããŒæäžåœ¢æ
ããã®å¶åŸ¡æŸåºãä»ããŠãç
å€éšäœã«è¬å€ãå®è³ªçã«é£ç¶ããŠæäžããããšãã§ãããæäžåœ¢æ
ã¯ããã£ã«ã ã貌ä»å€ãããŒã¹ãããã¯ãã¹ãã§ã¢ãã€ã³ãã©ã³ããã²ã«ãã¹ãã¬ãŒåã¯æ¶²äœã溶液ãæžæ¿æ¶²ã§ããããšãã§ããç±³åœè¬å±æ¹ã®ä¹³é
žå ãªã³ã¬ãŒæ³šå°æ¶²ã§ããããšãã§ããããã³ã€ãã³ã§ããããšãã§ãããã«ã³ãšã®äœµçšã§äœçšå€ãæäžããããšãã§ãããæ¬æ现æžã®ïŒä»¥äžã®ãã®ã»ãã®äœçšå€åã¯ãã®ã»ãã®æ²»çå€ã§ããããšãã§ãã第ïŒã®äœçšå€ãšã®äœµçšã§äœçšå€ãæäžããããšãã§ããã
æ¬çºæã¯ãŸããç·ç¶æ§ççãæå¶ããããã«æ§æãããå»è¬çµæç©ãæäŸãããã該çµæç©ã¯ãç·ç¶æ§ççãæå¶ããããã«éžæãããæ²»çäžæå¹éã®ãã«ã³ãç·ç¶æ§ççãæå¶ããããã«éžæãããæ²»çäžæå¹éã®å°ãªããšãïŒçš®ã®æ²»çäžæå¹ãªæ¬æ现æžã®äœçšå€ãåã³å°ãªããšãïŒçš®ã®è¬åŠäžèš±å®¹å¯èœãªè³Šåœ¢å€ããã£ãªã¢åã¯åžéå€ãå«ããææã§ããã°ãè¬åŠäžèš±å®¹å¯èœãªè³Šåœ¢å€ããã£ãªã¢åã¯åžéå€ã¯ããã«ãããã¯ãã»ã«ããŒã¹ãã¢ã«ã®ããŒããã¢ã¯ãªã¬ãŒãããã¢ã«ãã³é
žãããªãšãã¬ã³ã°ãªã³ãŒã«åã³ãããµã³ããæã矀ããéžæããããšãã§ããã
çµæç©ããç·ç¶æ§ççãæ²»çããããã®è¬ç©ã®è£œé ã«äœ¿çšããããšãã§ããããæ£è
ã«ãããç·ç¶æ§ççã«é¢é£ããçç¶ã軜æžããããšãã§ããè¬ç©ã補é ããæ¹æ³ãããšãã°ãè¬åŠäžæå¹éã®ãã³ã€ãã³ãç·ç¶æ§ççãæå¶ããããã«éžæãããæ²»çäžæå¹éã®å°ãªããšãïŒçš®ã®æ²»çäžæå¹ãªæ¬æ现æžã®äœçšå€åã³è¬åŠäžèš±å®¹å¯èœãªè³Šåœ¢å€åã¯ç·©è¡å€ãçµã¿åãããããšãå«ãæ¹æ³ã«äœ¿çšããããšãã§ããã
ããã«ä»ã®åŽé¢ã§ã¯ãæ¬çºæã¯ãåç©ã«ãããŠå°ãªããšãïŒçš®ã®éç·ç¶æ§ççã®çŸæ£åã¯éç·ç¶æ§ççã®çç¶ãæ²»çããæ¹æ³ãå«ããæ¹æ³ã¯ãå°ãªããšãïŒçš®ã®éç·ç¶æ§ççã®çŸæ£åã¯çç¶ãåå®ããããšãå«ã¿ãéç·ç¶æ§ççã®çŸæ£åã¯çç¶ããã®å°ãªããšãïŒçš®ã®æ²»çå€ãéžæããããšãå°ãªããšãïŒçš®ã®éç·ç¶æ§ççæå¶å€ãéžæããããšãéç·ç¶æ§ççã®çŸæ£åã¯çç¶ã®ããã®æ²»çéã®å°ãªããšãïŒçš®ã®æ²»çå€åã³æ²»çéã®å°ãªããšãïŒçš®ã®ç·ç¶æ§ççæå¶å€ãå«ãå°ãªããšãïŒçš®ã®å»è¬çµæç©ãæäžããããšãå«ãããšãã§ããã
éç·ç¶æ§ççã®çŸæ£åã¯çç¶ã®ããã®å°ãªããšãïŒçš®ã®æ²»çå€åã³æ²»çéã®å°ãªããšãïŒçš®ã®ç·ç¶æ§ççæå¶å€ãå°ãªããšãïŒçš®ã®ç°ãªã£ãçµæç©ã«å
¥ããæ¹æ³ã¯ããã«ãã®çµæç©ãå®è³ªçã«åæã«æäžããããšãå«ãããšãã§ããããŸããäœçšå€ãã¹ãŠãåäžã®çµæç©ã«å
¥ããããšãã§ããã溶液ãšããŠãæžæ¿æ¶²ãšããŠãåã¯ãããªããã°ææã«å¿ããŠãããªããŒã®æäžåœ¢æ
ããã®å¶åŸ¡æŸåºãä»ããŠäœçšå€ãéšäœã«æäžããããšãã§ããã
ããã«å¥ã®åŽé¢ã«ãããŠãæ¬çºæã¯ãåç©ã«ãããŠå°ãªããšãïŒçš®ã®éç·ç¶æ§ççã®çŸæ£åã¯éç·ç¶æ§ççã®çç¶ãæ²»çããç·ç¶æ§ççãæå¶ããããã«æ§æãããå»è¬çµæç©ãå«ã¿ã該çµæç©ã¯ãéç·ç¶æ§ççã®çŸæ£åã¯çç¶ãæ²»çããããã«éžæãããéç·ç¶æ§ççã®çŸæ£åã¯çç¶ã®ããã®æ²»çäžæå¹éã®å°ãªããšãïŒçš®ã®æ²»çå€ãç·ç¶æ§ççãæå¶ããããã«éžæãããæ²»çäžæå¹éã®å°ãªããšãïŒçš®ã®ç·ç¶æ§ççæå¶å€ãåã³å°ãªããšãïŒçš®ã®è¬åŠäžèš±å®¹å¯èœãªè³Šåœ¢å€ããã£ãªã¢åã¯åžéå€ãå«ãã
çµæç©ããåç©ã«ãããŠå°ãªããšãïŒçš®ã®éç·ç¶æ§ççã®çŸæ£åã¯éç·ç¶æ§ççã®çç¶ãæ²»çããäžã€ç·ç¶æ§ççãæå¶ããããã®è¬ç©ã®è£œé ã«ãããŠäœ¿çšããããšãã§ããã
æ¬çºæã¯ãããæ£è
ã«ãããŠãå°ãªããšãïŒçš®ã®éç·ç¶æ§ççã®çŸæ£åã¯éç·ç¶æ§ççã®çç¶ã«é¢é£ããçç¶ã軜æžããäžã€ãç·ç¶æ§ççã«é¢é£ããçç¶ãæå¶ããããšãã§ããè¬ç©ã®è£œé æ¹æ³ãå«ã¿ãéç·ç¶æ§ççã®çŸæ£åã¯çç¶ãæ²»çããããã«éžæãããéç·ç¶æ§ççã®çŸæ£åã¯çç¶ã®ããã®æ²»çäžæå¹éã®å°ãªããšãïŒçš®ã®æ²»çå€ãç·ç¶æ§ççãæå¶ããããã«éžæãããæ²»çäžæå¹éã®å°ãªããšãïŒçš®ã®ç·ç¶æ§ççæå¶å€åã³å°ãªããšãïŒçš®ã®è¬åŠäžèš±å®¹å¯èœãªè³Šåœ¢å€ããã£ãªã¢åã¯åžéå€ãå«ãè¬ç©ã補é ããæ¹æ³ãå«ãã
ããã«ãã®äžãããªãåŽé¢ã§ã¯ãæ¬çºæã¯ãç·ç¶æ§ççãæå¶ããããã«äœçšå€ãéžæããç·ç¶æ§ççãæãããšçãããéšäœã«ãæ²»çäžæå¹éã®äœçšå€ãå«ãçµæç©ãæäžããããšãå«ãåç©ã«ãããŠç·ç¶æ§ççãæå¶ããæ¹æ³ãå«ã¿ããã®éãçµæç©ã¯ãç·ç¶æ§ççã®ç¹å®ã®éšåãããšãã°ãç·ç¶æ§ççã®çŽïŒïŒïŒ
ãïŒïŒïŒ
ãïŒïŒïŒ
åã¯å®è³ªçã«ãã®ãã¹ãŠãæå¶ããããã«æ§æããããšãã§ãããæå¹æ§ã¯ãããšãã°ããããã©ããåã¯ãŠãµã®ã®ã¢ãã«ã§äœ¿çšããããšãã§ãããææã®åºæºãããšãã°ããããªãç·ç¶æ§ççæå¶å€ãå«ãŸãªãã¢ã«ãã³é
žãã£ã«ã ãšæ¯ã¹ãŠæ±ºå®ããããšãã§ãããå®æœæ
æ§ã¯ãŸããéžæãããç·ç¶æ§ççæå¶å€ãå«ã¿ãåç©ã«ãããŠç·ç¶æ§ççãæå¶ããããã«æ§æãããå»è¬çµæç©ãå«ã¿ããã®éãçµæç©ã¯ãå°ãªããšãç·ç¶æ§ççã®ç¹å®ã®éšåãããšãã°ãç·ç¶æ§ççã®çŽïŒïŒïŒ
ãïŒïŒïŒ
ãïŒïŒïŒ
åã¯å®è³ªçã«ãã®ãã¹ãŠãæå¶ããããã«æ§æããããšãã§ããã
ããã«ãã®äžãå¥ã®ãããªãåŽé¢ã§ã¯ãæ¬çºæã¯ãããããæäŸããããããã¯ãæ¬æ现æžã®çµæç©ãå«æãã容åšåã³ç·ç¶æ§ççãæå¶ããããã®çµæç©ã®å»è¬ç䜿çšã«é¢ããæ瀺æžãå«ãã©ãã«ãå«ãããšãã§ãããã©ãã«ã¯ãããšãã°ïŒŠïŒ€ïŒ¡ã®ãããªæ¿åºã«èªå¯ãããã©ãã«ã§ããã容åšã¯ãç¹æ»Žçšå€åã¯æ¬æ现æžã®ææã®çµæç©åœ¢æ
ãä¿æããããã«æ§æããããã€ã¢ã«ã§ããããšãã§ãããã©ãã«ã¯ãå°ãªããšãïŒçš®ã®éç·ç¶æ§ççã®çŸæ£åã¯éç·ç¶æ§ççã®çç¶ãæ²»çããããã®çµæç©ã®å»è¬ç䜿çšã«é¢ããæ瀺æžãããã«å«ãããšãã§ããã
ããããåã³ãã®ã»ãã®åŽé¢ãç¹åŸŽåã³å®æœæ
æ§ã¯ã以äžã®è©³çŽ°ãªèª¬æåã³æ·»ä»ã®å³é¢ãå«ãæ¬åºé¡ã®ç¯å²å
ã«ãããŠè¿°ã¹ããããããã«ãé¢é£ããåºé¡ã«å¯Ÿããã¯ãã¹ãªãã¡ã¬ã³ã¹ãå«ã¿ãç¹å®ã®ç³»ãè£
眮ãæ¹æ³åã¯ãã®ã»ãã®æ
å ±ãèå¯ããçš®ã
ã®åèæç®ã¯ãæ¬åºé¡ã«çŸããŠãããããšã«ãããããããã®æ瀺åã³èå¯ã«é¢ããŠãã®ãã¹ãŠãå
šäœãšããŠåç
§ã«ããæ¬æ现æžã«çµã¿å
¥ããã
å®æœæ
æ§ã®äžéšã§ã¯ãæ¬çºæã¯ãæè¡åŸãå€å·åŸãåã¯æŸå°ç·ç
§å°è¥ããã¯ååŠçæ³ã®åŸãåã¯ä»ã®åå ã®çµæã圢æãããŠãããç·ç¶æ§ççã®åœ¢æãæå¶ãããããšãã°ãæ²»çããåã¯äºé²ããããã«ãç·ç¶æ§ççã®çºçãçãããéšäœãããšãã°ãæŸå°ç·ãžã®æŽé²ãæè¡ãçŸæ£åã¯å·å®³ã«ããé床ã«ç·ç¶æ§çççºçã®å¯Ÿè±¡ãšãªãéšäœãåã³ç·ç¶æ§ççãçºçãããåã¯åºããéçšã«ããéšäœã«ãŠããããã€ãããã³ããŠãããŠã·ãåã¯ãã®ã»ãã®åºä¹³é¡ãåã¯ããªãç¬è«é¡åã¯ãã®ã»ãã®åç©ã®ãããªåç©ã®çµç¹ã«äœçšå€ãé©çšããããšã«ãã£ãŠæ¬æ现æžã«ãŠèå¯ãããäœçšå€ã䜿çšãããåèšãããåäœçšå€ã«ã¯ãæçœã«è¿°ã¹ãªãéããäŸå€ãªããäœçšå€åã³ãããã®ãã¹ãŠã®èªå°äœãå¡©åã³é¡çžäœãå«ãŸãããç·ç¶æ§ççã®æå¶ã®ããã«ç°ãªã£ãåŠæ¹ã§äœçšå€ãæäžããããšãã§ããããããååç©ã®äžéšã®å
šèº«æ§ééã«é¢ä¿ããå¯èœæ§ãããæ¯æ§ãæžããããã«ãææã§ããã°ãçµæç©ã¯ãç
å€éšäœã®ã¿ã«æå¹éã®äœçšå€ãæŸåºããããã«ããããšãã§ãããçµæç©ã¯ãŸããæ¬æ现æžã®äœçšå€ïŒãã®ãã¹ãŠã®èªå°äœãå¡©åã³é¡çžäœãå«ãïŒã®ããªããŒè£œå€åã¯ææã«ãã£ãŠãã®ã»ãã®è£œå€ãå«ãããšãã§ãããããã¯ãç·ç¶æ§ççã®å¯èœæ§ãããéšäœãžã®äœçšå€ã®æç¶çãªæŸåºãæäŸãããæ¬æ现æžã§èå¯ãããçµæç©ãæ¹æ³çã¯ãåç¬ã§äœ¿çšãããããšããã³ã€ãã³ïŒåã¯ãã®ã»ãã®ãã«ã³ïŒãšã®äœµçšã§ãåã¯æ¬æ现æžã§èå¯ããããã®ã»ãã®äœçšå€ãšã®äœµçšã§ãåã¯ãã®ã»ãã®äœçšå€è£
眮ãåã¯ããªã¢ãåã¯ãã³ã€ãã³ãå«ãè¬å€åã³æ¬æ现æžã§èå¯ãããäœçšå€åã³ãã®ã»ãã®äœçšå€ãšã®äœµçšã§äœ¿çšãããããšãæ¬æ现æžã§èå¯ãããåäœçšå€ãå«ãåŠæ¹ãå«ããéšäœã«çŽæ¥ãå
šèº«æ§ã«åã¯ãããªããã°ææã®ããã«çµæç©ãæäžããããšãã§ãããç¹å®ã®å®æœæ
æ§ã§ã¯ãæ¬æ现æžã®çµæç©ã¯ãã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããåã¯ãéºäŒåæ²»çãã¯ã¬ãªããã®ãããªãªãªãŽãã¯ã¬ãªããå€ãå«ãŸãªãã
å®æœæ
æ§ã®äžéšã§ã¯ãæ¬æ现æžã®æ¹æ³åã³çµæç©ã¯ãæ¬æ现æžã®çš®ã
ã®ç·ç¶æ§ççæå¶å€ã®ãã£ãïŒçš®ã®äœ¿çšãåã¯ãã®ãããªäœçšå€ã®ïŒçš®ä»¥äžã®äœ¿çšã«é¢ãããå®æœæ
æ§ã®äžéšã§ã¯ãåäžã®åã³è€æ°ã®äœçšå€æ··åç©çµæç©ãå«ããã®ãããªçµæç©ã«ãããäœçšå€ã®å°ãªããšãïŒã€ããã«ã³ã§ããããã®ã»ãã«ãããŠã¯ãæ··åç©çµæç©ã¯ãã«ã³ãå«ãŸãªãã
æ¬æ现æžã®çµæç©ã¯ãç·ç¶æ§ççãšé¡äŒŒã®çç©åŠãå
±æããã±ãã€ãã®ãããªç·ç¶æ§å¢æ®åã³ãã®ç¶æ
ã®æ²»çã«ãæçšã§ãããåŸã£ãŠãæ¬æ现æžã«ãããèå¯ã¯ãã®ãããªç·ç¶æ§å¢æ®ã«ãåæ§ã«é©çšãããã
æ¬æ现æžã®å®æœæ
æ§ã¯ãéç·ç¶æ§ççã®çŸæ£åã¯çç¶ãåå®ãã次ãã§éç·ç¶æ§ççã®çŸæ£åã¯çç¶åã³ç·ç¶æ§ççã®åæ¹ãåæã«æ²»çããåã¯æå¶ããç·ç¶æ§ççæå¶å€ãå«ãçµæç©ãéžæããæäžããããšãå«ãããšãã§ãããå®æœæ
æ§ã®äžéšã§ã¯ãçµæç©åã³æ¹æ³ã¯ããã«ãäžæ¹ãéç·ç¶æ§ççã®çŸæ£åã¯çç¶ã«å¯Ÿããäž»ãªå¹æãæããä»æ¹ãç·ç¶æ§ççã«å¯ŸããŠäž»ãªå¹æãæããããã«ãïŒçš®ä»¥äžã®æ¬æ现æžã®äœçšå€ãéžæããããšãå«ããããã«ãçµæç©åã³æ¹æ³ã¯ãåäžã®åã¯åæã®çµæç©ã§äžç·ã«æäžããããæ¬æ现æžã§èå¯ããããã®ã®ãããªå°ãªããšãïŒçš®ã®ç·ç¶æ§ççæå¶å€åã³éç·ç¶æ§ççã®çŸæ£åã¯çç¶ã«å¯Ÿããå°ãªããšãïŒçš®ã®äœçšå€ãåå®ããéžæããäžã€æäžããããšãå«ãããšãã§ãããåŸã£ãŠãæ¹æ³ã¯ãç·ç¶æ§ççãæå¶ããããã«äœçšå€ãéžæããéç·ç¶æ§ççã®çŸæ£åã¯çç¶ãæå¶ããããã«åäžã®åã¯å°ãªããšãïŒçš®ã®ãã®ã»ãã®äœçšå€ãéžæããéç·ç¶æ§ççã®çŸæ£åã¯çç¶åã³ç·ç¶æ§ççã®çºçãçãããéšäœã«æ²»çäžæå¹éã®äœçšå€ãæäžããããšãå«ãããšãã§ãããäŸç€ºãšãªãéç·ç¶æ§ççã®çŸæ£åã¯çç¶ã«ã¯ãçããæŸå°ç·æŽé²ãæ©æ¢°çãªåã³ãã®ã»ãã®å·å®³ãé¢ç¯çã也ç¬ãæè¡ãå±æçç¶ãæ¶ååšã®çŸæ£åã³çç¶ãããšãã°ãé®æåã¯ãã®ã»ãã®æ©æ¢°çãªç Žå£ã®åŸŽåã®å®è³ªçãªãªã¹ã¯ãæãããã®ãæããããã
æ¬çºæã®ç¹å®ã®å®æœæ
æ§ã®ç¯å²å
ã§ã¯ãç·ç¶æ§ççæå¶å€ã¯ãããšãã°ãè»èã溶液ãã¯ãªãŒã ãããŒã·ã§ã³ãã²ã«ãã¹ãã¬ãŒãã ãŒã¹ã被èŠãã©ãããããŒã¹ããããªã¢ãã€ã³ãã©ã³ãããã¯ãã¹ãã§ã¢ã埮ç²åããã£ã«ã ãç²åç¶ç©è³ªã液äœãã€ã³ãã©ã³ããã£ã«ã ãç¹æ»Žçšå€ãªã©ã®ãããªãã®ã»ãã®ååç©åã¯çµæç©ãšå
±ã«è£œå€åãããŠãããã
äžè¬ã«ãæ¬æ现æžã®çµæç©ã¯ãããŒã¹ããã²ã«ãã¹ãã¬ãŒãç²åç¶ç©è³ªããã£ã«ã ã溶液ã液äœãããŒã·ã§ã³ãã¯ãªãŒã åã¯ã€ã³ãã©ã³ããšããŠå¡åžåã¯æ³šå°ã«ãã£ãŠåç¬ã§ãåã¯çµæç©ã®äžéšãšããŠæäžããããšãã§ãããæäžã®çµè·¯åã³éšäœã«ã¯ãçµå£ãå
šèº«æ§ãçŒå
ãç®äžãè
¹è
å
ãçèå
ãé¢ç¯å
ãç
å€å
ãè£å
ãçŽè
žãåã¯è²Œä»å€ã®ãããªå±æãæãããããäœçšå€ã®æ²»çäžã®æå¹éã¯ãçµæç©ã®ææã«ãã£ãŠïœïŒïœåã¯ïœïŒïœã«ãŠçŽïŒïŒïŒïŒ
ãïŒïŒïŒïŒ
ãïŒïŒ
ãïŒïŒ
ãïŒïŒïŒ
ãïŒïŒãïŒïŒïŒ
ãïŒïŒïŒ
ãïŒïŒïŒïŒ
ãå«ãããšãã§ãããæ¬æ现æžã®çµæç©ã¯ã奜é©ãªå®¹åšåã¯å
¥ãç©ã§æäŸãããããšãã§ããèšãæããã°ããããã§æäŸãããããšãã§ããã©ãã«ã奜ãŸããã¯ãç±³åœé£åå»è¬åå±ã®ãããªé©åœãªæ¿åºèŠå¶åœå±ã«ããèªå¯ãããã©ãã«ãèšããããšãã§ãããã©ãã«ã¯çµæç©ã®å»è¬ç䜿çšã«é¢ããæ瀺æžãå«ãããšãã§ããã容åšã¯ãããšãã°ããã€ã¢ã«ã§ããããšãã§ãããã£ã«ã ãã²ã«ãç¹æ»Žçšå€åã¯æ¬æ现æžã§èå¯ãããã»ãã®åœ¢æ
ãšããŠåã¯ãããªããã°ææã®ããã«çµæç©ãæäŸããããã«æ§æããããšãã§ããã
ç·ç¶æ§ççæå¶å€ãšå
±ã«äŸãããååç©åã¯çµæç©ã¯ãããªããŒã§ãã£ãŠããéããªããŒã§ãã£ãŠãããããã£ãªã¢åã³ïŒåã¯ç©ççããªã¢ãšããŠæ©èœããŠããããæ¬æ现æžã§èå¯ããçµæç©ã¯ãŸããåç¬ã§ãåã¯æ°Žæ§æº¶æ¶²äžãè¥ããã¯éæ°Žæ§æº¶æ¶²äžãè¥ããã¯ããã¯ã«è¥ããã¯ãã£ãªã¢å
ã§ã®æžæ¿ãšããŠåæ£ããããäœçšå€ïŒåã¯ãã³ã€ãã³è¥ããã¯ãã®ã»ãã®ãã«ã³ãå«ãæ¬æ现æžã§èå¯ãããäœçšå€ã®ãªã¹ãããã®äœçšå€ã®ä»»æã®çµã¿åããïŒãå«ããããªããŒã®ãã£ãªã¢ãããªã¢åã³è³Šåœ¢å€ã®ä»£è¡šäŸã«ã¯ããããµã³ãããªããã©ãã«ãªããšãã¬ã³ãããªïŒä¹³é
žïŒãããªïŒãšãã¬ã³é
¢é
žããã«ïŒãããªïŒã°ãªã³ãŒã«é
žïŒããšãã¬ã³ãšé
¢é
žããã«ã®ã³ããªããŒãããªãšãã¬ã³ã°ãªã³ãŒã«ãã¡ããã·ããªãšãã¬ã³ã°ãªã³ãŒã«ãããªã«ããã©ã¯ãã³ãä¹³é
žãšã°ãªã³ãŒã«é
žã®ã³ããªããŒãããªïŒä¹³é
žïŒãšããªã«ããã©ã¯ãã³ã®ã³ããªããŒããŒã©ãã³ãã³ã©ãŒã²ã³ãã»ã«ããŒã¹ãã¢ã«ãã¡ã³ããã«ãããã¯ãããªïŒãã¬ãã©ã¯ãã³ïŒãããªâïŒç¡æ°Žç©ïŒãå€ç³é¡ãã¢ã«ã®ããŒãã®ãããªã¢ã«ã®ã³é
žããã¢ã«ãã³é
žã泚å°å¯èœãªè³Šåœ¢å€ããã®ã»ãã®ããªããŒç³»ããã¯ã«åã³ãããã®ã³ããªããŒãèªå°äœãæ··åç©åã³æ··åç©ãæããããããã®ã»ãã®å¥œé©ãªãã£ãªã¢ã®ä»£è¡šäŸã«ã¯ããšã¿ããŒã«ããšãã¬ã³ã°ãªã³ãŒã«ããããã¬ã³ã°ãªã³ãŒã«ãå«ãã°ãªã³ãŒã«ããã©ã³ã¹ã¯ããŒã«ïŒç»é²åæšïŒããšã¿ããŒã«ãšã°ãªã³ãŒã«ã®æ··åç©ãããªã¹ãã³é
žã€ãœãããã«ããã«ããã³é
žã€ãœãããã«ããšã¿ããŒã«ãšããªã¹ãã³é
žã€ãœãããã«åã¯ãã«ããã³é
žã€ãœãããã«ã®æ··åç©ãæããããããã®ãããªããªããŒã¯ããèªäœãç¹å®ã®çµæç©ã§ççæå¶æŽ»æ§ãæäŸããŠãããã
äŸç€ºãšãªãç·ç¶æ§ççæå¶å€ã®äžè¬çèå¯
æ¬æ现æžã®çµæç©ã®è¬å€æåã¯ãä»ã®çµæç©åã³ç®çã§éåžžãåšç¥ã§ããã以äžã¯ããããã®äžéšã«é¢ããæ å ±ã®äžéšãæäŸããã
äŸç€ºãšãªãç·ç¶æ§ççæå¶å€ã®äžè¬çèå¯
æ¬æ现æžã®çµæç©ã®è¬å€æåã¯ãä»ã®çµæç©åã³ç®çã§éåžžãåšç¥ã§ããã以äžã¯ããããã®äžéšã«é¢ããæ å ±ã®äžéšãæäŸããã
ïŒïŒ®ïŒ³ïŒ¡ïŒ©ïŒ€ããã®æ²»çå¹æïŒè§£ç±ãé®çãæçç掻æ§ïŒãçºæ®ããäž»ãªã¡ã«ããºã ã¯ãããã¹ã¿ã°ã©ã³ãžã³ïŒïŒ°ïŒ§ïŒåæã®é»å®³ã§ãããå
·äœçã«ã¯ãã¯ãããã¹ã¿ã°ã©ã³ãžã³ã圢æããããã®ã¢ã©ããã³é
žããç°ç¶ãšã³ããã«ãªãã·ãã®åæã觊åªããé
µçŽ ã§ããã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒã競åçã«ïŒã»ãšãã©ã®éšåã§ïŒé»å®³ãããã®æçç掻æ§ã«å¯äžããŠããããã®ã»ãã®ã¡ã«ããºã ã«ã¯ãã¹ãŒããŒãªãã·ãã©ãžã«ã«ã®éå
ãã¢ãããŒã·ã¹ã®èªå°ãæ¥çååã®çºçŸã®é»å®³ãé
žåçªçŽ åæé
µçŽ ã®äœäžãççèªçºæ§ãµã€ãã«ã€ã³ã®ã¬ãã«ã®äœäžïŒè
«çå£æ»å åαãã€ã³ã¿ãŒãã€ãã³âïŒïŒããªã³ãç掻æ§ã®ä¿®é£Ÿåã³çŽ°èèæ©èœã®æ¹å€ãæããããã
âïŒé»å®³å€ïŒInt. J. Immunopathol. Pharmacol., May-Aug:16(2) Suppl.:17-22, 2003ïŒ
ãã®äœçšã¯ãã¢ã©ããã³é žãããã¹ã¿ã°ã©ã³ãžã³åã³ãããããµã³ã«å€æããã®ã«é¢äžããã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé µçŽ ã®é»å®³ãäžå¿ãšãããïŒïŒïŒïŒå¹Žãã«ã¯ïŒã€ã®ç°ãªã£ãã¢ã€ãœã¶ã€ã ãååšãããã®ãã¡ã®ïŒã€ãâïŒã¯äž»ãšããŠççã«é¢äžããããæ¶å管ã®æŽåæ§åã¯è¡å°æ¿ã®åéã«ã¯æããã«é¢äžããªãããšãé瀺ãããããã®çç±ã§ãæè¿ããã®ã¢ã€ãœã¶ã€ã ã«éžææ§ãããæ°èŠã®ååç©ãæçç掻æ§ã¯ä¿æããããæ¶å管æ¯æ§åã³åºè¡ã®ãªã¹ã¯ãæå°éã«æãããããããéžææ§ïŒ£ïŒ¯ïŒžâïŒé»å®³å€åã¯ïŒ£ïŒ¯ïŒžïŒ©ïŒ¢ãéçºããããâïŒé»å®³å€ã®ïŒ£ïŒ¯ïŒžéäŸåæ§ã®ã¡ã«ããºã ã®äžéšã«ã¯ãã¿ã³ãã¯è³ªãããŒãŒïŒ§ã®æŽ»æ§åãκ掻æ§åã®é»å®³ãæã¢ãããŒã·ã¹ã¿ã³ãã¯è³ªïŒ¢ïœïœâã®äžæ¹å¶åŸ¡ãΎã®é»å®³åã³ïŒ°ïŒ°ïŒ¡ïŒ²Î³ã®æŽ»æ§åãæããããã
ãã®äœçšã¯ãã¢ã©ããã³é žãããã¹ã¿ã°ã©ã³ãžã³åã³ãããããµã³ã«å€æããã®ã«é¢äžããã·ã¯ããªãã·ã²ããŒãŒïŒïŒ£ïŒ¯ïŒžïŒé µçŽ ã®é»å®³ãäžå¿ãšãããïŒïŒïŒïŒå¹Žãã«ã¯ïŒã€ã®ç°ãªã£ãã¢ã€ãœã¶ã€ã ãååšãããã®ãã¡ã®ïŒã€ãâïŒã¯äž»ãšããŠççã«é¢äžããããæ¶å管ã®æŽåæ§åã¯è¡å°æ¿ã®åéã«ã¯æããã«é¢äžããªãããšãé瀺ãããããã®çç±ã§ãæè¿ããã®ã¢ã€ãœã¶ã€ã ã«éžææ§ãããæ°èŠã®ååç©ãæçç掻æ§ã¯ä¿æããããæ¶å管æ¯æ§åã³åºè¡ã®ãªã¹ã¯ãæå°éã«æãããããããéžææ§ïŒ£ïŒ¯ïŒžâïŒé»å®³å€åã¯ïŒ£ïŒ¯ïŒžïŒ©ïŒ¢ãéçºããããâïŒé»å®³å€ã®ïŒ£ïŒ¯ïŒžéäŸåæ§ã®ã¡ã«ããºã ã®äžéšã«ã¯ãã¿ã³ãã¯è³ªãããŒãŒïŒ§ã®æŽ»æ§åãκ掻æ§åã®é»å®³ãæã¢ãããŒã·ã¹ã¿ã³ãã¯è³ªïŒ¢ïœïœâã®äžæ¹å¶åŸ¡ãΎã®é»å®³åã³ïŒ°ïŒ°ïŒ¡ïŒ²Î³ã®æŽ»æ§åãæããããã
âïŒé»å®³å€ã«ã¯ããã¡ã¹ãªãïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒïŒDrugs, Suppl. 1:9-22, 2003ïŒãæããããã
ãã§ãã¡ãŒãïŒPrim. Care, Suppl. 17(3):589-601, 1990ïŒã
ãããã®äœçšå€ã¯ãããèªäœããµãªãã«é
žã®çäœåé
äœã§ããã¢ã³ãã©ãã«é
žã®ïŒ®âã¢ãªãŒã«çœ®æèªå°äœã§ãããšã¿ãªãããŠããããããã®äœçšå€ã¯ãäœçšå€ã®ãã®éšé¡ã«ç¹åŸŽçã§ããé
žæ§ç¹æ§ãä¿æããŠãããæã掻æ§ã®é«ããã§ãã¡ãŒãã¯ãâã¢ãªãŒã«éšåã®ã¡ãã§ãã¡ãŒãã®ïŒâãïŒâåã³ïŒåã¯ïŒâäœã«å°ããªã¢ã«ãã«çœ®æåºåã¯ããã²ã³çœ®æåºãæããïŒã¡ãã§ãã¡ãŒãã以äžåç
§ïŒãè±çœ®æããâã¢ãªãŒã«ãã§ãã¡ãŒãã®éã§ã¯ãïŒâãïŒââèªå°äœãæã掻æ§ãé«ããšããããšã¯ãïŒâãïŒâäœã®çœ®æåºãã¢ã³ãã©ãã«é
žãšå
±ã«ãâã¢ãªãŒã«ç°ã匷å¶çã«å
±æ¥µæ§ã®å€ã«åºãããäœçšããããšã瀺åããŠãããåŸã£ãŠããã®ç«äœçå¹æã¯ãã·ã¯ããªãã·ã²ããŒãŒã®é»å®³éšäœã§ã®ãã§ãã¡ãŒãã®å¹æçãªçžäºäœçšã«éèŠã§ãããšææ¡ãããŠãããäœçšïŒã¢ã³ãã©ãã¬ãŒãã¯ãããã€ãã®é®ç掻æ§åã³è§£ç±æŽ»æ§ãšå
±ã«äž»ãšããŠæççæ§ãæããééžææ§ã§ãããã¢ã³ãã©ãã¬ãŒãã¯ãç©ãããªé®çå€ãšããŠäœ¿çšãããæã«ã¯ççæ§çŸæ£ã®æ²»çã«äœ¿çšãããã
ãã§ãã¡ãŒããšããŠã¯ãã¡ã¯ããã§ãã é
žïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒâïŒïŒâïŒïŒãã¡ã¯ããã§ãã¡ãŒãïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒããããåã³è¡åŸçŒçã«äœ¿çšããããïŒâã¢ãªãŒã«é
¢é
žã«ç±æ¥ãããžã¯ããã§ããã¯ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ãªãã·ã«ã ïŒArthritis Rheum., Jan 40(1):143-53, 1997ïŒã
ãªãã·ã«ã ã¯ãïŒâããããã·ãã³ãŸãã¢ãžã³è€çŽ ç°ãç¹åŸŽãšããããªãã·ã«ã ã®é
žæ§åºŠã¯ãå
éšååã®ïŒšçµåã«ãã£ãŠã¢ããã®ïŒ®âåºã«å®å®åããããšãã¬ãŒãã¢ããªã³ã䌎ãïŒâã«èµ·å ããããŸãããã³ãŸãã¢ãžã³ç°ã®ïŒäœã«ãããã«ã«ãããµãã眮æåºã®ååšã¯ãã€ãªã³åã®é圢æãããè² ã®é»è·ãå®å®åããïŒå
±é³Žå®å®åïŒããšã«ãã£ãŠé
žæ§ã«åãã£ãŠå¯äžããããããã®ååç©ã¯é
žæ§ã§ã¯ãããïŒïœïŒ«ïŒïŒïŒïŒïŒãã«ã«ãã³é
žïŒ®ïŒ³ïŒ¡ïŒ©ïŒ€ããã幟åé
žæ§åºŠã¯äœããããã«ããªãã·ã«ã ã¯çççïœïŒšã§äž»ãšããŠã€ãªã³åãããŠãããã®é»å®³æŽ»æ§ã«ã¯é
žæ§åºŠãå¿
èŠãšããã
ãªãã·ã«ã ãšããŠã¯ããããã·ã«ã ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ã¢ã»ãã«é
žèªå°äœïŒFASEB J., Oct, 15(12):2057-72, 2001ïŒã
ãããã®ååç©ãé
¢é
žã®èªå°äœã§ãããïŒäœã«è€çŽ ç°åã¯é¢é£ããççŽ ç°ã§ãã眮æåºãæã€ã
ã¢ã»ãã«é
žèªå°äœã«ã¯ãã€ã³ãã¡ã¿ã·ã³ïŒïŒ£ïŒ¡ïŒ³ ïœïŒïŒïŒâïŒïŒâïŒïŒïŒã€ã³ãã·ããã€ã³ãããã¯ïŒâãã³ãŸã€ã«åã€ã³ããŒã«çªçŽ ãå«æããã€ã³ããŒã«âïŒâé
¢é
žèªå°äœãæãããããã€ã³ããŒã«ç°ã®ïŒäœã®ã¡ãã«åºã¯ãâçµåã«é¢ããéé¢ã®å転ã劚ããã®çµååã³æ²»ç掻æ§ã«ã€ããŠïŒã€ã®è³éŠæç°ãæ£ããé¢ä¿ã«ä¿æãããã€ã³ãã¡ã¿ã·ã³ã¯ããâïŒéžææ§ãã§ããã幟åã®é®ç掻æ§åã³è§£ç±æŽ»æ§ãšå
±ã«äž»ãšããŠæççäœçšãçããã
ãµãªãã«é
žèªå°äœãæ§é åã³ååŠïŒãµãªãã¬ãŒãã¯ãïŒâããããã·å®æ¯éŠé
žïŒãµãªãã«é
žïŒã®èªå°äœã§ãããã€ãã®ã®æš¹ç®ããã®ãµãªãã«é
žã®æœåºã«ç¶ããŠããµãªãã¬ãŒãã¯ïŒïŒïŒïŒå¹Žã«çºèŠãããããµãªãã«é
žã¯ãããªãŠã å¡©ãšããŠå»çšã«äœ¿çšãããããïŒïŒïŒïŒå¹Žä»£åŸæã«æ²»ççšã«ã¯ãã¢ã»ãã«åèªå°äœãã¢ã»ãã«ãµãªãã«é
žïŒïŒ¡ïŒ³ïŒ¡ïŒåã¯ã¢ã¹ããªã³ã«çœ®ãæãããããæ²»ççæçšæ§ã¯ãã¢ã¹ããªã³ã®ããã«ãã§ããŒã«ããããã·ã«åºã®ãšã¹ãã«åã«ãã£ãŠãåã³ãžãã«ãã¶ã«ã®ããã«ïŒ£âïŒã«ãããçæ°Žæ§ïŒèŠªæ²¹æ§ã®åºã®çœ®æã«ãã£ãŠé«ããããŠããããµãªãã¬ãŒãã¯ãç©ãããªé®ç掻æ§åã³è§£ç±æŽ»æ§ãšå
±ã«åŒ·åãªæçç掻æ§ãæããããããã®ååç©ã¯äž»ãšããŠãâïŒéžææ§ãã§ãããé«ã芪åæ§ã§ïŒ£ïŒ¯ïŒžâïŒã«çµåãããæ¯æ§ã«ã¯ãæ¶ååšåºæ¿æ§ãéæçåå¿ãè¡å°æ¿åéã®é»å®³åã³å
è³ç¥çµæ¯æ§ïŒè³é³ŽãïŒãæãããããã¢ã¹ããªã³ã®æ²»çäžã®åã³ç¹å®ã®æ¯æ§äœçšïŒããªãã¡ãæ¶å管ïŒã¯ãçš®ã
ã®çµç¹ã«ããããé»å®³ãããã®èœååã³è©Šéšç®¡å
ã®ãã©ã³ã¹ã¢ã»ãã«ååå¿ã«é¢äžãããã®èœåã«é¢ä¿ããããããšãã°ãã®ã¢ã»ãã«åã¯ããã®é
µçŽ ã®äžå¯éçé»å®³ããé¢ç¯ã§ã¯æççå¹æåã³æ¶ååšã§ã¯æ害ãªå¹æãçµæãšããŠçããã埪ç°ã¿ã³ãã¯è³ªã®ã¢ã»ãã«åã¯ãçµæãšããŠéæçåå¿ãçããå¯èœæ§ãããã
ãµãªãã«é
žèªå°äœã«ã¯ãã¢ã»ãã«ãµãªãã«é
žïŒïŒ£ïŒ¡ïŒ³çªå·ïŒïŒâïŒïŒâïŒïŒããžãã«ãã¶ã«ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒãæãããããµãªãã«é
žã®ãžãã«ãªããã§ãã«é¡çžäœã¯ãäž»ãšããŠé®ç掻æ§åã³è§£ç±æŽ»æ§ãæãããšããç¹ã§ããµãªãã¬ãŒãã®éšé¡ã®ãã®ã»ãã®ã¡ã³ããŒãšç°ãªãããåã³çèã®çŒçã«é¢ä¿ããçµè·¯ãæ²»çããã®ã«äœ¿çšããããã¢ã¹ããªã³ãããæ¶ååšã®æœ°çåãèµ·ããããèŽèŠã®å¯äœçšãäœãããšãå ±åãããããã®è¬å€ã¯ããµãªãã¬ãŒããšåæ§ã«ãäž»ãšããŠãã§ããŒã«åã³ã«ã«ããã·ââã°ã«ã¯ãã³åã«ãã£ãŠã¯ãªã¢ã©ã³ã¹ãããã
ãã©ãŸãã³ïŒäœçšå€ã®ãã®éšé¡ã¯ãïŒâã¢ãªãŒã«âïŒïŒïŒâãã©ãŸãªãžã³ãžãªã³æ§é ãç¹åŸŽãšããæ§é çã«è³éŠæååç©ãã©ãŸãŒã«ã«é¢ä¿ããããããã«ååç©ã¯ãé®çäœçšã解ç±äœçšãæççäœçšïŒãã®åŒ±ãé
žæ§åºŠã®ããã«ïŒããããæ¯æ§çšéä»è¿ã§å°¿é
žææ³æ§ã§ããããããã®ååã®é
žæ§åºŠã¯ãïŒäœã«ããããšããŒã«åå¯èœãªæ°ŽçŽ ã®ååšã«ãã£ãŠãããïœïŒ«ïœäŸåæ§ã§ããã
ãã©ãŸãã³ã«ã¯ããã§ãã«ãã¿ãŸã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒâïŒïŒâïŒïŒãæããããã
ã³ã«ãã³ã¹ããã€ãïŒã³ã«ãã³ã¹ããã€ãã¯ãå¯è
ç®è³ªããç£çããã倩ç¶ã®ã³ã«ãã³ã¹ããã€ãã«é¡äŒŒããæççå€ã®äžçŸ€ã§ãããã³ã«ãã³ã¹ããã€ãæ²»çã§æ¹åããããšãå€ãçŸæ£ã«ã¯ãåæ¯ãã¢ã¬ã«ã®ãŒæ§éŒ»çãã¢ã¬ã«ã®ãŒæ§æ¹¿ç¹åã³é¢ç¯ãªãŠãããããããããã®æççå€ãã©ã®ããã«åŸæã¢ã¬ã«ã®ãŒåå¿ãé»å®³ããã®ãã¯ãç²èè¡šé¢ã«æ²¿ã£ãè¥æºçŽ°èå¯åºŠã®äœäžãèµ°åæ§ã®äœäžåã³å¥œé
žçã®æŽ»æ§åããªã³ãçãåçãè¥æºçŽ°èåã³å¥œé
žçã«ãããµã€ãã«ã€ã³ç£çã®äœäžãã¢ã©ããã³é
žä»£è¬ã®é»å®³åã³ãã®ã»ãã®ã¡ã«ããºã ãå«ãæ§ã
ãªã¡ã«ããºã ãä»ããŠçããã
ã³ã«ãã³ã¹ããã€ãã«ã¯ããããµã¡ã¿ãŸã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒâïŒïŒâïŒïŒãæããããã
ã¢ã«ãã«åå€ïŒã¢ã«ãã«åå€ã¯ãäž»èŠãªæšçãšããŠã®ïŒ€ïŒ®ïŒ¡ãšå
±ã«ãææ©ååç©ã«ããã掻æ§æ°ŽçŽ ååã«ã€ããŠã¢ã«ãã«åºãn2n+1ã眮æããååç©ã§ãããã¢ã«ãã«åå€
ã¯ãïŒïŒïŒïŒå¹Žããã¹ã¿ãŒãã¬ã¹ããéçºãããããåã¯ã¿ã³ãã¯è³ªãšã®åå¿ãã¢ã«ãã«åãå°ããããã¯ãäºå®èœæ§ã§ãã£ãŠããããè¬å€äžŠã³ã«ãã®ã»ããå«æããçªçŽ ããã¹ã¿ãŒããããããœãŠã¬ã¢åã³çœéãå«ãæ¶æ©åºãçãããã¢ã«ãã«åå€ã¯ãã¹ãŠãã«ã«ãããŠã ã€ãªã³äžéäœã®åœ¢æãä»ããŠåŒ·åãªæ±é»åç©è³ªã圢æããããããçµæãšããŠãçš®ã ã®æ±æ žéšåã®ã¢ã«ãã«åã«ãã£ãŠå ±æçµåã®åœ¢æãçãããååŠçæ³å¹æåã³çŽ°èå·å®³å¹æã¯ãä»ã®éšåãã¢ã«ãã«åãããŠããããäž»ãšããŠã°ã¢ãã³ã®ïŒåã®çªçŽ ååãä»ããã®ã¢ã«ãã«åã«çŽæ¥é¢ä¿ãããæ±æ žç©è³ªãšã®ïŒçš®ã®å ±æçµåã®åœ¢æã¯çµæãšããŠçªç¶å€ç°èªçºåã¯å¬å¥åœ¢æãæãããããæ¶æ©ãä»ããïŒã€ã®ãããã®çµåã®åœ¢æã¯çŽ°èå·å®³æ§ãçããã
ã¯ãïŒïŒïŒïŒå¹Žããã¹ã¿ãŒãã¬ã¹ããéçºãããããåã¯ã¿ã³ãã¯è³ªãšã®åå¿ãã¢ã«ãã«åãå°ããããã¯ãäºå®èœæ§ã§ãã£ãŠããããè¬å€äžŠã³ã«ãã®ã»ããå«æããçªçŽ ããã¹ã¿ãŒããããããœãŠã¬ã¢åã³çœéãå«ãæ¶æ©åºãçãããã¢ã«ãã«åå€ã¯ãã¹ãŠãã«ã«ãããŠã ã€ãªã³äžéäœã®åœ¢æãä»ããŠåŒ·åãªæ±é»åç©è³ªã圢æããããããçµæãšããŠãçš®ã ã®æ±æ žéšåã®ã¢ã«ãã«åã«ãã£ãŠå ±æçµåã®åœ¢æãçãããååŠçæ³å¹æåã³çŽ°èå·å®³å¹æã¯ãä»ã®éšåãã¢ã«ãã«åãããŠããããäž»ãšããŠã°ã¢ãã³ã®ïŒåã®çªçŽ ååãä»ããã®ã¢ã«ãã«åã«çŽæ¥é¢ä¿ãããæ±æ žç©è³ªãšã®ïŒçš®ã®å ±æçµåã®åœ¢æã¯çµæãšããŠçªç¶å€ç°èªçºåã¯å¬å¥åœ¢æãæãããããæ¶æ©ãä»ããïŒã€ã®ãããã®çµåã®åœ¢æã¯çŽ°èå·å®³æ§ãçããã
ã¢ã«ãã«åå€ã®äŸã«ã¯ããã¹ã«ãã¡ã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒâïŒïŒâïŒïŒïŒãã¹ã«ãã§ãã¯ã¹ããã¬ã©ã³ïŒãã·ã¯ããã¹ãã¡ããïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒïŒãããµã€ããã¯ã¹ïŒããšã¹ãã©ã ã¹ãã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒïŒãšã ã·ã¹ãïŒãã·ã¹ãã©ãã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒåã³ãã«ããžã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
代è¬æå¶å€ïŒSemin. Oncol., Dec, 19(6):695-706, 1992ïŒã
代è¬æå¶å€ã¯ãé¡äŒŒã®ååŠæ§é ãæããããšã«ãã£ãŠå€©ç¶ã®ä»£è¬ç£ç©ã®å©çšã劚害ããååç©ãšããŠå®çŸ©ãããã代è¬æå¶å€ã¯äžè¬ã«ãã¹ããã€ããã«ã¢ã³åã¯æ žé
žåé§äœã®é¡çžäœã§ãããåã³ïŒåã¯ïŒ²ïŒ®ïŒ¡ã®é»å®³ã«ãã£ãŠæ žé
žåã³èé
žã®ä»£è¬æå¶å€ãäœçšãããåŸã£ãŠããããã®äœçšæ§åŒã¯ããã®æ¯æ§å¹æãæ¥éã«å¢æ®ããŠããçµç¹ã§æãé¡èã§ããããšãæå³ããã代è¬æå¶å€ã«ã€ããŠã¯å¹Ÿã€ãã®ç°ãªã£ã现èæ§æšçãããã代è¬æå¶å€ã®äžè¬çãªéšé¡ã¯ãèé
žæ®æå€ãããªã³æ®æå€åã³ããªããžã³æ®æå€ã§ããã
代è¬æå¶å€ã®äŸã«ã¯ã¡ãœãã¬ãã»ãŒãïŒïŒ£ïŒ¡ïŒ³ïŒïŒâïŒïŒâïŒïŒãæããããã
ãªããã¯ã¬ã¢ãŒãŒéå
é
µçŽ é»å®³å€ïŒãªããã¯ã¬ã¢ãŒãŒéå
é
µçŽ é»å®³å€ã¯ãããªãã·ãªããã¯ã¬ãªã·ãã®ãããçåæã觊åªããé
µçŽ ããªããã¯ã¬ã¢ãŒãŒéå
é
µçŽ ã®ïŒ²ïŒãµããŠãããã«çµåããŠããããåŸã£ãŠïŒ€ïŒ®ïŒ¡åæã劚害ããïŒExpert Rev. Anticancer Ther., Aug, 2(4):437-48, 2002ïŒã
ãªããã¯ã¬ã¢ãŒãŒéå
é
µçŽ é»å®³å€ã®äŸã«ã¯ãããããã·ãŠã¬ã¢ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒâïŒïŒâïŒïŒïŒããã¬ã¢ïŒãæããããã
现èå·å®³æ§æçç©è³ª
现èå·å®³æ§æçç©è³ªã®äŸã«ã¯ãããã¿ã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒâïŒïŒâïŒïŒãæããããã
现èå·å®³æ§æçç©è³ªã®äŸã«ã¯ãããã¿ã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒâïŒïŒâïŒïŒãæããããã
ã¿ããµã³ïŒã¿ããµã³ã¯ã埮å°ç®¡ãå®å®åããããšã«ãã现èåšæã®é²è¡ãé®æãããã®çµæãäžå¿äœã®æå·ãç°åžžãªçŽ¡é糞ã®èªå°åã³çŽ¡é糞埮å°ç®¡ã®åæ
æå¶ãçããïŒCurr. Cancer Drug Targets, Jun, 3(3):193-203, 2003ïŒã
ããã€ãœã¡ã©ãŒãŒé»å®³å€ã®äŸã«ã¯ããã»ã¿ãã»ã«ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒïŒâïŒïŒâïŒïŒïŒã¿ã¯ãœãã¬ïŒãæããããã
ãã³ã«ã¢ã«ã«ãã€ãåã³é¡çžäœïŒCurr. Med. Chem. Anti-Canc. Agents, Jan, 2(1):1-17, 2002ïŒã
ãã³ã«ã¢ã«ã«ãã€ãã¯ã管ã®åŽé¢ã«çµåããããšã«ãã埮å°ç®¡ã®éåãé»å®³ããåŸã£ãŠãäžæïŒåŸæã®éæž¡æã§æ糞åè£ãé»æ¢ãã现èæ»ãèªå°ããã
ãã³ã«ã¢ã«ã«ãã€ãã®äŸã«ã¯ãã³ãã©ã¹ãã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ãããã¢ãœãŒã é»å®³å€ïŒCancer Treat Rev., May, 29 Suppl., 1:41-8, 2003ïŒã
ãããã¢ãœãŒã ã¯ãκïŒïŒ®ïŒŠÎºïŒ¢ãïœïŒïŒãåã³ãµã€ã¯ãªã³äŸåæ§ãããŒãŒé»å®³å€ïœïŒïŒåã³ïœïŒïŒãå«ãå€æ°ã®çŽ°èå
調ç¯æ§ã¿ã³ãã¯è³ªã®éèŠãªç°åçµè·¯ã«é¢äžããæçµçãªå解é
µçŽ ã§ããããããã¢ãœãŒã é»å®³å€ã®æè
«çå¹æã«ã¯ã现èå¢æ®ã·ã°ãã«äŒéçµè·¯ã®é»å®³ãã¢ãããŒã·ã¹ã®èªå°åã³çŽ°èæ§æ¥çååã®çºçŸã®é»å®³ãå«ãã幟ã€ãã®ç°ãªã£ãã¡ã«ããºã ãé¢äžããŠãããã
ãããã¢ãœãŒã é»å®³å€ã®äŸã«ã¯ãïŒïŒ§ïŒïŒïŒïŒCytokine, Nov, 7;24(3):67-73, 2003ïŒãæããããããã¯ïŒ®ïŒŠÎºïŒ¢ã®åœ¢æåã³ãã®é»å®³å€ïŒ©ÎºïŒ¢ã®å解ãé»å®³ããã
ã€ãªã³ãã¬ãŒãå€ïŒAdv. Exp. Med. Biol., 509:231-49, 2002ïŒã茞液ã®ã€ãªã³éå°è² æ
ã®çç¶ã§æ²»ççã«äœ¿çšããããµã©ã»ãã¢ã§ã®ã€ãªã³éå°è² æ
ã®æ²»çã«äœ¿çšãããçµå£æŽ»æ§ã®ããã€ãªã³ãã¬ãŒãå€ã
ã€ãªã³ãã¬ãŒãå€ã®äŸã«ã¯ãããã§ãããµãã³ã¡ã·ã¬ãŒãïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒâïŒïŒâïŒïŒãæããããããã¯ãéé¢ã®ã€ãªã³ããã§ãªãã³ã®ã€ãªã³åã³ãã¢ã·ããªã³ã«çµåããŠãã§ãªãªããµãã³ã圢æãã氎溶æ§ã®ãã¬ãŒãå€ã§ãããè
èïŒå°¿ã¯èµ€ã¿ã垯ã³ãè²ïŒã«ãã£ãŠäžŠã³ã«èæ±ãä»ããŠç³äŸ¿ã«ãã£ãŠææ³ããããè¡æŒ¿é
µçŽ ã«ããæ¥éã«ä»£è¬ãããå°¿ã«ææ³ãããã
ïŒâããããã·âïŒâã¡ãã«ã°ã«ããªã«âïœïŒ¡éå
é
µçŽ é»å®³å€ããããã®è¬å€ã¯ãã³ã¬ã¹ãããŒã«çåæã®åæã®åŸé段éã§ãããïŒïŒ§âïœïŒ¡ã®ã¡ããããŒããžã®å€æã觊åªããïŒâããããã·âïŒâã¡ãã«ã°ã«ããªã«è£é
µçŽ âïœïŒ¡éå
é
µçŽ ãé»å®³ããã
ïŒâããããã·âïŒâã¡ãã«ã°ã«ããªã«âïœïŒ¡éå
é
µçŽ é»å®³å€ã®äŸã«ã¯ãã¹ã¿ãã³é¡åã³ã·ã ãã¹ã¿ãã³ïŒãŸã³ãŒã«ïŒïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ã¬ããã€ãåã³ã¬ããã€ãé¡çžäœïŒJ. Dermatol., May, 30(5):355-80, 2003ïŒã
ã¬ããã€ãïŒãã¿ãã³ïŒ¡ã®å€©ç¶åã³åæã®èªå°äœïŒã¯ãå€æ§ãªæ£åžžçŽ°èãåç现èåã³ç现èã«ãããŠåŒ·åãªåååã³å¢æ®æå¶ã®å¹æãã·ã°ãã«äŒéãããã¬ããã€ãã¯ãå
šãã©ã³ã¹ã¬ããã€ã³é
ž()ãçããããã¯ãã¿ãã³ïŒ¡ïŒã¬ãããŒã«ïŒã®äž»ãªæŽ»æ§åã§ããããã®çäœåé
äœã¯ãæ žã®ãã®å容äœãã¬ããã€ã³é
žå容äœïŒïŒ²ïŒ¡ïŒ²ïŒã«çµåããããšã«ãã£ãŠçç©å¹æãçºæ®ããã
ã¬ããã€ãåã³ã¬ããã€ãé¡çžäœã®äŸã«ã¯ãå
šãã©ã³ã¹ã¬ããã€ã³é
žãæããããïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒâïŒïŒâïŒïŒïŒJ. Biol. regul. Homeost. Agents, Jan-Mar, 17(1):98-114, 2003ïŒã
æè¡æ å€ïŒããã³ãã³ãšçžäºäœçšãããã£ããªããŒã²ã³ãè¡å°æ¿åã³ãã®ã»ãã®åºè³ªã®è§ŠåªæŽ»æ§ãé»æ¢ããè¬å€ïŒExpert Opin. Pharmacother., May, 4(5):635-66, 2003ïŒã
æè¡æ å€ã®äŸã«ã¯ããããªã³ãããªãŠã ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
äœååéãããªã³ïŒSemin. Tromb. Hemost., 26: Suppl. 1:31-8, 2000ïŒãæšæºã®ãããªã³ã«æ¯ã¹ãŠãïŒïŒ·ïŒšã¯ãç°ãªã£ãè¬ç©ååŠåã³è¬ç©åæ
ã®ç¹æ§ãæããèšåºçãªå©çãç°ãªããïŒïŒ·ïŒšã¯ãæªåç»ãããªã³ã«æ¯ã¹ãŠããã«å€§ããªçç©å©çšæ§ãé·ãåæžæãäºæž¬å¯èœãªè¬çåå¿ãå®å
šæ§ã®æ¹åã®å¯èœæ§ãåã³é¡äŒŒã®åã¯ããã«å€§ããªæå¹æ§ãæããã
æååºå€
æååºå€ã®äŸã«ã¯ããã³ããã·ãã£ãªã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
æååºå€ã®äŸã«ã¯ããã³ããã·ãã£ãªã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ãã©ã¹ãããŒã²ã³æŽ»æ§åå€
ãã©ã¹ãããŒã²ã³æŽ»æ§åå€ã®äŸã«ã¯ãã¹ãã¬ãããããŒãŒïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ãã©ã¹ãããŒã²ã³æŽ»æ§åå€ã®äŸã«ã¯ãã¹ãã¬ãããããŒãŒïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ãµã€ãã«ã€ã³é¡
ãµã€ãã«ã€ã³é¡ã®äŸã«ã¯ã圢質転æå¢æ®å åβïŒïŒŽïŒ§ïŒŠâβãJ. Biol. Chem., Aug, 30:277(35):31938-48, 2002ïŒãæããããã
ãµã€ãã«ã€ã³é¡ã®äŸã«ã¯ã圢質転æå¢æ®å åβïŒïŒŽïŒ§ïŒŠâβãJ. Biol. Chem., Aug, 30:277(35):31938-48, 2002ïŒãæããããã
ãããªã¯ã¹ã¡ã¿ããããã€ããŒãŒé»å®³å€ïŒHematol. Oncol. Clin. North. Am., Oct, 16(5):1189-227, 2002ïŒã
ãããªã¯ã¹ã¡ã¿ããããã€ããŒãŒïŒïŒŽïŒ©ïŒïŒ°ïŒã®çµç¹é»å®³å€ããè
«ç现èã®äŸµè¥²ãé»æ¢ãããšããããšã¯ããããã転移æå¶éºäŒåãšããŠäœçšããããšã瀺åããŠããããããã®äž»ãªæ©èœã¯ãïŒã®çš®ã
ã®æåãå解ããïœïŒïŒïŒïŒçµåã®ãšã³ããããããŒãŒã§ãããããªã¯ã¹ã¡ã¿ããããã€ããŒãŒïŒïŒïŒïŒ°ïŒãé»å®³ããããšã§ãããïŒïŒïŒ°ã¯ãæ£åžžã®åã³ç
çãªçµç¹ãªã¢ããšãªã³ã°éçšãåµå·æ²»çãè¡ç®¡åœ¢æåã³è
«ç䟵襲ã«é¢ä¿ãããšæãããé
µçŽ ã§ããã
ãããªã¯ã¹ã¡ã¿ããããã€ããŒãŒé»å®³å€ã®äŸã«ã¯ãïŒïŒ°âïŒãæããããã
ããã©ãµã€ã¯ãªã³ïŒããã©ãµã€ã¯ãªã³ã¯ãå€ç°åŒããã¿ã»ã³ã«ã«ããã·ã¢ããã®è¿ãé¡çžéºäŒåç³»ã®èªå°äœã§ãããããã©ãµã€ã¯ãªã³ã¯ãã°ã©ã éœæ§åã³ã°ã©ã é°æ§ã®çŽ°èã«å¯Ÿããåºç¯å²ã®æè掻æ§ãæã€ãè©Šéšç®¡å
ã§ã¯ããããã®è¬å€ã¯ãäž»ãšããŠéèçã§ãããããã©ãµã€ã¯ãªã³åã³éæèçã«æ¹å€ããé¡çžäœã¯ãã³ã©ãŒã²ã³ã®ç Žå£ãçãããããªã¯ã¹ã¡ã¿ããããã€ããŒãŒã®æŽ»æ§ãé»å®³ããããšã«ãã宿䞻ã®å¿çã調ç¯ãããšæãããç¹æ§ãæããããããã¯ãŸããç ŽéªšçŽ°èã®æ©èœãé»å®³ãã骚èœçŽ°èã®éªšåœ¢æãåºæ¿ããè管圢æã調ç¯ããã
ããã©ãµã€ã¯ãªã³ã®äŸã«ã¯ãããã©ãµã€ã¯ãªã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒâïŒïŒâïŒïŒïŒãããµã€ã¯ãªã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒåã³ããã·ãµã€ã¯ãªã³ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ã¢ã³ã®ãªãã³ã·ã³å€æé
µçŽ ïŒïŒ¡ïŒ£ïŒ¥ïŒé»å®³å€ïŒïŒ¡ïŒ£ïŒ¥é»å®³å€ã¯ãåºæ¬çã«ã¬ãã³âã¢ã³ã®ãªãã³ã·ã³è¡ç®¡å瞮系ã®é»å®³å€ãšããŠäœçšããé«è¡å§åã³é¬±è¡æ§å¿äžå
šãæ²»çããã®ã«äœ¿çšãããããããã¯ãŸããã€ã³ã¿ãŒãã€ãã³âïŒã®ãããªççèªçºæ§ã¡ãã£ãšãŒã¿ãäœäžãããã€ã³ã¿ãŒãã€ãã³âïŒïŒã®ãããªæççæ§ãµã€ãã«ã€ã³ã®æ¿åºŠãé«ããããšã瀺ãããŠããã
ã¢ã³ã®ãªãã³ã·ã³å€æé
µçŽ é»å®³å€ã®äŸã«ã¯ãã«ããããªã«(ïŒïŒïŒïŒïŒâïŒïŒâ
ïŒïŒåã³ãã¬ã€ã³é žãšãã©ããªã«ïŒããšãã°ïŒïŒ ïœïŒïœïŒã®ãããªãã®å¡©ãå«ããšãã©ããªã«ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ïŒïŒåã³ãã¬ã€ã³é žãšãã©ããªã«ïŒããšãã°ïŒïŒ ïœïŒïœïŒã®ãããªãã®å¡©ãå«ããšãã©ããªã«ïŒïŒ£ïŒ¡ïŒ³ïŒïŒïŒïŒïŒâïŒïŒâïŒïŒãæããããã
ãã®ä»
ç¹å®ã®ãã®ã»ãã®ææã®äœçšå€ã®äŸã«ã¯ãã¬ãã«ãããïŒã¢ã©ãïŒãæããããããã¯ãããã³ã³ããªã¢ã«ããããžãããâãªãããŒãããããã²ããŒãŒïŒïŒ€ïŒšïŒ¯âïŒãé»å®³ããããšã«ããããªããžã³ã®ä»£è¬ã劚害ããããã«ãã£ãŠïŒŽçŽ°èåã³ïŒ¢çŽ°èã®å¢æ®ãé»æ¢ããã€ãœããµãŸãŒã«å ç«ã¢ãžã¥ã¬ãŒã¿ã§ããïŒExpert Opin. Pharmacother., Jun, 4(6):987-97, 2003ïŒããã®ã»ãã®äŸã«ã¯ããšãªã¹ããã€ã·ã³ãããã¹ãã©ã³ç¡«é žãã¢ã«ã®ã³é žãããã¹ãããŒã¹ãããã¹ãã©ã³ïŒŽïŒïŒããã³ãã³ãã±ã«ã»ãã³äºæ°Žåç©ãã«ãã§ã€ã³ãγã«ã©ã®ãŒãã³ãλã«ã©ã®ãŒãã³ãããããã·ãããã«ã»ã«ããŒã¹ãã¹ã¿ããªãŒã¹ãã³ã³ããã€ãã³ç¡«é žïŒ¡ãæããããã
ç¹å®ã®ãã®ã»ãã®ææã®äœçšå€ã®äŸã«ã¯ãã¬ãã«ãããïŒã¢ã©ãïŒãæããããããã¯ãããã³ã³ããªã¢ã«ããããžãããâãªãããŒãããããã²ããŒãŒïŒïŒ€ïŒšïŒ¯âïŒãé»å®³ããããšã«ããããªããžã³ã®ä»£è¬ã劚害ããããã«ãã£ãŠïŒŽçŽ°èåã³ïŒ¢çŽ°èã®å¢æ®ãé»æ¢ããã€ãœããµãŸãŒã«å ç«ã¢ãžã¥ã¬ãŒã¿ã§ããïŒExpert Opin. Pharmacother., Jun, 4(6):987-97, 2003ïŒããã®ã»ãã®äŸã«ã¯ããšãªã¹ããã€ã·ã³ãããã¹ãã©ã³ç¡«é žãã¢ã«ã®ã³é žãããã¹ãããŒã¹ãããã¹ãã©ã³ïŒŽïŒïŒããã³ãã³ãã±ã«ã»ãã³äºæ°Žåç©ãã«ãã§ã€ã³ãγã«ã©ã®ãŒãã³ãλã«ã©ã®ãŒãã³ãããããã·ãããã«ã»ã«ããŒã¹ãã¹ã¿ããªãŒã¹ãã³ã³ããã€ãã³ç¡«é žïŒ¡ãæããããã
ãã«ã³
ãã«ã³ïŒãã³ã€ãã³ãå«ãïŒã¯ãè€è²æµ·èããæœåºãããé«ååéã®ç¡«é žåå€ç³é¡ã§ããïŒPercival E. & McDowell R. H., æµ·æŽè»é¡ã®å€ç³é¡ã®ååŠåã³é µçŽ åŠãïŒïŒïŒãïŒïŒ
ïŒããŒãžãAcademic Press, New York, 1967ïŒãåšç¥ã®ããã«ãåæ§ã«ãã®ã»ãã®åºå žãVasseur E., 玫ãŠãåµã®ãŒãªãŒè¢«èã®ååŠçç 究ãActa Chem. Scand., 2:900-913, 1948; Muorao, PAS & Bastos IG, ããã³ã®é žæ§åºŠã®é«ãã°ãªã«ã³ãEur. J. Biochem., 166:6
39-645, 1987; Pereira et al., ç¡«é žåãã«ã³ã®æ§é åã³æååºãJ. Biol. Chem., 274:12. 7656-7667, 1999ã«èŠãåºãããšãã§ããããã³ã€ãã³ïŒåã¯ãã³ã€ãžã³ïŒã¯ãè€è²
æµ·èã«ç±æ¥ãããã«ã³ãæããç±³åœç¹èš±ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒããã«ã³ã¯ãåç¬ã§ããããããåã¯æ··åç©ãããšãã°ããã·ããŒã¹ãã¬ã©ã¯ããŒã¹ãã°ã«ã³ãŒã¹åã³ïŒåã¯ãã³ããŒã¹ã®ãããªç³ã®æ··åç©ã§ããããããããã®ç³ã¯ãæµ·æŽè»é¡ã«å«æãããããšãç¥ãããŠããããã«ã³ãšãšãã«æœåºãããŠããããDuarte, Maria ER, Cardoso, Marc A, Noseda, Miguel D., Cerezo, Alberto S., ãã¯ã«ã¡ãïœïœïœïœïœïœïœïœ ïœïœïœ ïœïœïœïœïœïœïœïœïœã®ãã³ã€ãã³ã«ãããæ§é çç 究ããCarbohydrate Research 333:281-293, 2001ã
ãã«ã³ïŒãã³ã€ãã³ãå«ãïŒã¯ãè€è²æµ·èããæœåºãããé«ååéã®ç¡«é žåå€ç³é¡ã§ããïŒPercival E. & McDowell R. H., æµ·æŽè»é¡ã®å€ç³é¡ã®ååŠåã³é µçŽ åŠãïŒïŒïŒãïŒïŒ
ïŒããŒãžãAcademic Press, New York, 1967ïŒãåšç¥ã®ããã«ãåæ§ã«ãã®ã»ãã®åºå žãVasseur E., 玫ãŠãåµã®ãŒãªãŒè¢«èã®ååŠçç 究ãActa Chem. Scand., 2:900-913, 1948; Muorao, PAS & Bastos IG, ããã³ã®é žæ§åºŠã®é«ãã°ãªã«ã³ãEur. J. Biochem., 166:6
39-645, 1987; Pereira et al., ç¡«é žåãã«ã³ã®æ§é åã³æååºãJ. Biol. Chem., 274:12. 7656-7667, 1999ã«èŠãåºãããšãã§ããããã³ã€ãã³ïŒåã¯ãã³ã€ãžã³ïŒã¯ãè€è²
æµ·èã«ç±æ¥ãããã«ã³ãæããç±³åœç¹èš±ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒããã«ã³ã¯ãåç¬ã§ããããããåã¯æ··åç©ãããšãã°ããã·ããŒã¹ãã¬ã©ã¯ããŒã¹ãã°ã«ã³ãŒã¹åã³ïŒåã¯ãã³ããŒã¹ã®ãããªç³ã®æ··åç©ã§ããããããããã®ç³ã¯ãæµ·æŽè»é¡ã«å«æãããããšãç¥ãããŠããããã«ã³ãšãšãã«æœåºãããŠããããDuarte, Maria ER, Cardoso, Marc A, Noseda, Miguel D., Cerezo, Alberto S., ãã¯ã«ã¡ãïœïœïœïœïœïœïœïœ ïœïœïœ ïœïœïœïœïœïœïœïœïœã®ãã³ã€ãã³ã«ãããæ§é çç 究ããCarbohydrate Research 333:281-293, 2001ã
ãããã®ååç©ã¯å ±åã«ããã°ãæè¡æ ãæå¢æ®ãæè£äœãæçãåã³æ奜äžç移åã®å¹æãå«ãçäœå
åã³è©Šéšç®¡å
ã§ã®è€æ°ã®é»å®³äœçšãæããããã«ã³ã¯ãã€ã³ãã°ãªã³âã»ã¬ã¯ãã³ååãä»ãã现èâ现èã®çµåãå«ã现èè¡šé¢ã«ãŠãè¡äžã®ããã³ãã³åã¯è£äœæãã¯çŽ°èè¡šé¢ã®ãã³ãŒã¹å容äœãçµåããããšã«ããã现èè¡šé¢ã§ã®çš®ã
ã®çµåäºè±¡ãé»æ¢ããŠãããã
ãã®ãããªæŽ»æ§ã¯ããããã®çŽ°èã®çµç¹ãžã®äŸµè¥²ãããã«ç¶ãççã劚ããŠããããïŒããšãã°)è¡ç®¡å
ç®çŽ°èãžã®ãªã³ãçåã¯å¥œäžçã®çµåã®é»å®³ãä»ããæççç¹æ§ã«é¢äž
ãããšèããããŠããïŒPatankar, MS et al., J. Biol. Chem., 268:21770-21778, 1993; Brandley BK et al., J. Cell Biol., 105:991-997, 1987ïŒãæè¿ã®ç 究ããŸãããã«ã³ãè¡ç®¡å¹³æ»ç现èã®å¢æ®ãé»å®³ããããšã瀺ããŠãããšããããšã¯ïŒLogeart D. et al., Eur. J. Cell Biol., 74:376-384 & 385-390, 1997ïŒããããååç©ã®åççªæå¶èœ
ã®å¯èœæ§ã瀺ããŠããïŒãã決å®ã§ã¯ãªãïŒããã«ã³ã¯ãå ç®çŽ°èåã³å¹³æ»ç现èã®åæ¹ã®è¡šé¢ã«çµåããåŸããã£ãããšçŽ°èå ã«åã蟌ãŸããããšã瀺ãããŠããïŒGiabe CG et al., J. Cell Science 61:475-490, 1983; Logeart D. et al., Eur. J. Cell Biol., 74:375-384, 1997ïŒã
ãããšèããããŠããïŒPatankar, MS et al., J. Biol. Chem., 268:21770-21778, 1993; Brandley BK et al., J. Cell Biol., 105:991-997, 1987ïŒãæè¿ã®ç 究ããŸãããã«ã³ãè¡ç®¡å¹³æ»ç现èã®å¢æ®ãé»å®³ããããšã瀺ããŠãããšããããšã¯ïŒLogeart D. et al., Eur. J. Cell Biol., 74:376-384 & 385-390, 1997ïŒããããååç©ã®åççªæå¶èœ
ã®å¯èœæ§ã瀺ããŠããïŒãã決å®ã§ã¯ãªãïŒããã«ã³ã¯ãå ç®çŽ°èåã³å¹³æ»ç现èã®åæ¹ã®è¡šé¢ã«çµåããåŸããã£ãããšçŽ°èå ã«åã蟌ãŸããããšã瀺ãããŠããïŒGiabe CG et al., J. Cell Science 61:475-490, 1983; Logeart D. et al., Eur. J. Cell Biol., 74:375-384, 1997ïŒã
æ¥æ¬ã§ã¯ãçš®ã
ã®æµ·èããæœåºããããã³ã€ãã³ãå¥åº·é£åãšããŠè²©å£²ãããŠããïŒRiou, D. et al., Anticancer Res., 16(3A):1213-1218, 1996; Itoh, H., Anticancer res., 13(6A):2045-2052, 1983; NishinoT., et al., Thromb. Res., 82: 765-773, 1991; Blondin C. et al., Mol. Immunol., 31:247-253, 1994; Patanker MS et al., J. Biol. Chem., 268:21770-21776, 1993ïŒããã³ã€ãã³ã¯å粧ååã¯ç®èå€ãšããŠææ¡ãããŠãããïŒïŒïŒïŒïŒïŒïŒïŒåã³ïŒªïŒ°ïŒïŒïŒïŒïŒïŒïŒïŒããã³ã€ãã³ã¯åŒ·åãªæçå€ãšããŠå ±åãããŠããïŒRiou D. Anticancer Res., 16 3a:1213-18, 1996; Itoh H. et al., Anticancer Res., 15 5b:1937-47, 1995ïŒããã³ã€ãã³ã¯ãè©Šéšç®¡å
ã§è¡ç®¡åœ¢æãé»å®³ããããšãå ±åãããŠããïŒSoeda S. et al., Bichem. Biophys. Acta (1):127-134, 2000ïŒãåæ§ã«ããã³ã€ãã³ã¯ãè¡æž
ã§èªå°ããã现èã®ïŒè©Šéšç®¡å
ïŒå¢æ®ãåºæ¿ããããšãèŠãåºããããšããããšã¯ãè¡ç®¡åœ¢æèªçºå¹æã®å¯èœæ§ã瀺ããŠããïŒç·ç¶èœçŽ°èå¢æ®å åãååšããã°é»å®³ãå¯èœã§ãããïŒïŒGiraux J. et al., Eur. J. Cell Biol., 774:352-9, 1998ïŒãç 究ã¯ãŸãããã«ã³ãå
ç®çŽ°èã®åå±€çµåãé»å®³ããããšã瀺ããïŒGlabe CG, J. Cell Science, 61:475-490, 1983ïŒãæ¯çŽ°è¡ç®¡ãæ§æãã现èã¯å
ç®çŽ°èãªã®ã§ããã®å ±åã¯ãè©Šéšç®¡å
ã§çŽ°èæ¥çã®äžéšãé»å®³ãããŠãããããšã瀺ããŠãããããããã®ããŒã¿ã¯ãçäœå
ã§ã®ãã³ã€ãã³ã®è¡ç®¡åœ¢æå¹æãæããã«ã¯ããŠããªãããã³ã€ãã³ãè现èãžã®ããªã³ãã¯ã¿ãŒã®çµåãé»å®³ãããšå ±åããããšããããšã¯ãè朰çæå¶å¹æã瀺åããŠããïŒShibat HJ, Nutr. Sci. Vitaminol., 45:325-336, 1999ïŒã
çŽéãåæéåã³çŽéç¡«é
žåãã«ã³ãå«ããã®ã»ãã®ç¡«é
žåãã«ã³ã¯å·®åçãªæååºæŽ»æ§ãæããããšãå ±åãããŠããïŒPerelra MS., J. Biol. Chem., 12:7656-67, 1999ïŒ
ãããã¹ãã©ã³ç¡«é žåã³èªå°äœã¯ç现èã®å¢æ®ãé»å®³ããããšïŒBittoun P., Carbohydrate Res., (3-4):247-255, 1999ïŒåã³æååºå¹æãæããããšïŒMauray S., J. Biomat. Sci. Poly ed. 9:373-87, 1989ïŒãå ±åãããŠãããç¡«é žåå€ç³é¡ã¯ãããšãã°ãã«å¯ŸããŠäœ¿çšããããã®æãŠã€ã«ã¹å€ãšããŠææ¡ãããŠãããïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒªïŒ°ïŒïŒïŒïŒïŒïŒïŒïŒã
ãããã¹ãã©ã³ç¡«é žåã³èªå°äœã¯ç现èã®å¢æ®ãé»å®³ããããšïŒBittoun P., Carbohydrate Res., (3-4):247-255, 1999ïŒåã³æååºå¹æãæããããšïŒMauray S., J. Biomat. Sci. Poly ed. 9:373-87, 1989ïŒãå ±åãããŠãããç¡«é žåå€ç³é¡ã¯ãããšãã°ãã«å¯ŸããŠäœ¿çšããããã®æãŠã€ã«ã¹å€ãšããŠææ¡ãããŠãããïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒªïŒ°ïŒïŒïŒïŒïŒïŒïŒïŒã
ãã³ã€ãã³ã®ãããªãã«ã³ã¯ãïœïœ
ïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïœïœïœãïœïœïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœãïœïœïœïœïœ ïœïœïœïœïœãïœïœïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïœïœãïœïœïœïœïœïœ
ïœïœïœ ïœïœïœïœ
ïœ ïœïœïœïœïœïœãïœïœïœïœïœïœïœ ïœïœïœïœïœïœ
ãïœïœïœïœ ïœ
ïœïœïœïœ
ïœïœïœ
ïœïœãïœïœïœïœ ïœïœ
ïœïœïœïœïœïœïœïœïœãïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïœ
ãïœïœ
ïœïœïœïœïœïœïœ
ïœïœïœ ïœïœïœïœïœïœïœïœïœïœïœãïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœ
ïœïœïœïœãïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïœïœïœ
ïœãïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïŒäžè¬ã«ã³ã³ããšåŒã°ããïŒãïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïœïœãïœ
ïœïœïœ
ïœïœïœ ïœïœïœïœïœïœïœïœïœïœãïœïœïœïœïœïœïœïœ ïœïœïœ
ïœïœïœïœïœïœïœïœãïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœ
ïœïœïœïœåã³ïŒµïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïœïœïœãå«ããããããã«éå®ãããªãè€è²è»é¡ã®æ§ã
ãªçš®ããåŸãããšãã§ããããããã®çš®ã¯ãã¹ãŠåé¡åŠäžã«éšé¡ãïœïœïœ
ïœïœïœïœïœïœ
ïœïœ
ã«ç±æ¥ãããããã®çš®ã®å€§åã¯ãïœïœïœïœïœ
ïœç§åã³ïŒ¬ïœïœïœïœïœïœïœïœïœïœ
ïœïœ
ç§ã«åé¡ãããã
æ¬çºæã«å¥œé©ãªãã«ã³ã¯ãäžã«åèšãããèµ·æºãåæ§ã«åé¡äžïŒŠïœïœïœïœïœ
ïœç§åã³ïŒ¬ïœïœïœïœïœïœïœïœïœïœ
ïœïœ
ç§ã«ãããè¿œå ã®èµ·æºãåã¯ææã®ãã®ã»ãã®èµ·æºããåŸããããã®ã§ãããããã«ãæµ·æŽè»é¡åã³æµ·èããã®ãã«ã³ã®ãã¹ãŠã®èµ·æºãæ¬çºæã«å«ãŸããã
ãã£ã«ã
æ¬æ现æžã§èå¯ãããäœçšå€ã¯ãç·ç¶æ§ççã®æ²»çã®ããã«ãããå«ãåç©ã«çŽæ¥é©çšããã®ã«å¥œé©ãªãã£ã«ã ãšããŠè£œå€åããããšãã§ããããã£ã«ã ã®ææã®ç¹æ§ã«ã¯ãèããæè»ã§ãåãæ±ãããšãã§ããçµç¹ã«è²Œãããšãã§ããããšãæãããããæ¬æ现æžã§èå¯ãããåäœçšå€ãããªããŒã«çµã¿å ¥ããŠãã£ã«ã ãåµè£œããããšãã§ããã奜é©ãªè³Šåœ¢å€ã®æ·»å ã«ãã£ãŠããªããŒãã£ã«ã 補å€ã®ç¹æ§ãé«ããããšãã§ãããå®æœæ æ§ã®ïŒã€ã§ã¯ãäœçšå€ããã¢ã«ãã³é žããªããŒãšçµã¿åãããŠãã£ã«ã ãäœè£œããããšãã§ãããæ·»å ã§ãã賊圢å€ã«ã¯ãïŒâãšãã«âïŒâïŒâïŒãžã¡ãã«ã¢ããïŒãããã«ïŒœã«ã«ããžã€ããïŒïŒ¥ïŒ€ïŒ¡ïŒ£ïŒåã³ã°ãªã»ããŒã«ãæããããã
æ¬æ现æžã§èå¯ãããäœçšå€ã¯ãç·ç¶æ§ççã®æ²»çã®ããã«ãããå«ãåç©ã«çŽæ¥é©çšããã®ã«å¥œé©ãªãã£ã«ã ãšããŠè£œå€åããããšãã§ããããã£ã«ã ã®ææã®ç¹æ§ã«ã¯ãèããæè»ã§ãåãæ±ãããšãã§ããçµç¹ã«è²Œãããšãã§ããããšãæãããããæ¬æ现æžã§èå¯ãããåäœçšå€ãããªããŒã«çµã¿å ¥ããŠãã£ã«ã ãåµè£œããããšãã§ããã奜é©ãªè³Šåœ¢å€ã®æ·»å ã«ãã£ãŠããªããŒãã£ã«ã 補å€ã®ç¹æ§ãé«ããããšãã§ãããå®æœæ æ§ã®ïŒã€ã§ã¯ãäœçšå€ããã¢ã«ãã³é žããªããŒãšçµã¿åãããŠãã£ã«ã ãäœè£œããããšãã§ãããæ·»å ã§ãã賊圢å€ã«ã¯ãïŒâãšãã«âïŒâïŒâïŒãžã¡ãã«ã¢ããïŒãããã«ïŒœã«ã«ããžã€ããïŒïŒ¥ïŒ€ïŒ¡ïŒ£ïŒåã³ã°ãªã»ããŒã«ãæããããã
æ¬çºæã®å®æœæ
æ§ã¯ãïŒïŒïŒïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®è¬å€ïŒäœçšå€ïŒãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒã®å®æœæ
æ§ã¯ãïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒã®å®æœæ
æ§ã¯ãïŒïŒïŒïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒã®å®æœæ
æ§ã¯ãïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒã®å®æœæ
æ§ã¯ãïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒã®å®æœæ
æ§ã¯ãïŒïŒïŒïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒã®å®æœæ
æ§ã¯ãïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒã®å®æœæ
æ§ã¯ãïŒïŒïŒïŒïŒïŒ
ãïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒã®å®æœæ
æ§ã¯ãïŒïŒ
ãïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ããã第ïŒïŒã®å®æœæ
æ§ã¯ãïŒïŒ
ãïŒïŒ
ïœïŒïœã®ãåã¯æ¬æ现æžã§èå¯ããããã®ã»ãã®æ¿åºŠã®è¬å€ãè² è·ãããã£ã«ã ã補é ããããã®äœçšå€ã®çµã¿èŸŒã¿ã§ãããå®æœæ
æ§ã®ïŒã€ã¯ãäœçšå€ã®çµã¿èŸŒã¿ãå«ã¿ããã¢ã«ãã³é
žãïŒïŒ
ïœïŒïœã®è¬å€ãè² è·ãããã£ã«ã ãããããããã£ã«ã ã®æ®ãã®éšåã¯ããããïŒïŒïŒïŒïŒïŒïŒã®æ¯çã§ããã¢ã«ãã³é
žãã°ãªã»ããŒã«åã³ïŒ¥ïŒ€ïŒ¡ïŒ£ã§æ§æãããã
ã²ã«
æ¬æ现æžã§èå¯ãããåäœçšå€ã¯ãæ¬æ现æžã§ã²ã«ãšåŒã°ããç²æ§æº¶æ¶²ã«çµã¿å ¥ããããšãã§ããããã®ã²ã«ã¯ããããå«ãåç©ã®äœè ã«æäžããããšãã§ããç·ç¶æ§ççã®åœ¢æã®æå¶åã³äºé²ã«æå¹ã§ããã
æ¬æ现æžã§èå¯ãããåäœçšå€ã¯ãæ¬æ现æžã§ã²ã«ãšåŒã°ããç²æ§æº¶æ¶²ã«çµã¿å ¥ããããšãã§ããããã®ã²ã«ã¯ããããå«ãåç©ã®äœè ã«æäžããããšãã§ããç·ç¶æ§ççã®åœ¢æã®æå¶åã³äºé²ã«æå¹ã§ããã
ã²ã«ã®ææã®ç¹æ§ã«ã¯ãç¹å®ã®äœçœ®ã«é©çšãããã®ã«è²Œã£ããŸãŸã«ããŠããã®ã«ååã«ç²æ§ã§ãããåŸã£ãŠããèªäœã®ééã§æµããã泚å°åšã®äœ¿çšåã¯éãä»ãã泚å
¥ã«ãã£ãŠå¥œãŸããäœçœ®ã«æäžã§ããããšãæãããããæ¬çºæã®å®æœæ
æ§ã®ïŒã€ã§ã¯ãç²æ§ã®æ¶²äœã¯ãïŒïŒïŒïŒ
ã®ãã¢ã«ãã³é
žæº¶æ¶²ãçšããŠäœè£œããããæ¬æ现æžã§èå¯ãããäœçšå€ãçµã¿èŸŒãã§ïŒïŒïŒïŒïŒïŒ
ãïŒïŒ
ïœïŒïœã®ã²ã«ãåŸãããšãã§ãããäœçšå€ãå ããŠïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®ã²ã«ã補é ããŠããããäœçšå€ãè² è·ããŠãïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®ãåã¯æ¬æ现æžã§èå¯ããããã®ã»ãã®æ¿åºŠã®ã²ã«ã補é ããŠãããã
ç¹æ»Žçšå€
æ¬æ现æžã§èå¯ãããåäœçšå€ã液äœã«æº¶è§£åã¯æžæ¿ããããããããå«ãåç©ã®äœè ã«æäžããããšãã§ããå¢å€§ããå¢æ®ãå«ãç·ç¶æ§ççã®åœ¢æãæå¶ãããæ²»çãããäºé²ããçã«äœ¿çšããããšãã§ããããããã®è£œå€ãæ¬æ现æžã§ã¯ç¹æ»Žçšå€è£œå€ãšåŒã¶ããããã®è£œå€ããããšãã°ãæè¡åŸã®æ£è ã®è ¹è å ã«æäžããŠè¡åŸççãé²ãããšãã§ããåã¯ãã®ã»ãã®ææã®å·ãç å€çã®éšäœã®äžïŒäžã«æäžããããšãã§ããããã®æ¶²äœã¯æº¶åªã§ããããšãã§ããç¶ããŠäœçšå€ã®æº¶æ¶²ã補é ããããšãã§ãããããã«ãäœçšå€ã溶解ããã®ã«äœ¿çšããã溶åªã¯æ°Žç³»ã§ãã£ãŠããããé»è§£æº¶æ¶²ãžã®äœçšå€ã®æº¶è§£ãç¹æ»Žçšå€è£œå€ãäœè£œããã次ãã§ãç·ç¶æ§ççã®åœ¢æãé²ã奜é©ãªäœè ã«ç¹æ»Žçšå€ãæäžããã
æ¬æ现æžã§èå¯ãããåäœçšå€ã液äœã«æº¶è§£åã¯æžæ¿ããããããããå«ãåç©ã®äœè ã«æäžããããšãã§ããå¢å€§ããå¢æ®ãå«ãç·ç¶æ§ççã®åœ¢æãæå¶ãããæ²»çãããäºé²ããçã«äœ¿çšããããšãã§ããããããã®è£œå€ãæ¬æ现æžã§ã¯ç¹æ»Žçšå€è£œå€ãšåŒã¶ããããã®è£œå€ããããšãã°ãæè¡åŸã®æ£è ã®è ¹è å ã«æäžããŠè¡åŸççãé²ãããšãã§ããåã¯ãã®ã»ãã®ææã®å·ãç å€çã®éšäœã®äžïŒäžã«æäžããããšãã§ããããã®æ¶²äœã¯æº¶åªã§ããããšãã§ããç¶ããŠäœçšå€ã®æº¶æ¶²ã補é ããããšãã§ãããããã«ãäœçšå€ã溶解ããã®ã«äœ¿çšããã溶åªã¯æ°Žç³»ã§ãã£ãŠããããé»è§£æº¶æ¶²ãžã®äœçšå€ã®æº¶è§£ãç¹æ»Žçšå€è£œå€ãäœè£œããã次ãã§ãç·ç¶æ§ççã®åœ¢æãé²ã奜é©ãªäœè ã«ç¹æ»Žçšå€ãæäžããã
å®æœæ
æ§ã®äžéšã§ã¯ãç¹æ»Žçšå€æº¶æ¶²ã¯ãããšãã°ããããå°å
¥ãããç¹å®ã®äœè
ã®å®è³ªçã«ãã¹ãŠã®é åã«éããããšãå¯èœã§ããæ°Žã«å®è³ªçã«é¡äŒŒããç²æ§ãæãããå®è³ªçã«éç²æ§ã®æ¶²äœã§ãããææã®æ··åç©ã¯ãæ¬æ现æžã§èå¯ãããå°ãªããšãïŒçš®ã®äœçšå€ã液äœã«çµã¿å
¥ããŠãçŽïŒïŒïŒïŒïŒïŒïœïŒïœïŒ
ãïŒïŒ
ïœïŒïœã®éãïŒïœïŒïœïŒ
ãïŒïŒ
ïœïŒïœã®éãïŒïœïŒïœïŒ
ãïŒïŒ
ïœïŒïœã®éãïŒïœïŒïœïŒ
ãïŒïŒïŒ
ïœïŒïœã®éãïŒïŒïœïŒïœïŒ
ãïŒïŒïŒ
ïœïŒïœã®éãïŒïŒïœïŒïœïŒ
ãïŒïŒïŒ
ïœïŒïœã®éã®æ¿åºŠåã¯æ¬æ现æžã§èå¯ããããã®ã»ãã®æ¿åºŠã«ãŠæº¶æ¶²ïŒåã¯æžæ¿æ¶²çïŒã補é ããŠãããã
åèšãããåäœçšå€ã¯ãæããã«ç€ºãããªãéããäŸå€ãªããäœçšå€äžŠã³ã«ã³ãã®èªå°äœãå¡©åã³é¡çžäœãã¹ãŠãå
å«ãããããšãã°ããã³ãã¯é
žãã¯ãã³ãã¯é
žãã¹ã¯ã·ããŒã䞊ã³ã«ãããã®å¡©åã³é¡çžäœãã¹ãŠãå
å«ãããç·ç¶æ§ççãäºé²ããããã«æ§ã
ãªè£œå€ã§äœçšå€ãæäžããããšãã§ãããæ¬æ现æžã§èå¯ããã補å€ãæ¹æ³ãç³»çã¯ãæ¬æ现æžã§èå¯ãããåäœçšå€ãå«ã補å€ã補å€ãåç¬ã§äœ¿çšãããããšããã³ã€ãã³ïŒåã¯ãã®ã»ãã®ãã«ã³ïŒãšã®äœµçšãåã¯æ¬æ现æžã§èå¯ããããã®ã»ãã®äœçšå€ãšã®äœµçšã§äœ¿çšãããããšããã®ã»ãã®äœçšå€ãè£
眮ãåã¯ãã³ã€ãã³ãå«ãè¬å€ãšã®çµã¿åãããåã³æ¬æ现æžã§èå¯ãããäœçšå€åã³ãã®ã»ãã®äœçšå€ãå
å«ããããã«ç解ãããã¹ãã§ããã
æããã«è¿°ã¹ãããªãéããåã¯èæ¯ããæããã§ãªãéããå®æœæ
æ§ãåŽé¢ãç¹åŸŽçã¯ãã¹ãŠãææã®æ§åŒã«ãŠæ··åãããäžèŽãããããçµã¿åãããããé åºãå€ããããããç¹ã«æ瀺ãããªãéããã¯ã¬ãŒã ãé€ããŠããåã¯ãã®äœ¿çšã¯ããåã³ããå
å«ããéããŸãåæ§ã§ãããæããã«è¿°ã¹ãããªãéããåã¯èæ¯ãæããã«ç€ºããªãããããééå®ççšèªã¯éå®ãšããŠè§£éãããã¹ãã§ã¯ãªãïŒããšãã°ããå
å«ãããããæãããåã³ãå«ããã¯ããéå®ãªãå
å«ãããããšãæãïŒãã¯ã¬ãŒã ãå«ããŠããïœãããïœïœãåã³ãïœïœïœ
ãã®ãããªåäžåœ¢æ
ã¯ãæããã«è¿°ã¹ãããªãéããåã¯èæ¯ãæããã«ç€ºããªãããããè€æ°ã®åç
§ãå
å«ããã
æâïŒå€
ã±ã¢ã«ã€ã³ã¯ãççéçšã®éãçœè¡çã®ç§»åã掻æ§ååã³èµ°åæ§ã®äž»ãªèª¿ç¯å€ãšããŠæ©èœããäœååéïŒïŒãïŒïŒïœïœïŒã®æ§é çã«é¡äŒŒããã¿ã³ãã¯è³ªã®å€§ããªãã¡ããªãŒãæ§æããïŒæŠèª¬ã«ã¯ãRollins BJ., Blood 90:909-928, 1997ãåç §ã®ããšïŒãä»æ¥ãŸã§ã
ã®ãµã€ãã«ã€ã³ã¹ãŒããŒãã¡ããªãŒã®ïŒïŒãè¶ ããã¡ã³ããŒãåå®ãããŠãããå¿ é ã®ãžã¹ã«ãã£ãçµåã圢æãã2âæ«ç«¯ã®ã·ã¹ãã€ã³ã®äœçœ®ã«åºã¥ããŠïŒã€ã®äºçŸ€ãã
ãåã³ïŒ£ïŒžïŒïŒ£ã«å€§å¥ãããã
ã±ã¢ã«ã€ã³ã¯ãççéçšã®éãçœè¡çã®ç§»åã掻æ§ååã³èµ°åæ§ã®äž»ãªèª¿ç¯å€ãšããŠæ©èœããäœååéïŒïŒãïŒïŒïœïœïŒã®æ§é çã«é¡äŒŒããã¿ã³ãã¯è³ªã®å€§ããªãã¡ããªãŒãæ§æããïŒæŠèª¬ã«ã¯ãRollins BJ., Blood 90:909-928, 1997ãåç §ã®ããšïŒãä»æ¥ãŸã§ã
ã®ãµã€ãã«ã€ã³ã¹ãŒããŒãã¡ããªãŒã®ïŒïŒãè¶ ããã¡ã³ããŒãåå®ãããŠãããå¿ é ã®ãžã¹ã«ãã£ãçµåã圢æãã2âæ«ç«¯ã®ã·ã¹ãã€ã³ã®äœçœ®ã«åºã¥ããŠïŒã€ã®äºçŸ€ãã
ãåã³ïŒ£ïŒžïŒïŒ£ã«å€§å¥ãããã
ã¹ãããŒã现èç±æ¥å åïŒïŒ³ïŒ€ïŒŠâïŒïŒã¯ïŒ£ïŒžïŒ£ã±ã¢ã«ã€ã³ã§ãããïŒã€ã®åœ¢æ
ã®ïŒ³ïŒ€ïŒŠâïŒãâïŒÎ±åã³Î²ïŒæ¬æ现æžã§ã¯äžç·ã«ïŒ³ïŒ€ïŒŠâïŒãšåŒã¶ïŒãåå®ãããŠãããéžæçã¹ãã©ã€ã·ã³ã°ã«ãã£ãŠïŒ³ïŒ€ïŒŠéºäŒåã«ç±æ¥ãããåæ¹ã®åœ¢æ
ãã³ãŒãããã²ãã é
åã¯æ±ºå®ãããŠããïŒç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·åã³ç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãåç
§ã®ããšïŒãâïŒã¯ã骚é«ãèžè
ºãèŸèãå¿èãèºãçèãè
èåã³èèãå«ãå€æ°ã®çµç¹ã§æ§æçã«ç£çãããŠããããã®ããšã¯ãççèªçºæ§ãµã€ãã«ã€ã³ã«ãã£ãŠãã®çºçŸãé«åºŠã«èª¿ç¯ãããŠãããã®ã»ãã®å€æ°ã®ã±ã¢ã«ã€ã³ãšã¯å¯Ÿç
§çã§ãããâïŒããããšãã°ãçœè¡çåã³é è¡å¹¹çŽ°èã®èŒžéïŒNakasawa T. et al., Proc. natl. acad. Sci. USA, 91:2305-2309, 1994; McGrath KE. et al., Dev. Biol., 213:442-456, 1999; Tashiro K. et al., Science 261:600-603, 1993ïŒããªã³ãèœçãè圢
æäžã®éªšé«åœ¢æã®ç¢ºç«ãç¥çµåœ¢æãå¿è圢æåã³è¡ç®¡åœ¢æïŒAluti A. et al., Eur. J. Immunol., 29:1823-1831, 1999; Zou YR. et al., Nature 393:595-599, 1998; Tachibana K. et al., Nature 393:591-594, 1998ïŒãå«ãå®åžžç¶æ ã®æåžžæ§éçšã§åœ¹å²ãæ ã£ãŠãããšããèããå°ããã
æäžã®éªšé«åœ¢æã®ç¢ºç«ãç¥çµåœ¢æãå¿è圢æåã³è¡ç®¡åœ¢æïŒAluti A. et al., Eur. J. Immunol., 29:1823-1831, 1999; Zou YR. et al., Nature 393:595-599, 1998; Tachibana K. et al., Nature 393:591-594, 1998ïŒãå«ãå®åžžç¶æ ã®æåžžæ§éçšã§åœ¹å²ãæ ã£ãŠãããšããèããå°ããã
ã»ãã®ã±ã¢ã«ã€ã³åã¯ã±ã¢ã«ã€ã³å容äœãéºäŒçã«æ¬ æãããŠäœåºãããããã¯ã¢ãŠããããŠã¹ã¯ãçåå¯èœã§ãããæçãªæ··ä¹±ã¯ç€ºããªãäžæ¹ã§ãâïŒã®éºäŒçæ¬ æã¯åå®®å
ã§èŽæ»ã§ãããèå
ã¯å€æ°ã®ç°åžžã瀺ããããã«ã¯ãé è¡ç³»ã埪ç°åšç³»ãæ¶ååšç³»åã³ç¥çµç³»ã«ãããæ¬ é¥ã䞊ã³ã«ïŒ¢ãªã³ãç圢æåã³éªšé«åœ¢æã«ãããæ¬ é¥ãå«ãŸããïŒNagasawa T. et al., Nature 382:653-658, 1996; Ma Q. et al., Proc. Natl. Acad. Sci. USA 95:9448-9453, 1998; Bleul C. et al., Nature 382:829, 1998; Oberiln E. et al., Nature 382:833, 1996ïŒãâïŒã¯ãåã³ïŒ¢ãªã³ãçã奜äžçãåçåã³é¡
ç²çãå«ãå€ãã®çš®é¡ã®çŽ°èã®ããã®ã±ã¢ã«ã€ã³ã§ããïŒBleul C. et al., Nature 382:829, 1998; Oberiln E. et al., Nature 382:833, 1996ïŒã
ç²çãå«ãå€ãã®çš®é¡ã®çŽ°èã®ããã®ã±ã¢ã«ã€ã³ã§ããïŒBleul C. et al., Nature 382:829, 1998; Oberiln E. et al., Nature 382:833, 1996ïŒã
âïŒã¯ãä»ã®ïŒ£ïŒžïŒ£ã±ã¢ã«ã€ã³ãšã®éã§ãã£ãçŽïŒïŒïŒ
ã®ã¢ããé
žé
ååäžæ§ããæããªãããä»ã®çš®ãšã®é²åççžåæ§ãä¿æããŠãããšããç¹ã§ä»ã®ã±ã¢ã«ã€ã³ãšæ§é çã«ç°ãªããâïŒã¯ãåäžå容äœãïŒïŒä»¥åã¯ããïŒïŒ³ïŒŽïŒ¥ïŒ²åã¯ãã·ã³ãšåŒã°ããïŒã«å¯Ÿããæãããªç¹ç°æ§ïŒFedersopiel B. et al., Genomics 16:707-712, 1993; Loetscher M. et al., J. Biol. Chem., 269:232-237, 1994; Feng et al., Science 272:872-877, 1996ïŒåã³ã¯ããã«å¹
åºãäœçšç¯å²ã§ä»ã®å€æ°ã®ã±ã¢ã«ã€ã³ãšç°ãªããïŒã¯ã奜äžçããªã³ãçåã³åçïŒBieul et al., J. Exp. Med., 184:1101-1109, 1998; Foster R. et al., J. Immunol., 160:1522-1531, 1998ïŒãå·š
æ žçïŒWang JF. et al., Blood 92:756-764, 1998ïŒããã¯ãã°ãªã¢çŽ°èåã³æç¶çŽ°èïŒTanabe S. et al., J. Immunol., 159:905-911, 1997ïŒãåã³æš¹ç¶çŽ°è䞊ã³ã«æªçãªé è¡
ç³»åé§äœå¹¹çŽ°èïŒMohie R. et al., 91:4523-4530, 1998; Aluti et al., Eur. J. Immunol., 29:1823-1831, 1999ïŒã«çºçŸãããŠãããïŒã¯ãŸããå¿èãè³ãèŸèãè
èåã³çµè žãå«ãå€çš®å€æ§ãªãã®ã»ãã®èåšåã³çµç¹ã«ããã现èäžã§ãçºçŸãããŠããïŒFedersopiel B. et al., Genomics 16:707-712, 1993; Loetscher M. et al., J. Biol. Chem., 269:232-237, 1994; Tanabe et al., J. Immunol., 159:905-911, 1997; Zou YR. et al., Nature 393:595-599, 1998; Tachibana et al., Nature 393:591-594, 1998
ïŒã
æ žçïŒWang JF. et al., Blood 92:756-764, 1998ïŒããã¯ãã°ãªã¢çŽ°èåã³æç¶çŽ°èïŒTanabe S. et al., J. Immunol., 159:905-911, 1997ïŒãåã³æš¹ç¶çŽ°è䞊ã³ã«æªçãªé è¡
ç³»åé§äœå¹¹çŽ°èïŒMohie R. et al., 91:4523-4530, 1998; Aluti et al., Eur. J. Immunol., 29:1823-1831, 1999ïŒã«çºçŸãããŠãããïŒã¯ãŸããå¿èãè³ãèŸèãè
èåã³çµè žãå«ãå€çš®å€æ§ãªãã®ã»ãã®èåšåã³çµç¹ã«ããã现èäžã§ãçºçŸãããŠããïŒFedersopiel B. et al., Genomics 16:707-712, 1993; Loetscher M. et al., J. Biol. Chem., 269:232-237, 1994; Tanabe et al., J. Immunol., 159:905-911, 1997; Zou YR. et al., Nature 393:595-599, 1998; Tachibana et al., Nature 393:591-594, 1998
ïŒã
æ¬çºæã¯ãããšãã°ãâïŒã®å°ååé»å®³å€ã®ãããªæâïŒãç·ç¶æ§ççã®çºçãçãããéšäœã«ééããããšã«ãã£ãŠãè¡åŸç·ç¶æ§ççã®ãããªç·ç¶æ§ççãæ²»çãããäºé²ããåã³æå¶ããæ¹æ³ãå
å«ããããã®ãããªäœçšå€ã®ä»£è¡šäŸã«ã¯ãâïŒã®ïœïŒ²ïŒ®ïŒ¡ã®ç¿»èš³ãé»å®³ããæâïŒã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããïŒïŒ¡ïŒ³ïŒ¯ïŒãâïŒã®ïœïŒ²ïŒ®ïŒ¡ã®ç¿»èš³ãé»å®³ããæâïŒå°ååãâïŒã®ïœïŒ²ïŒ®ïŒ¡ã®è»¢åãé»å®³ããæâïŒïœïœïŒ²ïŒ®ïŒ¡ïŒïŒ²ïŒ®ïŒ¡ïœãâïŒã®ïœïŒ²ïŒ®ïŒ¡ãåæããæâïŒãªãã¶ã€ã ãâïŒã®æ©èœãé»å®³ããâïŒã®å°ååé»å®³å€ãæâïŒã¢ãã¿ããŒã®ãããªæâïŒçµåããŒãããŒåã³ïŒ³ïŒ€ïŒŠâïŒã®æ©èœãé»å®³ããæâïŒæäœãåã³æâïŒããªãã·ãªãªãŽãã¯ã¬ãªãããæããããã
æ¬çºæã®ç¹å®ã®å®æœæ
æ§ã®ç¯å²å
ã§ã¯ãæâïŒäœçšå€ã¯ãããªããŒæäžåœ¢æ
ããã®æ°æéããæ°æ¥ã«ãããå¶åŸ¡æŸåºãä»ããŠãå®è³ªçã«é£ç¶ããŠæšççµç¹ã«æŽé²ãããã
ç¹å®ã®å®æœæ
æ§ã®ç¯å²å
ã§ã¯ãæâïŒäœçšå€åã¯æ¬æ现æžã®ãã®ã»ãã®ç·ç¶æ§ççæå¶å€ãšå
±ã«äžããããååç©ã¯ãæ¬æ现æžã§èå¯ãããå°ãªããšãïŒçš®ã®ãã®ã»ãã®äœçšå€åã³ïŒåã¯ã«ã³ãããã·ã³ãã¡ããžãªã³è¥ããã¯ãšããã·ãã®ãããªããããããããã«éå®ãããªãããã€ãœã¡ã©ãŒãŒããããªã³è¥ããã¯ãžããªãã¢ãŒã«ã®ãããªããããããããã«éå®ãããªãæååºå€ãã©ã¶ãã€ãã®ãããªããããããããã«éå®ãããªãæé
žåå€ãã±ãããã§ã³ã®ãããªããããããããã«éå®ãããªãæãã¹ã¿ãã³å€ãã¬ããã€ãã®ãããªããããããããã«éå®ãããªãå¢æ®æå¶å€ããã£ããªããªã·ã³ãã¹ãã¬ãããããŒãŒåã³ãŠããããŒãŒã®ãããªããããããããã«éå®ãããªãç·ç¶å解å€ãçµæãçµç¹ãã©ã¹ãããŒã²ã³æŽ»æ§åå€ãã€ããããã§ã³ãã»ãã³ãã·ãã®ãããªããããããããã«éå®ãããªãéã¹ããã€ãç³»æççå€ãã©ããã€ã·ã³ã®ãããªããªãšã³ãã¯ãã©ã€ãæçç©è³ªã®ãããªããããããããã«éå®ãããªãå
ç«æå¶å€ãæãã¯ãã¯ãªã¿ãã»ã«è¥ããã¯ãã»ã¿ãã»ã«ã®ãããªããããããããã«éå®ãããªãã¿ããµã³ã§ãã£ãŠããããååç©ã¯ãŸããããšãã°ãå°ååéæ®æå€ãåã¯ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããïœïœïŒ²ïŒ®ïŒ¡ïŒïŒ²ïŒ®ïŒ¡ïœãâïŒãïŒïŒ£ïŒ°âïŒãâαãâïŒïŒã«å¯ŸããäžåæäœãαïŒÎ²ïŒåã¯Î±ïŒÎ²ïŒã®ãããªããããããããã«éå®ãããªãã€ã³ãã°ãªã³å容äœã®ãããªããããããããã«éå®ãããªããæ²»çäžæå¹éã®å¥ã®ã±ã¢ã«ã€ã³åã¯ãµã€ãã«ã€ã³ã®é»å®³å€ãå«ãããšãã§ãããâïŒã«å¯Ÿããäžåæäœã¯ç¥ãããŠãããåžè²©ãããŠãããæ²»çäžæå¹éã®ïŒ³ïŒ€ïŒŠâïŒé»å®³å€ãçµæç©ã®äžéšãšããŠééããããšãã§ããâïŒé»å®³å€ã¯ãçµæç©ã®çŽïŒïŒïŒïŒïŒïŒïŒ
ãïŒïŒïŒïŒïŒãïŒïŒïŒïŒãïŒïŒ
ïœïŒïœãåã¯ïŒïŒ
ãïŒïŒïŒ
ãïŒïŒ
ãïŒïŒïŒ
ãïŒïŒïŒ
ãïŒïŒïŒ
ãåã¯ïŒïŒïŒ
ãïŒïŒïŒïŒ
ïœïŒïœã§ããããšãã§ããã
äœçšå€ã¯ããã«ãç·ç¶æ§ççãçºçããŠããå¯èœæ§ã®ããå€ç§çéšäœã«ä»çããŠããããã¢ã«ãã³é
žãã£ã«ã ã®ãããªçäœé©åæ§ã®ãããªã¯ã¹ã«ïŒ³ïŒ€ïŒŠâïŒé»å®³å€ãå
¥ããããšãå«ãããšãã§ããããããã®è£œå€ã¯ã次ãã§æ°æéããæ°æ¥ã«ããã£ãŠååç©ãæŸåºããç·ç¶æ§ççã®åœ¢æã«é¢äžããççéçšåã³è¡ç®¡åœ¢æéçšãé»å®³ããæ£åžžãªåµå·æ²»çããããŠããããïŒïŒïŒ
ã®ã°ãªã»ããŒã«ã®æ·»å ã«ããæè»ã«ããïŒïœïŒã®ïŒ¥ïŒ€ïŒ¡ïŒ£ïŒæ°Žæº¶æ§ã«ã«ãã€ããïŒãšæ¶æ©ããããã¢ã«ãã³é
žãã£ã«ã ã¯ããããªãæ¯æ§ãèªçºããããšãªããæŠãå·éšäœã«é©çšããŠããããç²èä»çæ§ã§çäœé©åæ§ã§ããã
æ¬çºæã¯ãããã«ãããšãã°ããããµã³åã¯ããªïŒ¬âãªãžã³ã®ãããªæ£ã«è·é»ãã賊圢å€ã«ããè·é»ããæ°Žæ§ã²ã«ã®åœ¢æãå«ãããšãã§ããè² ã«è·é»ããâïŒé»å®³å€ãããšãã°ãã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããããªãã¶ã€ã ãïœïœïŒ²ïŒ®ïŒ¡ïŒïŒ²ïŒ®ïŒ¡ïœã®ãããªïŒ³ïŒ€ïŒŠâïŒçºçŸã®é»å®³å€ãç
å€éšäœã«é©çšããããã«ãã®ãããªã²ã«ã«çµã¿å
¥ããããšãã§ããã
æ¬çºæã¯ããã«ãâïŒã®çºçŸãé»å®³ã§ããæ žé
žéã®ããã®åœ¢è³ªç§»å
¥å€ãšããŠã®ãã«ã³ã®äœ¿çšãå«ãããšãã§ãããéºäŒåæ²»çãšããŠç¥ãããå»åŠã®å
端é åã¯ãè¬å€ééã®åé¡ã§å¶çŽãããŠããããã®ããã«ãã¢ã³ãã»ã³ã¹ãã¯ã¬ãªããããªãã¶ã€ã ãïœïœïŒ²ïŒ®ïŒ¡ïŒïŒ²ïŒ®ïŒ¡ïœãå«ããªãªãŽãã¯ã¬ãªããã®ãããªéºäŒåæçåã¯æ žé
žéã¯ããããååç©ã®é»è·åã³é«ååéã®ããã«çŽ°èãžã®åã蟌ã¿ãé»å®³ãããŠãããæ¬çºæã¯ããã«ãâïŒã®çºçŸãé»å®³ããããã«èšèšãããæ žé
žéããã³ã€ãã³ã®åŸ®ç²åãšçµåããåã¯ããã«å
å
ãããããšãå«ããæ¬çºæã¯ããã«ãå€ç§çéšäœã«é©çšããåã®æº¶è§£ãé»å®³ããããã«ç²åãååŠçã«æ¶æ©ããããšãããã«å«ãããšãã§ããã
æ¬çºæã¯ããã«ãâïŒã®çºçŸãé»å®³ããããã«èšèšãããæ žé
žéããããµã³ïŒã«ããªã³å€ç³é¡ïŒåã¯ãã®ã»ãã®ã«ããªã³ããªããŒã«çµåãããããšãå«ãããšãã§ããããã®ããã«åœ¢æãããè€åäœã¯ãå
å æ§é
µçŽ ã«ããå解ããã®æ žé
žã®ä¿è·ãæäŸããçµæãšããŠäœçšéšäœãžã®æ žé
žã®å¶åŸ¡æŸåºãçããã
å®æœæ
æ§ã®ïŒã€ã§ã¯ãæ¹æ³ã¯ãïœïŒ²ïŒ®ïŒ¡æçãç¹ã«ïŒ³ïŒ€ïŒŠâïŒã¿ã³ãã¯è³ªãã³ãŒãããïœïŒ²ïŒ®ïŒ¡ã«é
åã§çžè£çãªå°ïŒ²ïŒ®ïŒ¡ã®èšèšåã³åæãå«ããå°ïŒ²ïŒ®ïŒ¡ã®çºçŸã¯ãâïŒïœïŒ²ïŒ®ïŒ¡ã®ç¿»èš³ãå¹ççã«é»æ¢ããããšãã§ããã®ã§ãã±ã¢ã«ã€ã³ã®ç£çãé€å€ããããšãã§ãããå¥ã®å®æœæ
æ§ã§ã¯ãâïŒïœïŒ²ïŒ®ïŒ¡ã®è»¢åãé»æ¢ããããšãã§ããç¹ç°çãªã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã®ååšã«ãã£ãŠãåã¯ã±ã¢ã«ã€ã³ãã³ãŒãããïœïŒ²ïŒ®ïŒ¡ãèªèããåæããç¹ç°çãªãªãã¶ã€ã ã®æäžã«ãã£ãŠïŒ³ïŒ€ïŒŠâïŒã®çºçŸãé»å®³ãããã
çšèªããªãªãŽãã¯ã¬ãªãããã¯ããªãæ žé
žåã¯ããªãã·ãªãæ žé
žã®ãªãªãŽããŒåã¯ããªããŒãèšãããã®çšèªã¯ã倩ç¶ã«çãããã¯ã¬ãªå¡©åºãç³åã³ç³éïŒäž»éïŒå
±æçµåããæããªãªãŽãã¯ã¬ãªããã䞊ã³ã«åæ§ã«æ©èœããé倩ç¶ã«çããéšåãæãããªãªãŽãã¯ã¬ãªãããå
å«ããããã®ããã«ä¿®é£Ÿãããåã¯çœ®æããããªãªãŽãã¯ã¬ãªããã¯ãããšãã°ã现èãžã®åã蟌ã¿ã®åäžãæšçãžã®çµåã®åäžåã¯ãã¯ã¬ã¢ãŒãŒã®ååšäžã§ã®å®å®æ§ã®åäžã®ãããªæãŸããç¹æ§ã®ããã«ã倩ç¶ã®åœ¢æ
ããã奜ãŸããããšãå€ãã
代衚çãªã¢ã³ãã»ã³ã¹ååç©ã¯ãçŽïŒãçŽïŒïŒã®ãã¯ã¬ãªå¡©åºãå«ããç¹ã«äžè¬çãªã®ã¯ãçŽïŒãçŽïŒïŒã®ãã¯ã¬ãªå¡©åºãå«ãã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã§ãããããã«äžè¬çãªã®ã¯ãçŽïŒïŒãïŒïŒã®ãã¯ã¬ãªå¡©åºã®ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããïŒããšãã°ãçŽïŒïŒãçŽïŒïŒã®ã®é£çµããããã¯ã¬ãªã·ãïŒã§ãããæ¢ç¥ã®ããã«ããã¯ã¬ãªã·ãã¯å¡©åºâç³ã®çµã¿åããã§ããããã¯ã¬ãªã·ãã®å¡©åºéšåã¯éåžžãè€çŽ ç°å¡©åºã§ããããã®ãããªè€çŽ ç°å¡©åºã®æãäžè¬çãªïŒã€ã®éšé¡ãããªã³åã³ããªããžã³ã§ããããã¯ã¬ãªããã¯ããã¯ã¬ãªã·ãã®ç³éšåã«å
±æçµåããå°ãªããšãïŒçš®ã®ãªã³é
žåºãããã«å«ããã¯ã¬ãªã·ãã§ããããã³ããã©ãã·ã«ç³ãå«ããã¯ã¬ãªã·ãã«ã€ããŠã¯ããªã³é
žåºã¯ãç³ã®ïŒâãïŒâåã¯ïŒâããããã·ã«éšåã®ããããã«çµåããããšãã§ããããªãªãŽãã¯ã¬ãªããã®åœ¢æã§ã¯ããªã³é
žåºãé£æ¥ãããã¯ã¬ãªã·ãã«äºãã«å
±æçµåããç·ç¶ã®ããªããŒååç©ã圢æãããåæ§ã«ããã®ç·ç¶ã®ããªããŒæ§é ã®åæ«ç«¯ãããã«é£çµããŠç°ç¶æ§é ã圢æããããšãã§ããããéç°ãç·ç¶æ§é ãäžè¬ã«å¥œãŸããããªãªãŽãã¯ã¬ãªããæ§é ã®ç¯å²å
ã§ããªã³é
žåºã¯å
±éããŠããªãªãŽãã¯ã¬ãªããã®ãã¯ã¬ãªã·ãéäž»éã圢æãããšã¿ãªããããåã³ïŒ€ïŒ®ïŒ¡ã®æ£åžžãªçµååã¯äž»éã¯ãïŒâãïŒâã®ãã¹ããžãšã¹ãã«çµåã§ããã
æ¬çºæã§æçšãªå¥œãŸããã¢ã³ãã»ã³ã¹ååç©ã®å
·äœäŸã«ã¯ã修食ãããäž»éåã¯é倩ç¶ã®ãã¯ã¬ãªã·ãéçµåãå«æãããªãªãŽãã¯ã¬ãªãããæãããããæ¬æ现æžã§å®çŸ©ãããããã«ã修食ãããäž»éãæãããªãªãŽãã¯ã¬ãªããã«ã¯ãäž»éã«ãªã³ååãä¿æãããã®åã³äž»éã«ãªã³ååãæããªããã®ãæãããããæ¬æ现æžã®ç®çã§ããã¯ã¬ãªã·ãéäž»éã«ãªã³ååãæããªã修食ããããªãªãŽãã¯ã¬ãªããããªãªãŽãã¯ã¬ãªããã§ãããšã¿ãªãããšãã§ããã
奜ãŸãã修食ããããªãªãŽãã¯ã¬ãªããã«ã¯ãããšãã°ããã¹ããããªãšãŒãããã©ã«ãã¹ããããªãšãŒãããã¹ãããžããªãšãŒãããã¹ãããªãšã¹ãã«ãã¢ããã¢ã«ãã«ãã¹ãããªãšã¹ãã«ãã¢ã«ãã¬ã³ãã¹ãããŒãåã³ãã©ã«ãã¹ãããŒããå«ãã¡ãã«åã³ãã®ã»ãã®ã¢ã«ãã«ãã¹ãããŒãããã¹ãã£ããŒããïŒââã¢ãããã¹ãã«ã¢ãããŒãåã³ã¢ããã¢ã«ãã«ãã¹ãã«ã¢ãããŒããå«ããã¹ãã«ã¢ãããŒããããªããã¹ãã«ã¢ãããŒããããªãã¢ã«ãã«ãã¹ãããŒããããªãã¢ã«ãã«ãã¹ãããªãšã¹ãã«ãåã³æ£åžžãªïŒââïŒâçµåãæãããã©ããã¹ãã§ãŒãããã®ïŒââïŒâçµåé¡çžäœãåã³ãã¯ã¬ãªã·ãåäœã®é£æ¥å¯ŸãïŒââïŒâããïŒââïŒâåã¯ïŒââïŒâããïŒââïŒâã«çµåããé極æ§ãæãããã®ãæãããããçš®ã
ã®å¡©ãæ··åå¡©åã³éé¢ã®é
žã®åœ¢æ
ãå
å«ãããã
ãªã³å«æçµåã®èª¿è£œãé瀺ããŠãã代衚çãªç±³åœç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãåã³å第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãæãããããããããã«éå®ãããªãã
ãã®äžã«ãªã³ååãå
å«ããªã奜ãŸãã修食ããããªãªãŽãã¯ã¬ãªããäž»éã¯ãçéã¢ã«ãã«åã¯ã·ã¯ãã¢ã«ãã«ãã¯ã¬ãªã·ãéçµåãæ··åããããããåååã³ã¢ã«ãã«åã¯ã·ã¯ãã¢ã«ãã«ãã¯ã¬ãªã·ãéçµåãåã¯ïŒä»¥äžã®çéãžããååè¥ããã¯è€çŽ ç°ãã¯ã¬ãªã·ãéçµåã«ãã£ãŠåœ¢æãããäž»éãæããããããã«ã¯ãã¢ã«ãã©ãªãçµåïŒéšåçã«ã¯ããã¯ã¬ãªã·ãã®ç³éšåãã圢æãããïŒãã·ãããµã³äž»éãã¹ã«ãã£ããã¹ã«ããã·ãåã³ã¹ã«ãã³äž»éããã«ã ã¢ã»ãã«åã³ããªãã«ã ã¢ã»ãã«äž»éãã¡ãã¬ã³ãã«ã ã¢ã»ãã«åã³ããªãã«ã ã¢ã»ãã«äž»éãã¢ã«ã±ã³å«æäž»éãã¹ã«ãããŒãåã³ã¹ã«ãã³ã¢ããäž»éãã¢ããäž»éã䞊ã³ã«æ··åãããããåã³ïŒ£ïŒš2æåéšåãæãããã®ãæ
ããããã
ããããã
ãªãªãŽãã¯ã¬ãªãããèå¯ããŠãã代衚çãªç±³åœç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãåã³å第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãæãããããããããã«éå®ãããªãã
äžéšã®ãªãªãŽãã¯ã¬ãªããã§ã¯ããã¯ã¬ãªã·ãåäœã®ç³åã³ãã¯ã¬ãªã·ãéçµååæ¹ãããªãã¡ãäž»éã®æš¡å£ã¯ãæ°èŠã®åºã«ãã£ãŠå埩ããããå¡©åºåäœã¯ããã€ããªãã圢æã®ããã«é©åœãªæ žé
žæšçååç©ã«ãã£ãŠä¿æãããããã®ãããªãªãªãŽããŒååç©ã®ïŒã€ãåªãããã€ããªãã圢æç¹æ§ãæããããšã瀺ãããŠãããªãªãŽãã¯ã¬ãªããæš¡å£äœã¯ãããããæ žé
žïŒïŒ°ïŒ®ïŒ¡ïŒãšåŒã°ãããååç©ã§ã¯ããªãªãŽãã¯ã¬ãªããã®ç³äž»éãã¢ããé
žå«æäž»éãããšãã°ãã¢ãããšãã«ã°ãªã·ã³äž»éã§çœ®ãæããããããã¯ã¬ãªå¡©åºã¯ä¿æãããäž»éã®ã¢ããéšåã®ã¢ã¶çªçŽ ååã«çŽæ¥åã¯éæ¥çã«çµåããããååç©ã®èª¿è£œãé瀺ããŠãã代衚çãªç±³åœç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãåã³å第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãæãããããããããã«éå®ãããªããååç©ã®ãããªãèå¯ã¯ãNielsen et al., (Science 254:1497-1500, 1991ïŒã«èŠãåºãããã
æ¬çºæã®ç¹å®ã®å®æœæ
æ§ã¯ããã¹ããããªãšãŒãäž»éãæã€ãªãªãŽãã¯ã¬ãªããåã³ãããååäž»éãæã€ãªãªãŽãã¯ã¬ãªãããããšãã°ãäžèšåç
§ããç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ã®â2âââ2âãâ2âïŒïŒ£ïŒš3ïŒââ2âïŒã¡ã
ã¬ã³ïŒã¡ãã«ã€ããïŒåã¯ïŒïŒïŒ©äž»éãšããŠç¥ãããïŒãâ2âïŒïŒ£ïŒš3ïŒâ2âãâ2âïŒïŒ£ïŒš3ïŒâïŒïŒ£ïŒš3ïŒâ2âåã³ââïŒïŒ£ïŒš3ïŒâ2â
2âïŒå€©ç¶ã®ãã¹ããžãšã¹ãã«äž»éã¯ââââ2âãšè¡šãããïŒåã³äžèšåç §ããç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ã®ã¢ããäž»éãæã€ãªãªãŽãã¯ã¬ãªããã§ããããŸãã奜ãŸããã®ã¯ãäžèšåç §ããç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ã®ã¢ã«ãã©ãªãäž»éæ§é ãæãããªãªãŽãã¯ã¬ãªããã§ããã
ã¬ã³ïŒã¡ãã«ã€ããïŒåã¯ïŒïŒïŒ©äž»éãšããŠç¥ãããïŒãâ2âïŒïŒ£ïŒš3ïŒâ2âãâ2âïŒïŒ£ïŒš3ïŒâïŒïŒ£ïŒš3ïŒâ2âåã³ââïŒïŒ£ïŒš3ïŒâ2â
2âïŒå€©ç¶ã®ãã¹ããžãšã¹ãã«äž»éã¯ââââ2âãšè¡šãããïŒåã³äžèšåç §ããç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ã®ã¢ããäž»éãæã€ãªãªãŽãã¯ã¬ãªããã§ããããŸãã奜ãŸããã®ã¯ãäžèšåç §ããç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ã®ã¢ã«ãã©ãªãäž»éæ§é ãæãããªãªãŽãã¯ã¬ãªããã§ããã
修食ããããªãªãŽãã¯ã¬ãªããã¯ããŸãïŒä»¥äžã®çœ®æãããç³éšåãå«æããŠãããã奜ãŸãããªãªãŽãã¯ã¬ãªããã¯ãïŒâäœã«ãŠã以äžã®ïŒ¯ïŒšããâãâãåã¯ïŒ®âã¢ã«ãã«ãâã¢ã«ãã«âã¢ã«ãã«ãâãâãåã¯ïŒ®âã¢ã«ãã«ãåã¯ïŒ¯âãâåã¯ïŒ®âã¢ã«ãã«ã®ïŒã€ãå«ã¿ããã®éãã¢ã«ãã«ãã¢ã«ã±ãã«åã³ã¢ã«ããã«ã¯ã眮æåã¯é眮æã®ïŒ£1ã10ã®ã¢ã«ãã«åã¯ïŒ£2ã10ã®ã¢ã«ã±ãã«åã³ã¢ã«ããã«ã§ãã£ãŠããããç¹ã«å¥œãŸããã®ã¯ãïŒïŒ£ïŒš2ïŒïœïŒ¯ïŒœïœïŒ£ïŒš3ãïŒïŒ£ïŒš2ïŒïœïŒ¯ïŒ£ïŒš3ãïŒïŒ£ïŒš2ïŒ2ïŒïŒ£ïŒš3ïŒ2ãïŒïŒ£ïŒš2ïŒïœïŒ®ïŒš2ãïŒïŒ£ïŒš2ïŒïœïŒ£ïŒš3ãïŒïŒ£ïŒš2ïŒïœïŒ¯ïŒ®ïŒš2åã³ïŒ¯ïŒïŒ£ïŒš2ïŒïœïŒ¯ïŒ®ïŒ»ïŒïŒ£ïŒš2ïŒïœïŒ£ïŒš32ã§ããããã®éãïœã¯ïŒãçŽïŒïŒã§ããããã®ã»ãã®å¥œãŸãããªãªãŽãã¯ã¬ãªããã¯ãïŒâäœã«ãŠã以äžã®ïŒ£1ã10ã®äœçŽã¢ã«ã
ã«ã眮æäœçŽã¢ã«ãã«ãã¢ã«ã«ãªã«ãã¢ã©ã«ãã«ãâã¢ã«ã«ãªã«åã¯ïŒ¯âã¢ã©ã«ãã«ãã3ããïœãïœãã3ã3ã3ã2ã3ã2ã2ã3ã2ããããã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ã«ãªã«ãã¢ããã¢ã«ãã«ã¢ãããããªã¢ã«ãã«ã¢ããã眮æã·ãªã«ãåæåºããªããŒã¿ãŒåºãã€ã³ã¿ãŒã«ã¬ãŒã¿ããªãªãŽãã¯ã¬ãªããã®è¬ç©åæ ç¹æ§ãæ¹åããããã®åºããªãªãŽãã¯ã¬ãªããã®è¬ç©ååŠç¹æ§ãæ¹åããããã®åºãåã³é¡äŒŒã®ç¹æ§ãæãããã®ã»ãã®çœ®æåºã®ïŒã€ãå«ãã奜ãŸãã修食ã«ã¯ãïŒââã¡ããã·ãšããã·ïŒïŒâââ222ãïŒâââïŒïŒâã¡ããã·ãšããã·ïŒåã¯ïŒââïŒïŒ¯ïŒ¥ãšããŠãç¥ãããïŒïŒMartin et al., Heiv. Chim. Acta 78:486-504, 1995ïŒããªãã¡ãã¢ã«ã³ãã·ã¢ã«ã³ãã·åºãæ
ããããã
ã«ã眮æäœçŽã¢ã«ãã«ãã¢ã«ã«ãªã«ãã¢ã©ã«ãã«ãâã¢ã«ã«ãªã«åã¯ïŒ¯âã¢ã©ã«ãã«ãã3ããïœãïœãã3ã3ã3ã2ã3ã2ã2ã3ã2ããããã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ã«ãªã«ãã¢ããã¢ã«ãã«ã¢ãããããªã¢ã«ãã«ã¢ããã眮æã·ãªã«ãåæåºããªããŒã¿ãŒåºãã€ã³ã¿ãŒã«ã¬ãŒã¿ããªãªãŽãã¯ã¬ãªããã®è¬ç©åæ ç¹æ§ãæ¹åããããã®åºããªãªãŽãã¯ã¬ãªããã®è¬ç©ååŠç¹æ§ãæ¹åããããã®åºãåã³é¡äŒŒã®ç¹æ§ãæãããã®ã»ãã®çœ®æåºã®ïŒã€ãå«ãã奜ãŸãã修食ã«ã¯ãïŒââã¡ããã·ãšããã·ïŒïŒâââ222ãïŒâââïŒïŒâã¡ããã·ãšããã·ïŒåã¯ïŒââïŒïŒ¯ïŒ¥ãšããŠãç¥ãããïŒïŒMartin et al., Heiv. Chim. Acta 78:486-504, 1995ïŒããªãã¡ãã¢ã«ã³ãã·ã¢ã«ã³ãã·åºãæ
ããããã
ãã®ã»ãã®å¥œãŸãã修食ã«ã¯ãïŒââã¡ããã·ïŒïŒâââ3ïŒãïŒââã¢ããã
ããã«ïŒïŒââ2222ïŒåã³ïŒâãã«ãªãïŒïŒââïŒãæãããããé¡äŒŒã®ä¿®é£Ÿã¯ããªãªãŽãã¯ã¬ãªããã®ã»ãã®äœçœ®ãïŒâæ«ç«¯ãã¯ã¬ãªããã«ãããç³åã¯ïŒâãïŒâçµåã®ãªãªãŽãã¯ã¬ãªããã®ïŒâäœåã³ïŒâæ«ç«¯ãã¯ã¬ãªããã®ïŒâäœã§è¡ãããŠãããããªãªãŽãã¯ã¬ãªããã¯ããã³ããã©ãã·ã«ç³ã®ä»£ããã«ã·ã¯ãããã«éšåã®ãããªç³æš¡å£äœãæããŠãããã修食ãããç³æ§é ã®èª¿è£œãé瀺ããŠãã代衚çãªç±³åœç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãåã³å第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãæãããããããããã«éå®ãããªãã
ããã«ïŒïŒââ2222ïŒåã³ïŒâãã«ãªãïŒïŒââïŒãæãããããé¡äŒŒã®ä¿®é£Ÿã¯ããªãªãŽãã¯ã¬ãªããã®ã»ãã®äœçœ®ãïŒâæ«ç«¯ãã¯ã¬ãªããã«ãããç³åã¯ïŒâãïŒâçµåã®ãªãªãŽãã¯ã¬ãªããã®ïŒâäœåã³ïŒâæ«ç«¯ãã¯ã¬ãªããã®ïŒâäœã§è¡ãããŠãããããªãªãŽãã¯ã¬ãªããã¯ããã³ããã©ãã·ã«ç³ã®ä»£ããã«ã·ã¯ãããã«éšåã®ãããªç³æš¡å£äœãæããŠãããã修食ãããç³æ§é ã®èª¿è£œãé瀺ããŠãã代衚çãªç±³åœç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãåã³å第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãæãããããããããã«éå®ãããªãã
ãªãªãŽãã¯ã¬ãªããã¯ãŸãããã¯ã¬ãªå¡©åºïŒåã«ãå¡©åºããšåŒã¶ããšãå€ãïŒã®ä¿®é£Ÿåã³çœ®æãå
å«ããŠããããæ¬æ现æžã§äœ¿çšãããšãããæªä¿®é£Ÿã®ãåã¯ã倩ç¶ã®ããã¯ã¬ãªå¡©åºã«ã¯ãããªã³å¡©åºãã¢ããã³ïŒïŒ¡ïŒåã³ã°ã¢ãã³ïŒïŒ§ïŒäžŠã³ã«ããªããžã³å¡©åºãããã³ïŒïŒŽïŒãã·ãã·ã³ïŒïŒ£ïŒåã³ãŠã©ã·ã«ïŒïŒµïŒãæããããã修食ãã¯ã¬ãªå¡©åºã«ã¯ãããšãã°ãïŒâã¡ãã«ã·ãã·ã³ïŒïŒâïœïœ
âïŒãïŒâããããã·ã¡ãã«ã·ãã·ã³ãããµã³ãã³ãããããµã³ãã³ãïŒâã¢ããã¢ããã³ãã¢ããã³åã³ã°ã¢ãã³ã®ïŒâã¡ãã«åã³ãã®ã»ãã®ã¢ã«ãã«èªå°äœãã¢ããã³åã³ã°ã¢ãã³ã®ïŒâãããã«åã³ãã®ã»ãã®ã¢ã«ãã«èªå°äœãïŒâããªãŠã©ã·ã«ãïŒâããªããã³åã³ïŒâããªã·ãã·ã³ãïŒâãããŠã©ã·ã«åã³ã·ãã·ã³ãïŒâããããã«ãŠã©ã·ã«åã³ã·ãã·ã³ãïŒâã¢ãŸãŠã©ã·ã«ãã·ãã·ã³åã³ããã³ãïŒâãŠã©ã·ã«ïŒåœãŠã©ã·ã«ïŒãïŒâããªãŠã©ã·ã«ãïŒâãããïŒâã¢ãããïŒâããªãŒã«ãïŒâããªã¢ã«ãã«ãïŒâããããã·åã³ãã®ã»ãã®ïŒâ眮æãããã¢ããã³åã³ã°ã¢ãã³ãïŒâãããç¹ã«ïŒâããã¢ãïŒâãã«ãªãã¡ãã«åã³ãã®ã»ãã®ïŒâ眮æããããŠã©ã·ã«åã³ã·ãã·ã³ãïŒâã¡ãã«ã°ã¢ãã³åã³ïŒâã¡ãã«ã¢ããã³ãïŒâã¢ã¶ã°ã¢ãã³åã³ïŒâã¢ã¶ã¢ããã³ãïŒâãã¢ã¶ã°ã¢ãã³åã³ïŒâãã¢ã¶ã¢ããã³åã³ïŒâãã¢ã¶ã°ã¢ãã³åã³ïŒâãã¢ã¶ã¢ããã³ãæããããããããªããã¯ã¬ãªå¡©åºã«ã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ã§é瀺ããããã®ãããªããŒç§åŠåã³å·¥åŠã®ã³ã³ãµã€ã¹çŸç§äºå
žïŒïŒïŒïŒïŒå¹ŽãïŒïŒïŒãïŒïŒïŒããŒãžãKroschwitz JI. ed., John Wiley & Sons)ã§é瀺ã
ãããã®ãSangivi YS. Crooke ST & Lebieu B. ç·šã®ã¢ã³ãã»ã³ã¹ã®ç 究åã³å¿çšïŒCRC
Press Boca Raton, pages 289-302ïŒã§é瀺ããããã®ãæããããã
ãããã®ãSangivi YS. Crooke ST & Lebieu B. ç·šã®ã¢ã³ãã»ã³ã¹ã®ç 究åã³å¿çšïŒCRC
Press Boca Raton, pages 289-302ïŒã§é瀺ããããã®ãæããããã
å®æœæ
æ§ã®äžéšã§ã¯ããã¯ã¬ãªå¡©åºã¯ãïŒâã¢ãããããã«ã¢ããã·ã³ãïŒâããããã«ãŠã©ã·ã«åã³ïŒâããããã«ã·ãã·ã³ãå«ãïŒâ眮æããªããžã³ãïŒâã¢ã¶ããªããžã³äžŠã³ã«ïŒ®âïŒãâïŒåã³ïŒ¯âïŒçœ®æã®ããªã³ãå«ããïŒâã¡ãã«ã·ãã·ã³ã®çœ®æã¯ãïŒïŒïŒãïŒïŒïŒâã«ãã£ãŠæ žé
žã®äºæ¬éã®å®å®æ§ãé«ããããšã瀺ãããŠããïŒSangivi YS. Crooke ST & Lebieu B. ç·šã®ã¢ã³ãã»ã³ã¹ã®ç 究åã³å¿çšïŒCRC Press Boca Raton, pa
ges 276-278ïŒãçŸåšã奜ãŸããå¡©åºçœ®æã§ãããïŒâââã¡ããã·ãšãã«ç³ä¿®é£Ÿãšçµ
ã¿åãããå Žåãããã«äžå±€å¥œãŸããã
ges 276-278ïŒãçŸåšã奜ãŸããå¡©åºçœ®æã§ãããïŒâââã¡ããã·ãšãã«ç³ä¿®é£Ÿãšçµ
ã¿åãããå Žåãããã«äžå±€å¥œãŸããã
ãã®ã»ãã®ä¿®é£Ÿãã¯ã¬ãªå¡©åºãšåæ§ã«äžèšã®ä¿®é£Ÿãã¯ã¬ãªå¡©åºãèå¯ããŠãã代衚çãªç±³åœç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãåã³å第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãæãããããããããã«éå®ãããªãã
ãªãªãŽãã¯ã¬ãªããã®ããïŒã€ã®ä¿®é£Ÿã¯ããªãªãŽãã¯ã¬ãªããã®æŽ»æ§ã现èã§ã®ååžåã¯çŽ°èãžã®åã蟌ã¿ãé«ããïŒä»¥äžã®éšååã¯æ±åäœããªãªãŽãã¯ã¬ãªããã«ååŠçã«é£çµããããšãå«ãããã®ãããªéšåã«ã¯ãããªã³ã¬ã¹ãããŒã«ïŒOberhauser et al., Nucl. Acids Res., 20:533-538, 1992ïŒã®ãããªã³ã¬ã¹ãããŒã«éšåïŒLetsinger et al., Proc. Natl. Acad. Sci. USA 86:6553-6556, 1989ïŒã®ãããªè質éšåãåã¯ãªã¯ã¿ãã·ã«ã¢ãã³åã¯ããã·ã«ã¢ããâã«ã«ããã«âãªãã·ã³ã¬ã¹ãããŒã«éšåïŒCrooke et al., J. Pharmacol. Exp. Ther., 277:923-937, 1996ïŒãã³ãŒã«é
žïŒManoharan et al., Bioorg. Med. Chem. Lett., 4:1053-1059, 1994ïŒãããªãšãŒãã«ãããšãã°ãããã·ã«ââ
ããªãã«ããªãŒã«ïŒManoharan et al., Ann. N. Y. Acad. Sci., 660:306-309, 1992; Manoharan et al., Bioorg. Med. Chem. Lett., 3:2765-2770, 1993ïŒãèèªæéãããšã
ã°ãããã«ã³ãžãªãŒã«åã¯ãŠã³ãã·ã«æ®åºïŒSalson-Behmoaraset al., EMBO J., 10:1111-1118, 1991; Kabanov et al., FEBS Lett., 259:327-330, 1990; Svinarchuk et al., Biochemie 75:49-54, 1993ïŒããªã³è質ãããšãã°ããžãããµãã·ã«âïœïœïœâã°ãªã»ã
ãŒã«åã¯ããªãšãã«ã¢ã³ã¢ããŠã ïŒïŒïŒâãžââãããµãã·ã«âïœïœïœâã°ãªã»ãâïŒââãã¹ãããŒãïŒManoharan et al., Tetrahedron Lett., 36:3651-3654, 1995; Shea et al., Nucl. Acids Res., 18:3777-3783, 1990ïŒãããªã¢ãã³åã¯ããªãšãã¬ã³ã°ãªã³ãŒã«éïŒManoharan et al., Nucleosides & Nucleotides 14:969-973, 1995ïŒãã¢ãã
ã³ã¿ã³é ¢é žïŒManoharan et al., Tetrahedron Lett., 36:3651-3654, 1995ïŒããã«ãã
ã«éšåïŒMisshra et al., Biochem. Biophys. Acta, 1264:229-237, 1995 ïŒãæããã
ããããããã«éå®ãããªãã
ããªãã«ããªãŒã«ïŒManoharan et al., Ann. N. Y. Acad. Sci., 660:306-309, 1992; Manoharan et al., Bioorg. Med. Chem. Lett., 3:2765-2770, 1993ïŒãèèªæéãããšã
ã°ãããã«ã³ãžãªãŒã«åã¯ãŠã³ãã·ã«æ®åºïŒSalson-Behmoaraset al., EMBO J., 10:1111-1118, 1991; Kabanov et al., FEBS Lett., 259:327-330, 1990; Svinarchuk et al., Biochemie 75:49-54, 1993ïŒããªã³è質ãããšãã°ããžãããµãã·ã«âïœïœïœâã°ãªã»ã
ãŒã«åã¯ããªãšãã«ã¢ã³ã¢ããŠã ïŒïŒïŒâãžââãããµãã·ã«âïœïœïœâã°ãªã»ãâïŒââãã¹ãããŒãïŒManoharan et al., Tetrahedron Lett., 36:3651-3654, 1995; Shea et al., Nucl. Acids Res., 18:3777-3783, 1990ïŒãããªã¢ãã³åã¯ããªãšãã¬ã³ã°ãªã³ãŒã«éïŒManoharan et al., Nucleosides & Nucleotides 14:969-973, 1995ïŒãã¢ãã
ã³ã¿ã³é ¢é žïŒManoharan et al., Tetrahedron Lett., 36:3651-3654, 1995ïŒããã«ãã
ã«éšåïŒMisshra et al., Biochem. Biophys. Acta, 1264:229-237, 1995 ïŒãæããã
ããããããã«éå®ãããªãã
ãã®ãããªãªãªãŽãã¯ã¬ãªããæ±åäœã®èª¿è£œãèå¯ããŠãã代衚çãªç±³åœç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãå第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãåã³å第ïŒïŒïŒïŒïŒïŒïŒïŒïŒå·ãæãããããããããã«éå®ãããªãã
æ¬çºæã¯ãŸãããã¡ã©ãªãªãŽãã¯ã¬ãªããã§ãããªãªãŽãã¯ã¬ãªãããå
å«ãããæ¬çºæã®èæ¯ã§ã¯ãããã¡ã©ãªãªãŽãã¯ã¬ãªãããåã¯ããã¡ã©ãã¯ãããããå°ãªããšãïŒã€ã®ãã¯ã¬ãªããããæãïŒä»¥äžã®ååŠçã«èå¥å¯èœãªé åãå«æãããªãªãŽãã¯ã¬ãªããã§ããããããã®ãªãªãŽãã¯ã¬ãªããã¯éåžžå°ãªããšãïŒã€ã®é åãå«æãããã®éããªãªãŽãã¯ã¬ãªããã¯ããã¯ã¬ã¢ãŒãŒã®å解ã«å¯Ÿããé«ãèæ§ã现èãžã®é«ãåã蟌ã¿åã³ïŒåã¯æšçæ žé
žã«å¯Ÿããé«ãçµå芪åæ§ããªãªãŽãã¯ã¬ãªããã«ä»äžããããã«ä¿®é£ŸãããããªãªãŽãã¯ã¬ãªããã®è¿œå ã®é åã¯ãïŒïŒ€ïŒ®ïŒ¡åã¯ïŒ²ïŒ®ïŒ¡ïŒïŒ²ïŒ®ïŒ¡ã®ãã€ããªãããåæå¯èœãªé
µçŽ ã«å¯Ÿããåºè³ªãšããŠäœçšããŠããããäžäŸãšããŠãå解é
µçŽ ã¯ãïŒïŒ€ïŒ®ïŒ¡äºæ¬éã®ïŒ²ïŒ®ïŒ¡éãåæãã现èæ§ã®ãšã³ããã¯ã¬ã¢ãŒãŒã§ãããåŸã£ãŠãå解é
µçŽ ã®æŽ»æ§åã¯ãæšçã®å解ãçããããã«ãã£ãŠéºäŒåçºçŸã®ã¢ã³ãã»ã³ã¹é»å®³ã®å¹çã倧ããé«ãããããæšçã®åæã¯ãã²ã«é»æ°æ³³åãåã³å¿
èŠã«å¿ããŠãé¢é£ããæ žé
žãã€ããªãã圢æææ³ã«ãã£ãŠæ¥åžžçã«æ€åºããããšãã§ããã
ãã¡ã©ãªãªãŽãã¯ã¬ãªããã®äŸã«ã¯ãïŒã€ã®ç°ãªã£ãé åãååšããéåžžãååŠçã«ã¯äºãã«åçã§ããããã®ã£ãããšã¯ç°ãªãïŒã€ã®é åãé£æ¥ããäžå€®é åãæã€ãã®ã£ããããŒããæãããããããããã«éå®ãããªããã®ã£ããããŒã®äŸã¯ããªãªãŽãã¯ã¬ãªããã®äžå€®éšåïŒã®ã£ããïŒãå解é
µçŽ ã®åºè³ªãšããŠäœçšããïŒââããªãã·ãã¯ã¬ãªããããæãããé£æ¥éšåïŒïŒâåã³ïŒâã®ããŠã€ã³ã°ãïŒã¯ãæšçååã«å¯ŸããŠããã«å€§ããªèŠªåæ§ãæãããããã¯ã¬ã¢ãŒãŒæŽ»æ§ãæ¯ããããšã¯ã§ããªãããã«ä¿®é£ŸãããïŒããšãã°ããã«ãªãâåã¯ïŒâââã¡ããã·ãšãã«çœ®æã®ãåã¯ããã¯ãããæ žé
žïŒãªãªãŽãã¯ã¬ãªããã§ããããã¡ã©ãªãªãŽãã¯ã¬ãªããã¯ç³ã§ä¿®é£Ÿããããã®ã«éå®ãããªããã修食ãããäž»éãæã€ãããšãã°ããã¹ããããªãšãŒãïŒïŒ°ïŒïŒ³ïŒåã³ãã¹ããžãšã¹ãã«ïŒïŒ°ïŒïŒ¯ïŒã®äž»éçµåãæã€ãåã¯ïŒïŒïŒ©åã³ïŒ°ïŒïŒ³ã®äž»éçµåã®é åãæã€ãªãªãŽãã¯ã¬ãªã·ãåã¯ãªãªãŽãã¯ã¬ãªãããå
å«ããŠãããã
ãã®ã»ãã®ãã¡ã©ã«ã¯ããããããŒããšããŠãç¥ãããããŠã€ã³ã°ããŒããããªãã¡ãïŒã€ã®ç°ãªã£ãé åãæã€ãªãªãŽãã¯ã¬ãªãããæããããããŠã€ã³ã°ããŒã®å¥œãŸããäŸã§ã¯ããªãªãŽãã¯ã¬ãªããã®ïŒâäœããå解é
µçŽ ã®åºè³ªãšããŠäœçšãã奜ãŸããã¯ïŒââããªãã·ãã¯ã¬ãªããããæãããïŒâäœã¯ãæšçã«ããã«å€§ããªèŠªåæ§ãæãããããã¯ã¬ã¢ãŒãŒæŽ»æ§ãæ¯ããããšã¯ã§ããªãããã«ä¿®é£ŸããïŒããšãã°ããã«ãªãâåã¯ïŒâââã¡ããã·ãšãã«çœ®æïŒãéããŸãåæ§ã§ããã
æ¬çºæã«åŸã£ãŠãæ¬çºæã®ãªãªãŽãã¯ã¬ãªããã®ïŒã€ã®ãè€æ°ã®åã¯ãã¹ãŠã®ãã¯ã¬ãªããåäœããïŒââã¡ããã·ãšãã«ïŒââ223ïŒã®ä¿®é£Ÿãæã£ãŠããã
ãïŒââã¡ããã·ãšãã«ã®ä¿®é£Ÿãæããè€æ°ã®ãã¯ã¬ãªãããµããŠããããå«ããªãªãŽãã¯ã¬ãªããã¯ããªãªãŽãã¯ã¬ãªããã®ç¯å²å ã§ãããªããã¯ã¬ãªãããµããŠãããã«ãã®ãããªä¿®é£Ÿãæããããšãã§ãããã¡ã©ãªãªãŽãã¯ã¬ãªããã§ãã£ãŠããããïŒââã¡ããã·ãšãã«ã®ä¿®é£Ÿã®ã»ãã«ãåã¯ããã«å ããŠãã¢ã³ãã»ã³ã¹ã®æå¹æ§ãæœåšååã¯æšçãžã®èŠªåæ§ãé«ãããã®ã»ãã®ä¿®é£Ÿãå«æãããªãªãŽãã¯ã¬ãªããã奜ãŸãããïŒä»¥äžã®ãã®ãããªä¿®é£Ÿãå«ããã¡ã©ãªãªãŽãã¯ã¬ãªããã¯çŸåšå¥œãŸããã
ãïŒââã¡ããã·ãšãã«ã®ä¿®é£Ÿãæããè€æ°ã®ãã¯ã¬ãªãããµããŠããããå«ããªãªãŽãã¯ã¬ãªããã¯ããªãªãŽãã¯ã¬ãªããã®ç¯å²å ã§ãããªããã¯ã¬ãªãããµããŠãããã«ãã®ãããªä¿®é£Ÿãæããããšãã§ãããã¡ã©ãªãªãŽãã¯ã¬ãªããã§ãã£ãŠããããïŒââã¡ããã·ãšãã«ã®ä¿®é£Ÿã®ã»ãã«ãåã¯ããã«å ããŠãã¢ã³ãã»ã³ã¹ã®æå¹æ§ãæœåšååã¯æšçãžã®èŠªåæ§ãé«ãããã®ã»ãã®ä¿®é£Ÿãå«æãããªãªãŽãã¯ã¬ãªããã奜ãŸãããïŒä»¥äžã®ãã®ãããªä¿®é£Ÿãå«ããã¡ã©ãªãªãŽãã¯ã¬ãªããã¯çŸåšå¥œãŸããã
æ¬çºæã«åŸã£ãŠäœ¿çšãããªãªãŽãã¯ã¬ãªããã¯ãåºçžåæã®åšç¥ã®ææ³ãä»ããŠéœåããäžã€æ¥åžžçã«äœè£œããŠãããããã®ãããªåæçšã®æ©åšã¯ãã¢ãã©ã€ããã€ãªã·ã¹ãã ãºãå«ã幟ã€ãã®è²©å£²æ¥è
ã«ãã£ãŠè²©å£²ãããŠããããã®ãããªåæã®ããã®ãã®ã»ãã®ææã®ã¢ãããŒããæ¡çšããŠããããããšãã°ãåæ§ã®ææ³ãçšããŠããã¹ããããªãšãŒãåã³ãïŒâââã¡ããã·ãšãã«ãªãªãŽãã¯ã¬ãªãããå«ãïŒââã¢ã«ã³ãã·åã¯ïŒâã¢ã«ã³ãã·ã¢ã«ã³ãã·ã®èªå°äœã®ãããªãªãªãŽãã¯ã¬ãªããã調補ããããšã¯åšç¥ã§ããïŒMartin, P., Heiv. Chim. Acta 78:486-504, 1995ïŒãé¡äŒŒã®ææ³ãçšããåžè²©ã®ä¿®é£Ÿ
ã¢ããã€ãåã³å¶åŸ¡ããã现åã¬ã©ã¹è£œåãããšãã°ãããªãã³ããã«ãªã¬ã»ã€ã³ãã¢ã¯ãªãžã³åã¯ããœã©ã¬ã³ã§ä¿®é£Ÿããã¢ããã€ãåã³ïŒåã¯ã³ã³ãããŒã«ãã»ãã¢ã»ã¬ã©ã¹ïŒïŒ£ïŒ°ïŒ§ïŒïŒããŒãžãã¢å·ãã¹ã¿ãŒãªã³ã°ã®ã°ã¬ã³ãªãµãŒãããå ¥æå¯èœïŒãçšããŠãèå çã«æšèããããããªãã³åãããåã¯ãã®ã»ãã§å ±åœ¹ããããªãªãŽãã¯ã¬ãªãããåæããããšãåšç¥ã§ãã
ã¢ããã€ãåã³å¶åŸ¡ããã现åã¬ã©ã¹è£œåãããšãã°ãããªãã³ããã«ãªã¬ã»ã€ã³ãã¢ã¯ãªãžã³åã¯ããœã©ã¬ã³ã§ä¿®é£Ÿããã¢ããã€ãåã³ïŒåã¯ã³ã³ãããŒã«ãã»ãã¢ã»ã¬ã©ã¹ïŒïŒ£ïŒ°ïŒ§ïŒïŒããŒãžãã¢å·ãã¹ã¿ãŒãªã³ã°ã®ã°ã¬ã³ãªãµãŒãããå ¥æå¯èœïŒãçšããŠãèå çã«æšèããããããªãã³åãããåã¯ãã®ã»ãã§å ±åœ¹ããããªãªãŽãã¯ã¬ãªãããåæããããšãåšç¥ã§ãã
æ¬çºæã®ã¢ã³ãã»ã³ã¹ååç©ã«ã¯ãè¬åŠäžèš±å®¹å¯èœãªå¡©åã³ãããã©ãã°ãå«ãçç©åçæ§ã®ååç©ãæãããããããã¯ãè¬åŠäžèš±å®¹å¯èœãªå¡©ããšã¹ãã«åã¯ãã®ãããªãšã¹ãã«ã®å¡©ãåã¯ããããå«ãåç©ã«æäžããéãçç©æŽ»æ§ã®ãããã®ä»£è¬ç£ç©åã¯æ®åºãæäŸããããšãå¯èœã§ãããã®ã»ãã®ååç©ãå«ãããšãæå³ãããåŸã£ãŠãããšãã°ãé瀺ããŸããæ¬çºæã®æ žé
žã®è¬åŠäžèš±å®¹å¯èœãªå¡©åã³ãã®ãããªæ žé
žã®ãããã©ãã°ã«åŒãã€ããããããè¬åŠäžèš±å®¹å¯èœãªå¡©ãã¯ãæ¬çºæã®æ žé
žã®ççåŠçã«äžã€è¬åŠäžèš±å®¹å¯èœãªå¡©ãããªãã¡ãæ¯åååç©ã®ææã®çç©æŽ»æ§ãä¿æããææã§ãªãæ¯æ§å¹æãããã«ä»äžããªãå¡©ã§ããïŒããšãã°ãBerge et al., ãå»è¬çãªå¡©ãJ. of Pharma. Sci. 66:1-19, 1977ãåç
§ã®ããšïŒã
ãªãªãŽãã¯ã¬ãªããã«ã€ããŠã¯ãè¬åŠäžèš±å®¹å¯èœãªå¡©ã®äŸã«ã¯ãïŒïœïŒãããªãŠã ãã«ãªãŠã ãã¢ã³ã¢ããŠã ããã°ãã·ãŠã ãã«ã«ã·ãŠã ãã¹ãã«ãã³åã³ã¹ãã«ããžã³çã®ãããªããªã¢ãã³ã®ãããªã«ããªã³ãšãšãã«åœ¢æãããå¡©ïŒïŒïœïŒããšãã°ãå¡©é
žãèåæ°ŽçŽ é
žãç¡«é
žããªã³é
žãç¡é
žãªã©ã®ãããªç¡æ©é
žãšå
±ã«åœ¢æãããé
žä»å å¡©ïŒïŒïœïŒããšãã°ãé
¢é
žãã·ã¥ãŠé
žãé
ç³é
žãã³ãã¯é
žããã¬ã€ã³é
žãããã«é
žãã°ã«ã³ã³é
žãã¯ãšã³é
žããªã³ãŽé
žãã¢ã¹ã³ã«ãã³é
žãå®æ¯éŠé
žãã¿ã³ãã³é
žããã«ããã³é
žãã¢ã«ã®ã³é
žãããªã°ã«ã¿ãã³é
žãããã¿ã¬ã³ã¹ã«ãã³é
žãã¡ã¿ã³ã¹ã«ãã³é
žãïœâãã«ãšã³ã¹ã«ãã³é
žãããã¿ã¬ã³ãžã¹ã«ãã³é
žãããªã¬ã©ã¯ããã³é
žãªã©ã®ãããªææ©é
žãšå
±ã«åœ¢æãããå¡©ïŒäžŠã³ã«ïŒïœïŒå¡©çŽ ãèçŽ ãåã³ãšãŠçŽ ã®ãããªå
çŽ ã¢ããªã³ãã圢æãããå¡©ãæãããããããããã«éå®ãããªãã
æ¬çºæã®ãªãªãŽãã¯ã¬ãªããã¯ãè¿œå çã«åã¯ä»£æ¿çã«ããããã©ãã°ãã®åœ¢æ
ã§ééãããããã«èª¿è£œãããŠããããçšèªããããã©ãã°ãã¯ãå
å æ§ã®é
µçŽ åã¯ãã®ã»ãã®ååŠç©è³ªã®äœçšåã³ïŒåã¯æ¡ä»¶ã«ãã£ãŠäœå
åã¯çŽ°èå
ã§æŽ»æ§ååã«å€æãããäžæŽ»æ§åã§èª¿è£œãããæ²»çå€ãæããããšãã°ãæ¬çºæã®ãªãªãŽãã¯ã¬ãªããã®ãããã©ãã°åã¯ãïŒïŒïŒïŒïŒïŒïŒïŒã§é瀺ãããæ¹æ³ã«åŸã£ãŠïŒ³ïŒ¡ïŒŽïŒ¥ïŒ»ïŒïŒ³âã¢ã»ãã«âïŒâããªãšãã«ïŒãã¹ãã§ãŒãèªå°äœãšããŠèª¿è£œãããã
âïŒã¿ã³ãã¯è³ªã®é»å®³ã®ããã®ç¹å®ã®ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã®é
åã¯ã以äžã®å®æœäŸïŒã«ç€ºãããã
å®æœäŸïŒã§äžããããå®æœæ
æ§ããã倧ããªåã¯å°ããªæ°ã®çœ®æãã¯ã¬ãªãããæããïŒâæ¹ååã¯ïŒâæ¹åã®ããããã§ïŒ³ïŒ€ïŒŠâïŒïœïŒ²ïŒ®ïŒ¡ã«æ²¿ã£ãŠããã«äŒžã³ãé
åçªå·ïŒãïŒïŒã§å
æ¬çã«åå®ãããããâïŒã¿ã³ãã¯è³ªã®çºçŸãé»å®³ããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããæ¬çºæã®ç¯å²å
ã§ããã
å¥ã®å®æœæ
æ§ã§ã¯ãâïŒã®äœçšã¯ãç¹ç°çãªäžåæäœã®ååšã«ãã£ãŠé»å®³ããããšãã§ããã
ããã«å¥ã®å®æœæ
æ§ã§ã¯ãæ¬çºæã¯ãâïŒã®çºçŸãé»å®³ããããã«èšèšãããæ žé
žéã®ããã®åœ¢è³ªç§»å
¥å€ãšããŠã®ãã«ã³ã®äœ¿çšãæäŸãããéºäŒåæ²»çãšããŠç¥ãããå»åŠã®å
端é åã¯ãè¬å€ééã®åé¡ã§å¶çŽãããŠããããã®ããã«ãã¢ã³ãã»ã³ã¹ãã¯ã¬ãªããããªãã¶ã€ã ãé»å®³å€ãå«ããªãªãŽãã¯ã¬ãªããã®ãããªéºäŒåæçåã¯æ žé
žéã¯ããããååç©ã®é»è·åã³é«ååéã®ããã«çŽ°èãžã®åã蟌ã¿ãé»å®³ãããŠãããæè¿ãéºäŒååã¯æ žé
žãå«æãã埮ç²åïŒããšãã°ããªã³é
žã«ã«ã·ãŠã ïŒã®äœ¿çšãããããã现èè¡šé¢ã«çµåãããšã³ããµã€ããŒã·ã¹åã¯é¥å
¥ã«ãã£ãŠåã蟌ãŸããçµæãšããŠéºäŒååã¯æ žé
žã®çŽ°èå
ãžã®äŸµå
¥ãçãããããªåœ¢è³ªç§»å
¥å€ãšããŠææ¡ãããŠãããã»ãšãã©ã®çŽ°èã¯ãèè¡šé¢ã«ãã«ã³å容äœãå«æããããã®å®æœæ
æ§ã§ã¯ãâïŒã®çºçŸãé»å®³ããããã«èšèšãããæ žé
žéããã³ã€ãã³åŸ®ç²åã«çµåããåã¯å
å
ããããšãã§ããå€ç§çéšäœã«é©çšãããåã®æº¶è§£ãé»å®³ããããã«ç²åãæ¶æ©ããããšãã§ããã
äžè¿°ãããæ¬æ现æžã§ã¯ã説æã®ç®çã§ç¹å®ã®å®æœæ
æ§ãèå¯ããŠããããé瀺ã®ç²Ÿç¥åã³ç¯å²ããéžè±ããããšãªãæ§ã
ãªæ¹å€ãè¡ã£ãŠãããããšãååã«ç解ãããã§ããããåŸã£ãŠãç³»ããã³æ¹æ³çã¯ãæ¬æ现æžã§è¿°ã¹ããã察象ç©ã®é åçµã¿åãããšåæ§ã«ãã®ãããªæ¹å€ãå
å«ããéå®ãããªãã
ç¹ã«æ瀺ãããªãéããã¯ã¬ãŒã ãé€ããŠããåã¯ãã®äœ¿çšã¯ããåã³ããå
å«ããéããŸãåæ§ã§ãããæããã«è¿°ã¹ãããªãéããåã¯èæ¯ãæããã«ç€ºããªãããããééå®ççšèªã¯éå®ãšããŠè§£éãããã¹ãã§ã¯ãªãïŒããšãã°ããå
å«ãããããæãããåã³ãå«ããã¯éåžžããéå®ãªãå
å«ãããããšãæãïŒããïœãããïœïœãåã³ãïœïœïœ
ãã®ãããªåäžåœ¢æ
ã¯ãæããã«è¿°ã¹ãããªãéããåã¯èæ¯ãæããã«ç€ºããªãããããè€æ°ã®åç
§ãå
å«ããã
ç·ç¶æ§ççæå¶å€ã®å®éçæå¹æ§ã®èå¯
å®æœæ æ§ã®ïŒã€ã§ã¯ãæå®ã®è¬å€åã¯è¬å€ã®çµã¿åããã®æå¹æ§ã¯ãæè¡ã®ç·ç¶æ§ççã«ã€ããŠãã©ããã®ç²è žåŽå£ã¢ãã«ã«ãŠãè¬å€åã¯çµã¿åããã«å¯Ÿããæå®ã®æšæºãããšãã°ãè¬å€ãè² è·ãããã¢ã«ãã³é žãããªãŠã ãã£ã«ã ã«å¯Ÿããåœç©ãè² è·ããåã¯ãã¢ã«ãã³é žãããªãŠã ãã£ã«ã ã®ã¿ã®å¹³ååèšççå€ïŒåŒ·ãïœé¢ç©ããïŒã®äœäžãšããŠè©äŸ¡ããããšãã§ãããä»ã®æšæºã«ã¯ããã®ã»ãã®ãã£ã«ã ã溶液çãåã³ãã®ã»ãã®ã¢ãã«ãããšãã°ããŠãµã®ã®åå®®è§ã¢ãã«åã¯ããã«ãããæå¹æ§ãæããããšãã§ãããçš®ã ã®å®æœæ æ§ã§ã¯ãè¬å€ã¯ãå¯Ÿç §ã®å€ãããšãã°ãæè¡ã®ç·ç¶æ§ççã«é¢ããã©ããã®ç²è žåŽå£ã¢ãã«ãçšãããã¢ã«ãããŒããã£ã«ã ã®ã¿ã®å€ã®ïŒïŒïŒïŒïŒïŒ ãïŒïŒ ãïŒïŒ ãïŒïŒïŒ ãïŒïŒïŒ ãïŒïŒïŒ ãåã¯ïŒïŒïŒ 以äžã®å¹³åãæããããšãã§ãããä»ã®æž¬å®ãã©ã¡ãŒã¿ã§ã¯ãè¬å€ã¯ãæ£è ã«ãããç·ç¶æ§ççã®åœ¢æãå®è³ªçã«ãã¹ãŠæå¶ããããšãã§ããã
å®æœæ æ§ã®ïŒã€ã§ã¯ãæå®ã®è¬å€åã¯è¬å€ã®çµã¿åããã®æå¹æ§ã¯ãæè¡ã®ç·ç¶æ§ççã«ã€ããŠãã©ããã®ç²è žåŽå£ã¢ãã«ã«ãŠãè¬å€åã¯çµã¿åããã«å¯Ÿããæå®ã®æšæºãããšãã°ãè¬å€ãè² è·ãããã¢ã«ãã³é žãããªãŠã ãã£ã«ã ã«å¯Ÿããåœç©ãè² è·ããåã¯ãã¢ã«ãã³é žãããªãŠã ãã£ã«ã ã®ã¿ã®å¹³ååèšççå€ïŒåŒ·ãïœé¢ç©ããïŒã®äœäžãšããŠè©äŸ¡ããããšãã§ãããä»ã®æšæºã«ã¯ããã®ã»ãã®ãã£ã«ã ã溶液çãåã³ãã®ã»ãã®ã¢ãã«ãããšãã°ããŠãµã®ã®åå®®è§ã¢ãã«åã¯ããã«ãããæå¹æ§ãæããããšãã§ãããçš®ã ã®å®æœæ æ§ã§ã¯ãè¬å€ã¯ãå¯Ÿç §ã®å€ãããšãã°ãæè¡ã®ç·ç¶æ§ççã«é¢ããã©ããã®ç²è žåŽå£ã¢ãã«ãçšãããã¢ã«ãããŒããã£ã«ã ã®ã¿ã®å€ã®ïŒïŒïŒïŒïŒïŒ ãïŒïŒ ãïŒïŒ ãïŒïŒïŒ ãïŒïŒïŒ ãïŒïŒïŒ ãåã¯ïŒïŒïŒ 以äžã®å¹³åãæããããšãã§ãããä»ã®æž¬å®ãã©ã¡ãŒã¿ã§ã¯ãè¬å€ã¯ãæ£è ã«ãããç·ç¶æ§ççã®åœ¢æãå®è³ªçã«ãã¹ãŠæå¶ããããšãã§ããã
ããšãã°ãæè¡ã®ç·ç¶æ§ççã«é¢ããã©ããã®ç²è
žåŽå£ã¢ãã«ãçšãããã¢ã«ãã³é
žãããªãŠã ãã£ã«ã ã®ã¿ã«å¯Ÿããè¬å€ã®æå¹æ§ãæ¯èŒãã以äžã®å®æœäŸã§ã¯ãå³ïŒãïŒã«ç€ºãããã«ããã³ã€ãã³ã¯ãçŽïŒïŒïŒ
æªæºã®ïŒŽïŒ¡ïŒ¶ãæãïŒçŽïŒïŒ
ã«ãŸã§èœã¡ãïŒãæïœââïŒïŒïŒ°ïŒ¢ïŒ³ïŒŠæäœåã³ãã¿ã¡ã¿ãŸã³ã¯ãçŽïŒïŒïŒ
æªæºã®ïŒŽïŒ¡ïŒ¶ãæããã³ã³ããã€ãã³ç¡«é
žïŒ¡ãããã¹ãã©ã³ç¡«é
žããšãªã¹ããã€ã·ã³åã³ïŒŽïŒ©ïŒïŒ°âïŒã¯ãçŽïŒïŒïŒ
æªæºã®ïŒŽïŒ¡ïŒ¶ãæããã¹ãã¬ãããããŒãŒãããã©ãµã€ã¯ãªã³ããããµã€ã¯ãªã³ããã¬ã€ã³é
žãšãã©ããªã«ãã³ãã¯é
žããã³ãã³ãã¡ãœãã¬ãã»ãŒãããã»ã¿ãã»ã«ããã¡ã¹ãªããã¡ã¯ããã§ãã³é
žãã¡ã¯ããã§ãã³é
žãããªãŠã äžæ°Žåç©åã³ãããµã¡ã¿ãŸã³ã¯ãçŽïŒïŒïŒ
æªæºã®ïŒŽïŒ¡ïŒ¶ãæãããããã·ãããžãã«ããµã«ããã«ã«ããžã³ãã¹ã¿ããªãŒã¹ãããããã·ãããã«ã»ã«ããŒã¹ãã€ã³ãã¡ã¿ã·ã³ãã±ã«ã»ãã³ãã¢ã«ã®ã³é
žãã«ããããªã«ãããã·ãµã€ã¯ãªã³ãâβåã³ã·ã ãã¹ã¿ãã³ã¯ãçŽïŒïŒïŒ
æªæºã®ïŒŽïŒ¡ïŒ¶ãæãã䞊ã³ã«é
¢é
žã³ã«ããŸã³ããããã·ã«ã ãã·ã¯ããã¹ãã¡ãããã¬ãã«ããããã³ã©ãŒã²ã³ãããã¹ãããŒã¹ã¯ãçŽïŒïŒïŒïŒ
æªæºã®ïŒŽïŒ¡ïŒ¶ãæãããå¥ã®å®æœæ
æ§ã§ã¯ãå°ãªããšãïŒäººã®è©Šéšå¯Ÿè±¡åã¯æ£è
ã«ãããççãã¹ãŠãæå¶ããããšïŒããªãã¡åèšççå€ïŒåŒ·ãïœé¢ç©ïŒã®å°ºåºŠã§ãŒãã«ã¹ã³ã¢åãããïŒã«ãããæå¹æ§ã«åŸã£ãŠè¬å€ãè©äŸ¡ããããšãã§ãããããšãã°ã以äžã®å®æœäŸã§ã¯ãç·ç¶æ§ççã®çºçãçãããç²è
žåŽå£éšäœã«æ²»çäžã®æå¹éã®äœçšå€ãæäžããåŸãå°ãªããšãïŒå¹ã®è©Šéšåç©ã«ãŠããã³ã€ãã³ãã·ã¹ãã©ãã³ãã¡ãœãã¬ãã»ãŒãããã»ã¿ãã»ã«ããããµã¡ã¿ãŸã³åã³æâïŒæäœã®ãããããç·ç¶æ§ççãå®å
šã«æå¶ããã
å®æœäŸ
ç°¡åã«èŠçŽãããšãå®æœäŸïŒåã³ïŒã¯ãåç©ã¢ãã«ãçšããæè¡ã®ççã«å¯Ÿããçš®ã ã®äœçšå€ã®æå¹æ§ã®è§£æãæåããå®æœäŸïŒãïŒã¯ãã¢ã³ãã»ã³ã¹åã³ãã®ã»ãã®ïŒ³ïŒ€ïŒŠâïŒé»å®³å€ã«é¢ãããå®æœäŸïŒãïŒïŒã¯ãã©ããã€ã·ã³ã«é¢ãããå®æœäŸïŒïŒãïŒïŒã¯ãç·ç¶æ§ççæå¶å€ã®çš®ã ã®è£œå€ã«é¢ãããå®æœäŸïŒïŒã¯ãæ§ã ãªèµ·æºã«ç±æ¥ãããã³ã€ãã³ã®æå¹æ§ã«é¢ããã
ç°¡åã«èŠçŽãããšãå®æœäŸïŒåã³ïŒã¯ãåç©ã¢ãã«ãçšããæè¡ã®ççã«å¯Ÿããçš®ã ã®äœçšå€ã®æå¹æ§ã®è§£æãæåããå®æœäŸïŒãïŒã¯ãã¢ã³ãã»ã³ã¹åã³ãã®ã»ãã®ïŒ³ïŒ€ïŒŠâïŒé»å®³å€ã«é¢ãããå®æœäŸïŒãïŒïŒã¯ãã©ããã€ã·ã³ã«é¢ãããå®æœäŸïŒïŒãïŒïŒã¯ãç·ç¶æ§ççæå¶å€ã®çš®ã ã®è£œå€ã«é¢ãããå®æœäŸïŒïŒã¯ãæ§ã ãªèµ·æºã«ç±æ¥ãããã³ã€ãã³ã®æå¹æ§ã«é¢ããã
ã©ããã«ãããç²è
žåŽå£ã®æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã«é¢ããè¬å€è² è·ãã¢ã«ãã³é
žãã£ã«ã ã®æå¹æ§
æè¡ççã®ã©ããç²è žåŽå£ã¢ãã«ãçšããŠãæ¬æ现æžã§èå¯ããåäœçšå€ïŒä»¥äžãè¬å€ãšåŒã¶ïŒã®æäžã®å¹æãè¡åŸåã®ç·ç¶æ§ççã®é²æ¢ã«ã€ããŠæ€èšããããã®ã¢ãã«ã§ã¯ã©ãããïŒå¹ã®çŸ€ã«åãããæè¡ã®æå·åŸãã©ãããåŠçœ®ããªãããåã¯æ¶æ©ãããã¢ã«ãã³é žïŒïŒšïŒ¡ïŒãã£ã«ã åã¯ãã£ã«ã ã«ä»¥äžã®æ¿åºŠïŒïŒ ïœïŒïœïŒã®è¬å€ãå«æãããã£ã«ã ã§åŠçããã
æè¡ççã®ã©ããç²è žåŽå£ã¢ãã«ãçšããŠãæ¬æ现æžã§èå¯ããåäœçšå€ïŒä»¥äžãè¬å€ãšåŒã¶ïŒã®æäžã®å¹æãè¡åŸåã®ç·ç¶æ§ççã®é²æ¢ã«ã€ããŠæ€èšããããã®ã¢ãã«ã§ã¯ã©ãããïŒå¹ã®çŸ€ã«åãããæè¡ã®æå·åŸãã©ãããåŠçœ®ããªãããåã¯æ¶æ©ãããã¢ã«ãã³é žïŒïŒšïŒ¡ïŒãã£ã«ã åã¯ãã£ã«ã ã«ä»¥äžã®æ¿åºŠïŒïŒ ïœïŒïœïŒã®è¬å€ãå«æãããã£ã«ã ã§åŠçããã
ãã¢ã«ãã³é
žãã£ã«ã ã®èª¿è£œïŒæ°Žã«ãã¢ã«ãã³é
žãããªãŠã åã³ã°ãªã»ããŒã«ãäžæ©æº¶è§£ããããšã«ãã£ãŠãã¢ã«ãã³é
žæº¶æ¶²ã調補ããããã¢ã«ãã³é
žãããªãŠã ãšã°ãªã»ããŒã«ã®æ¯ã¯ãçŽïŒïŒïŒã§ããã溶質ïŒãã¢ã«ãã³é
žãããªãŠã åã³ã°ãªã»ããŒã«ïŒã®åèšæ¿åºŠã¯ãïŒãïŒïŒ
ïœïŒïœã®éã ã£ããååéãã¹ããŒãã«ã§æ··åããããšã«ããè¬å€ã溶液ã«çµã¿å
¥ãããã¢ã«ãã³é
žãããªãŠã åã³ã°ãªã»ããŒã«ã«å¯ŸããŠïŒïŒ
ãïŒïŒ
ãïŒïŒïŒ
ãŸãã¯çŽïŒïŒïŒ
ã®è¬å€æ··åç©ã補é ããïŒããªãã¡ãè¬å€ã®æ¿åºŠã¯æ°Žãèšç®ã«å«ããªãïŒã
æ¶æ©å€ããçŽïŒïŒïŒïŒ
ïœïŒïœïŒæ°Žã«ãããæçµæ¿åºŠïŒã§å«ãããïŒæã®ãã©ã¹ããã¯è£œãããªç¿ã«æº¶æ¶²ãããããã£ã³ã°ããïŒïŒâã«ãŠå°ãªããšãïŒïŒæé也ç¥ããããšã«ãã£ãŠãããã®æº¶æ¶²ãããã£ã«ã ãæ圢ãããå€ç§çšã®åãçšããŠå也ç¥ãã£ã«ã ããããªç¿ããå€ããïŒïŒïŒïœïœïœïŒïŒïŒïœïœã®å€§ããã«åæããã
åç©è©ŠéšïŒæè¡ã®æå·ã¯ä»¥äžã®ããã«èªå°ãããäœéãïŒïŒïŒãïŒïŒïŒïœã®æçããã¹ãã©ãŒã°ããŒãªãŒç³»ã©ããã¯ãããªãã£ãã·ã¥ã³ãã³ãã¢å€§åŠåç©æœèšããå
¥æãããèçŒçã«æ£åžžã«èŠããïŒããªãã¡ãæž
æœã§ä¹±ãã®ãªãæ¯ç®ãæããæŸãã ç®åã³æŽ»åçãªå§¿å¢ã瀺ãïŒåç©ã®ã¿ããã®è©Šéšã«çšãããåç©ãç¡äœçºã«åŠç矀ã«å²ãæ¯ããã€ãœãã«ã©ã³ã¬ã¹ã«ãã£ãŠéº»é
ãããè
¹éšãåæ¯ããç®èçšæèæŽå€ïŒã¹ããªã¹ã¿ããïŒïŒ
ïŒã§æž
æµããã¯ãããããµã³ãæ²ã¿ããŸããã¬ãŒãŒã§ã¬ãã£ããå°Ÿéèã«åãç®ãå
¥ããå°éã®è¡æ¶²è©ŠæãåŸãïŒïŒïŒïŒïœïŒ¬ä»¥äžïŒããã®è¡æ¶²è©Šæã§çœè¡çæ°ãæ°ãããæçç©è³ªïŒïŒïŒïŒïŒïŒïŒåäœïŒïœïœã®ããâããã·ãªã³ïŒãåã©ããã®å³å€§è
¿ã«æ³šå°ããé®çå€ïŒïŒïŒïŒïŒïœïœïŒïœïœã®ããã¬ãã«ãã£ã³ïŒã巊倧è
¿ã«æ³šå°ããããã³ã»ããã§çèã管çããªãããçœç·ã®åŸæ¹çŽïŒïœïœã«å§ãŸãç®èã«ïŒïœïœã®åéãäœã£ããç²è
žãèŠã€ããè
¹è
ããåŒãåºããèé¢ãšè
¹é¢åæ¹ã®è¡šé¢ããïŒïŒå·ã®å€ç§çšã¡ã¹ã§ç²è
žè¡šé¢ã«å¯ŸããŠïŒïŒåºŠã®è§åºŠã§ïŒïŒåããã£ãŠæªæãããããåãæããŠããæ¹åãšå察æ¹åã§ããã£ããççé£å¡©æ°Žã«æµžããã¬ãŒãŒã«ããã£ãç²è
žãå
ãã ããã€ã³ãçšããŠç®èããè
¹èå£ãé¢ãããã€ã³ãçšããŠè
¹èå£ãå転ããå£ã®å
åŽããããããæµ
ãåéã«ãã£ãŠãããŸãã«ïŒïŒïŒïœïœïœïŒïŒïŒïœïœã®é·æ¹åœ¢ã®å·ãè
¹èå£ã«äœã£ãããã³ã»ãããçšããŠäžã®èåã³çèçµç¹ã®å±€ãé€ãããïŒâïŒã®çž«å糞ãçšããŠãïŒã€ã®çž«ãç®ã®äžãçµæããããšãªããé·æ¹åœ¢ã®ïŒã€ã®è§ãçž«ãåãããããã£ã«ã ãäžæããã£ãé·æ¹åœ¢ã®äžã«çœ®ãã次ãã§ãïŒã€ã®çž«ãç®ã®äžããã€ãçµãã ãæªåŠçã®å¯Ÿç
§çŸ€ã®å Žåã§ã¯ãããã£ãäžã«ãã£ã«ã ã¯çœ®ããªãã£ããè
žç®¡ã«ããããããã®å¿åãé²ããããªæ¹æ³ã§ãããããèåšãè
¹ã®äžã«æ»ãããïŒâïŒã®çž«å糞ã§è
¹èå£ãéããïŒâïŒã®çž«å糞ã§æè¡ã®åéãéãããåç©ã®éŠã®åšãã«ã«ã©ãŒãä»ããŠãçž«ãåããã劚害ããã®ãé²ãã ãã©ãããæž
æœãªã±ãŒãžã«å
¥ããæèãæ»ããŸã§å ç±ã©ã³ãã§æž©ãããæè¡åŸæ¯æ¥ãã©ããã®äœéã枬å®ããã
æè¡ã®ïŒé±éåŸãç·ç¶æ§ççãè©äŸ¡ãããççã®åŸŽååã³åµå·æ²»çã®æ¬ åŠã«ã€ããŠåééšäœãèŠèŠçã«ãã§ãã¯ãããã©ããã麻é
ããå°Ÿéèã®åãç®ããçœè¡çæ°ã決å®ããããã«è¡æ¶²è©ŠæãåŸãã次ãã§ïŒ£ïŒ¯2ãçšããŠã©ãããå± æ®ºãã次ãã§æ£äžã«æ²¿ã£ãŠåå
éãããç°åžžã«ã€ããŠå èãèŠèŠçã«ãã§ãã¯ãããçž«å糞ãå€ããç²è žãšåŽå£ãšã®éãåæ§ã«çž«ãåããç¹ã«ãããç·ç¶æ§ççããäºåã«å®çŸ©ããã¹ã³ã¢åã·ã¹ãã ã«åŸã£ãŠè©äŸ¡ããããã®è©äŸ¡ã«äœ¿çšããïŒçš®é¡ã®åºæºããã£ããç·ç¶æ§ççã¯ã以äžã®å°ºåºŠã«åŸã£ãŠæ±ºå®ããã
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
éãããç°åžžã«ã€ããŠå èãèŠèŠçã«ãã§ãã¯ãããçž«å糞ãå€ããç²è žãšåŽå£ãšã®éãåæ§ã«çž«ãåããç¹ã«ãããç·ç¶æ§ççããäºåã«å®çŸ©ããã¹ã³ã¢åã·ã¹ãã ã«åŸã£ãŠè©äŸ¡ããããã®è©äŸ¡ã«äœ¿çšããïŒçš®é¡ã®åºæºããã£ããç·ç¶æ§ççã¯ã以äžã®å°ºåºŠã«åŸã£ãŠæ±ºå®ããã
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
é¢ç©ã¹ã³ã¢ãç·ç¶æ§ççã®åŒ·åºŠã¹ã³ã¢ã«ä¹ããããšã«ãã£ãŠåç©ã«ã€ããŠã®å
šäœçãªç·ç¶æ§ççã®ã¹ã³ã¢ã決å®ããã
è¬å€è² è·ãã£ã«ã ã®æ²»çå¹æã瀺ãäžé£ã®ã°ã©ããå³ïŒãïŒã«ç€ºããããŒã¿ããæå®ã®è² è·ã¬ãã«ã§ä»¥äžã®è¬å€ã«ãã£ãŠåŠçãããåç©ã¯å¯Ÿç
§çŸ€ã®åç©ãããäœãå
šäœçãªç·ç¶æ§ççã®ã¹ã³ã¢ãæããããšãèŠãåºãããããšãæããã«ããŠãããšããããšã¯ãè¬å€è² è·ãã£ã«ã ã«ãã£ãŠç·ç¶æ§ççã®åœ¢æãå¹æçã«æå¶ãããããšãæããã«ããŠãããççã¹ã³ã¢ã®äœäžã¯ãçåŽã¹ãã¥ãŒãã³ãã®ïœæ€å®ãçšããŠãããã¹ãã©ã³ç¡«é
žïŒïŒïŒ
ïœïŒïœïŒããã¬ã€ã³é
žãšãã©ããªã«ïŒïŒïŒ
ïœïŒïœïŒãã·ã¹ãã©ãã³ïŒïŒïŒ
ïœïŒïœïŒãããã¹ãã©ã³ç¡«é
žïŒïŒïŒïŒ
ïœïŒïœïŒããã³ã€ãã³ïŒïŒïŒïŒ
ïœïŒïœïŒããšãªã¹ããã€ã·ã³ïŒïŒïŒ
ïœïŒïœïŒãåã³ããã©ãµã€ã¯ãªã³ïŒïŒïŒ
ïœïŒïœïŒã«ã€ããŠçµ±èšåŠçã«ææïŒïŒ°ïŒïŒïŒïŒïŒïŒã§ãã£ãã
ãŠãµã®ã«ãããåå®®è§æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã«å¯Ÿããè¬å€è² è·ãã¢ã«ãã³é
žãã£ã«ã ã®æå¹æ§
ãŠãµã®ã«ãããåå®®è§æè¡ççã¢ãã«ãçšããŠãæ¬æ现æžã§èå¯ããéžæãããåäœçšå€ïŒä»¥äžãè¬å€ãšåŒã¶ïŒã®æäžã®å¹æãè¡åŸåã®ç·ç¶æ§ççã®é²æ¢ã«ã€ããŠæ€èšããããã®ã¢ãã«ã§ã¯ãŠãµã®ãïŒå¹ã®çŸ€ã«åãããæè¡ã®æå·åŸããŠãµã®ããæ¶æ©ãããã¢ã«ãã³é žïŒïŒšïŒ¡ïŒãã£ã«ã ãïŒïŒ ïœïŒïœã§è² è·ããè¬å€ãå«æããæ¶æ©ãããã£ã«ã ãïŒïŒ ïœïŒïœã§è² è·ããè¬å€ãå«æããæ¶æ©ãããã£ã«ã ãïŒïŒïŒ ïœïŒïœã§è² è·ããè¬å€ãå«æããæ¶æ©ãããã£ã«ã ãïŒïŒ ïœïŒïœãïŒïŒïŒ ïœïŒïœã®éã®æ¿åºŠã§è² è·ããè¬å€ãå«æããæ¶æ©ãããã£ã«ã ã§åŠçããåã¯åŠçããªãïŒå¯Ÿç §çŸ€ïŒãä»ã®åŠç矀ã¯ãïŒïŒïŒïŒïŒïŒïŒ ïœïŒïœãïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒåã¯ïŒïŒ ïœïŒïœãïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãåã¯ïŒïŒ ïœïŒïœãïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãåã¯ïŒïŒ ïœïŒïœãïŒïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãåã¯ïŒïŒïŒ ïœïŒïœãïŒïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãåã¯ïŒïŒïŒ ïœïŒïœãïŒïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãå«ãã
ãŠãµã®ã«ãããåå®®è§æè¡ççã¢ãã«ãçšããŠãæ¬æ现æžã§èå¯ããéžæãããåäœçšå€ïŒä»¥äžãè¬å€ãšåŒã¶ïŒã®æäžã®å¹æãè¡åŸåã®ç·ç¶æ§ççã®é²æ¢ã«ã€ããŠæ€èšããããã®ã¢ãã«ã§ã¯ãŠãµã®ãïŒå¹ã®çŸ€ã«åãããæè¡ã®æå·åŸããŠãµã®ããæ¶æ©ãããã¢ã«ãã³é žïŒïŒšïŒ¡ïŒãã£ã«ã ãïŒïŒ ïœïŒïœã§è² è·ããè¬å€ãå«æããæ¶æ©ãããã£ã«ã ãïŒïŒ ïœïŒïœã§è² è·ããè¬å€ãå«æããæ¶æ©ãããã£ã«ã ãïŒïŒïŒ ïœïŒïœã§è² è·ããè¬å€ãå«æããæ¶æ©ãããã£ã«ã ãïŒïŒ ïœïŒïœãïŒïŒïŒ ïœïŒïœã®éã®æ¿åºŠã§è² è·ããè¬å€ãå«æããæ¶æ©ãããã£ã«ã ã§åŠçããåã¯åŠçããªãïŒå¯Ÿç §çŸ€ïŒãä»ã®åŠç矀ã¯ãïŒïŒïŒïŒïŒïŒïŒ ïœïŒïœãïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒåã¯ïŒïŒ ïœïŒïœãïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãåã¯ïŒïŒ ïœïŒïœãïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãåã¯ïŒïŒ ïœïŒïœãïŒïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãåã¯ïŒïŒïŒ ïœïŒïœãïŒïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãåã¯ïŒïŒïŒ ïœïŒïœãïŒïŒïŒ ïœïŒïœã®éã®æ¿åºŠã®è¬å€ã®æº¶æ¶²ïŒæžæ¿æ¶²ïŒãå«ãã
ãã¢ã«ãã³é
žãã£ã«ã ã®èª¿è£œïŒæ°Žã«ãã¢ã«ãã³é
žãããªãŠã åã³ã°ãªã»ããŒã«ãäžæ©æº¶è§£ããããšã«ãã£ãŠãã¢ã«ãã³é
žæº¶æ¶²ã調補ããããã¢ã«ãã³é
žãããªãŠã ãšã°ãªã»ããŒã«ã®æ¯ã¯ãçŽïŒïŒïŒã§ããã溶質ïŒãã¢ã«ãã³é
žãããªãŠã åã³ã°ãªã»ããŒã«ïŒã®åèšæ¿åºŠã¯ãïŒãïŒïŒïŒïŒ
ïœïŒïœã®éã§ãããååéãã¹ããŒãã«ã§æ··åããããšã«ããè¬å€ã溶液ã«çµã¿å
¥ãããã¢ã«ãã³é
žãããªãŠã åã³ã°ãªã»ããŒã«ã«å¯ŸããŠïŒïŒ
ãïŒïŒ
ãåã¯çŽïŒïŒïŒ
ã®è¬å€æ··åç©ã補é ããïŒããªãã¡ãè¬å€ã®æ¿åºŠã¯æ°Žãèšç®ã«å«ããªãïŒã
æ¶æ©å€ããçŽïŒïŒïŒïŒ
ïœïŒïœïŒæ°Žã«ãããæçµæ¿åºŠïŒã§å«ããã§ããããïŒæã®ãã©ã¹ããã¯è£œãããªç¿ã«æº¶æ¶²ãããããã£ã³ã°ããïŒïŒâã«ãŠå°ãªããšãïŒïŒæé也ç¥ããããšã«ãã£ãŠãããã®æº¶æ¶²ãããã£ã«ã ãæ圢ããã次ãã§å€ç§çšã®åãçšããŠå也ç¥ãã£ã«ã ããããªç¿ããå€ããïŒïŒïŒïœïœïœïŒïŒïŒïœïœã®å€§ããã«åæããã
è¬å€æº¶æ¶²ïŒç¹æ»Žçšå€ïŒã®èª¿è£œïŒ
é©åœéã®è¬å€ãæ°Žæ§æº¶æ¶²ïŒããšãã°ãä¹³é žå ãªã³ã¬ãŒæ¶²ãïŒã«æº¶è§£ããããããã®æº¶æ¶²ããéããŠç²ãç²åãé€ããïŒïŒÎŒïœã®ãã£ã«ã¿ãŒåã¯ãªãŒãã¯ã¬ãŒãåã¯ãã®ã»ãã®é©åœãªæ段ã«ãã£ãŠæ» èãããè¬å€ã溶液ã§ã¯ãªãæžæ¿æ¶²ãšããŠæäžãããªãã°ããéå·¥çšã¯äœ¿çšããªããæè¡åŠçœ®ã®çµãããæè¡åéãéããããã®ãŠãµã®ã®æåŸã®çž«åã®çŽåã«ãæ» èããç¹æ»Žçšå€ã®è¬å€ãè ¹è ã«çŽæ¥æäžããã
é©åœéã®è¬å€ãæ°Žæ§æº¶æ¶²ïŒããšãã°ãä¹³é žå ãªã³ã¬ãŒæ¶²ãïŒã«æº¶è§£ããããããã®æº¶æ¶²ããéããŠç²ãç²åãé€ããïŒïŒÎŒïœã®ãã£ã«ã¿ãŒåã¯ãªãŒãã¯ã¬ãŒãåã¯ãã®ã»ãã®é©åœãªæ段ã«ãã£ãŠæ» èãããè¬å€ã溶液ã§ã¯ãªãæžæ¿æ¶²ãšããŠæäžãããªãã°ããéå·¥çšã¯äœ¿çšããªããæè¡åŠçœ®ã®çµãããæè¡åéãéããããã®ãŠãµã®ã®æåŸã®çž«åã®çŽåã«ãæ» èããç¹æ»Žçšå€ã®è¬å€ãè ¹è ã«çŽæ¥æäžããã
åç©è©Šéš
ãŠãµã®ã«ãããåå®®è§æè¡ççã¢ãã«ãçšããŠãããã®è£œå€ã調ã¹ããç°¡åã«èšãã°ããŠãµã®ã®è ¹éšã«åéãäœããåå®®è§ãèŠã€ããè§ã®åºéšãæå®ãã(åã³äžè²«ãã)æéãã€ããããšã«ãã£ãŠå·ã€ãããå€ç§çšã¡ã¹ã§ãããããšã«ãã£ãŠç¹å®ã®é åã§ãŠãµã®ã®è ¹èã®åŽå£ãå·ã€ãããè ¹èã®åŽå£ã®ããã£ãé åã«èŒãããããªæ¹æ³ã§åå®®è§ã眮ããè§ã®å 端ãçž«ãåããããçž«ãåããã¯ãåŽå£ã®ããã£ãé åã®å€ã«ããããåå®®è§ãããã£ãé åããå€ããã®ãé²ãã
ãŠãµã®ã«ãããåå®®è§æè¡ççã¢ãã«ãçšããŠãããã®è£œå€ã調ã¹ããç°¡åã«èšãã°ããŠãµã®ã®è ¹éšã«åéãäœããåå®®è§ãèŠã€ããè§ã®åºéšãæå®ãã(åã³äžè²«ãã)æéãã€ããããšã«ãã£ãŠå·ã€ãããå€ç§çšã¡ã¹ã§ãããããšã«ãã£ãŠç¹å®ã®é åã§ãŠãµã®ã®è ¹èã®åŽå£ãå·ã€ãããè ¹èã®åŽå£ã®ããã£ãé åã«èŒãããããªæ¹æ³ã§åå®®è§ã眮ããè§ã®å 端ãçž«ãåããããçž«ãåããã¯ãåŽå£ã®ããã£ãé åã®å€ã«ããããåå®®è§ãããã£ãé åããå€ããã®ãé²ãã
ããã£ãé åã®äžïŒè§ãšåŽå£ã®éïŒã«çŽæ¥çœ®ãããšã«ãã£ãŠãã£ã«ã 補å€ã®æå¹æ§ãè©äŸ¡ããã
æè¡åŠçœ®ãå®äºããåã«ããŠãµã®ã®è
¹éšã§èª¿ã¹ãããŠãã補å€ãïŒïŒïœïŒ¬ç¹æ»Žããããšã«ãã£ãŠç¹æ»Žçšå€ã®è£œå€ã®æå¹æ§ãè©äŸ¡ããã
æè¡åŠçœ®ãå®äºããåã«ããŠãµã®ã®è
¹éšã«ïŒïŒïœïŒ¬ã®ä¹³é
žå ãªã³ã¬ãŒæ³šå°æ¶²ïŒµïŒ³ïŒ°ãç¹æ»Žããããšã«ãã£ãŠèª¿ã¹ããã察ç
§çŸ€ãšããããã®è£œå€ãæ¯èŒããã
åŠçœ®ã®ïŒïŒæ¥åŸããŠãµã®ãå®æ¥œæ»ãããŠçç圢æã®çšåºŠãè©äŸ¡ãããè©äŸ¡è
ã¯ãã©ã®çŸ€ãè©äŸ¡ãããã®ãã«ã€ããŠç²æ€ãããççã«èŠãããé¢ç©ãšåœ¢æããççã®åŒ·åºŠã®ç©ãšããŠãããã®ççãã©ã³ã¯åããããççã«èŠãããé¢ç©ã¯ïŒç¹ã®å°ºåºŠã§ã©ã³ã¯åãããççã®åŒ·åºŠã¯ãïŒãïŒã®å°ºåºŠã§ã©ã³ã¯åãããã
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
次ãã§ãé¢ç©ã¹ã³ã¢ãç·ç¶æ§ççã®åŒ·åºŠã¹ã³ã¢ã«ä¹ããããšã«ãã£ãŠåãŠãµã®ã«ã€ããŠã®ççã¹ã³ã¢ãåŸããããè¬å€ã§åŠçãããåç©ãã察ç
§ã«ãããåç©ãããäœãå
šäœã®ç·ç¶æ§ççã®ã¹ã³ã¢ãæããããšãå€æãããšããããšã¯ã察ç
§çŸ€ãšæ¯ã¹ãå ŽåãåŠçãããã©ããã«ãããå€èŠ³ãäœéåã¯çœè¡çæ°ã§ã®å€åã®æ¬ åŠã«ãã£ãŠèªããããããã«æãããªæ¯æ§ã䌎ããã«ãè¬å€è² è·ãã£ã«ã åã³ïŒåã¯è¬å€è² è·ç¹æ»Žçšå€æº¶æ¶²ïŒåã¯æžæ¿æ¶²ïŒã«ãã£ãŠç·ç¶æ§ççã®åœ¢æãå¹æçã«æå¶ãããããšãæããã«ããŠããã
âïŒã¿ã³ãã¯è³ªã®é»å®³ã®ããã®å¥œé©ãªã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã®æ±ºå®
âïŒïœïŒ²ïŒ®ïŒ¡ã®ã¢ã³ãã»ã³ã¹ã®å¯èœæ§ãããé åã決å®ããããã«ãâïŒã®ïœïŒ²ïŒ®ïŒ¡é åããã€ãªãã¯ãããžãŒæ å ±åœç«ã»ã³ã¿ãŒïŒïŒ®ïŒ£ïŒ¢ïŒ©ïŒã®ããŒã¿ããŒã¹ããå ãå ¥æãããhttp://www.ncbi.nlm.nih.govïœã«ãŠããŒã¿ããŒã¹ã«ã¢ã¯ã»ã¹ã§ãããæ€
玢ãã©ã¡ãŒã¿ã«ãããŠããããå ¥åããããâïŒïœïŒ²ïŒ®ïŒ¡ã«çžåœããåèšçªå·ïŒ®ïŒïŒ¿ïŒïŒïŒïŒïŒïŒãæã€é åãèŠãåºããã
âïŒïœïŒ²ïŒ®ïŒ¡ã®ã¢ã³ãã»ã³ã¹ã®å¯èœæ§ãããé åã決å®ããããã«ãâïŒã®ïœïŒ²ïŒ®ïŒ¡é åããã€ãªãã¯ãããžãŒæ å ±åœç«ã»ã³ã¿ãŒïŒïŒ®ïŒ£ïŒ¢ïŒ©ïŒã®ããŒã¿ããŒã¹ããå ãå ¥æãããhttp://www.ncbi.nlm.nih.govïœã«ãŠããŒã¿ããŒã¹ã«ã¢ã¯ã»ã¹ã§ãããæ€
玢ãã©ã¡ãŒã¿ã«ãããŠããããå ¥åããããâïŒïœïŒ²ïŒ®ïŒ¡ã«çžåœããåèšçªå·ïŒ®ïŒïŒ¿ïŒïŒïŒïŒïŒïŒãæã€é åãèŠãåºããã
åã¯ïŒ€ïŒ®ïŒ¡ã®äºæ¬¡é
åãäºæž¬ãããªã³ã©ã€ã³ãµãŒãã¹ã§ããïœïœïœïœïœã«é
åãæåºããããããã¯ãhttp://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.htmlã«ãŠã¢ã¯ã»ã¹ã§ãããïœïœïœïœïœã®ãµãŒãã¹ã¯ïŒïŒïŒïŒå¡©åºã«éå®ãããŠãããã
âïŒã®é åã¯ïŒïŒïŒïŒå¡©åºã®é·ãã§ããããšã«æ³šæã«ã®ããšãâïŒé åã®æåã®ïŒïŒïŒïŒå¡©åºã®ã¿ãçšããã
âïŒã®é åã¯ïŒïŒïŒïŒå¡©åºã®é·ãã§ããããšã«æ³šæã«ã®ããšãâïŒé åã®æåã®ïŒïŒïŒïŒå¡©åºã®ã¿ãçšããã
ïœïœïœïœïœã¯é
åãåŠçããæ€çŽ¢çµæããªã³ã©ã€ã³ã§æ瀺ããã®ã«ïŒïŒæéããããïŒæ¥ä»¥å
ã«ïœïœïœïœïœã®ãµãŒããŒããåé€ãããã®ã§ãçµæãããŠã³ããŒããã¹ãã§ããã
ïœïœïœïœïœãµãŒãã¹ã¯ãïŒïŒã®å¯èœæ§ã®ããé
åãäºæž¬ããã¢ã³ãã»ã³ã¹é
åãïœïŒ²ïŒ®ïŒ¡ã«çµåããå¯èœæ§ã®ããéšäœã«ã€ããŠåæ§é ãçèŠããã以äžã«æããããã«ããããã®é åã¯ååå
çµåãæããªãã®ã§ãæ§é ã«ãããŠã«ãŒããæ¢ãããšã«ãã£ãŠãããè¡ã£ãã
äžèšã«ãŒãã«äœ¿çšããçžè£çé
åã¯ãïŒââïŒé
åçªå·ïŒïŒã§ãã£ãããã®æ¹æ³ã«åºã¥ããŠå
šéšã§ãïŒïŒã®é
åãèšèšãããã¢ã³ãã»ã³ã¹ãèšèšããã®ã«äœ¿çšããåã«ãŒãæ§é ã¯ãïŒïŒé
åã®ãã¡å°ãªããšãïŒïŒã«ååšããããšã確èªããã
âïŒã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã®è£œé åã³ããªã«ããã©ã¯ãã³ã®ããŒã¹ãããã®ãã®å¶åŸ¡æŸåº
ïŒïŒïŒ ïŒïœïŒïœïŒã®æ¿åºŠã«ãŠïŒïŒâã«ãŠã¹ããŒãã«ã§ãã朰ãããšã«ããâïŒé»å®³å€ãããªã«ããã©ã¯ãã³ïŒïŒ°ïŒ£ïŒ¬ãããŒãã³ã¬ã ããªããŒãºãååéïŒïŒïŒ«ïŒãšæ··åããã次ãã§ããã®æ··åç©ãïŒïœïŒ¬ã®ãã©ã¹ããã¯è£œæ³šå°åšã«è£ å¡«ããå·åŽããããã®è£œå€ãïŒïŒã²ãŒãžã®éãä»ããŠïŒïŒâã«ãŠæ³šå°ããããšãã§ããã
ïŒïŒïŒ ïŒïœïŒïœïŒã®æ¿åºŠã«ãŠïŒïŒâã«ãŠã¹ããŒãã«ã§ãã朰ãããšã«ããâïŒé»å®³å€ãããªã«ããã©ã¯ãã³ïŒïŒ°ïŒ£ïŒ¬ãããŒãã³ã¬ã ããªããŒãºãååéïŒïŒïŒ«ïŒãšæ··åããã次ãã§ããã®æ··åç©ãïŒïœïŒ¬ã®ãã©ã¹ããã¯è£œæ³šå°åšã«è£ å¡«ããå·åŽããããã®è£œå€ãïŒïŒã²ãŒãžã®éãä»ããŠïŒïŒâã«ãŠæ³šå°ããããšãã§ããã
ããŒã¹ãããã®è¬å€ã®æŸåºã枬å®ããã«ã¯ãïŒïŒïœïœã®è解ããããŒã¹ããïŒïŒïœïŒ¬ã®ã¬ã©ã¹ç®¡ã®åºã«æ³šå
¥ããå·åŽãåºãããïŒïŒïœïŒ¬ã®ãªã³é
žç·©è¡ççé£å¡©æ°ŽïŒïŒ°ïŒ¢ïŒ³ïŒã管ã«å ãã管ã«èãããŠãïŒïŒâã®ãªãŒãã³ã«ãŠç«¯ãã端ã«è»¢åããããç¹å®ã®æéã«ã管ãåãåºããæŸåºãããè¬å€ã®éãåžååå
å
床èšã«ãã£ãŠåæãããâïŒé»å®³å€ã®æŸåºã¯ãè¬å€æŸåºã®æåã®çªçºããã®åŸã®ç·©æ
¢ãªãªåŸæŸãç¹åŸŽãšãããâïŒé»å®³å€ã®ãã®æäžåœ¢æ
ã¯ãå¶åŸ¡ãããæ¹åŒã§è¬å€ãæŸåºãããé»å®³å€ã®çäœé©åæ§ã®ãçå解æ§ã®æ³šå°å¯èœãªè£œå€ãè¡šãã
ãã¯ããªèã®çµšæ¯å°¿èã«ãããè¡ç®¡åœ¢æã«å¯ŸããâïŒé»å®³å€ïŒç¹ç°çã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããïŒïŒ¡ïŒ³ïŒ¯ïŒããªãã¶ã€ã ãïœïŒ²ïŒ®ïŒ¡é»å®³å€åã¯äžåæäœïŒãè² è·ãããã¬ããã®å¹æ
ãã¯ããªã®å粟åµãå°æ¹ã®åµåå Žããå ¥æããïŒæ¥ãšåæ¥ãèªåå転åŒã®ïŒïŒâã®ã€ã³ãã¥ããŒã¿ã«å ¥ãããåµã®å°ã£ãå 端ãïŒãïŒïŒåéäžã«åããŠå èããåµã®å 容ç©ãå¥é¢ããããã«åµãæåã§å転ããããïŒïŒïŒ åã³ãã ã¯ã€ããçšããŠåµå šäœãã¬ãããåµã®å€åŽãæž æœäžã€è¡ççã«ä¿ã€ãå±€æµããŒãã®äžã§ãéãæ¹ãäžã«ããŠåµãä¿æãããã³ã»ããã®å 端ã§æ éã«æ®»ãå²ãããšã«ãã£ãŠåµã®éãå 端ã«ç©ŽãïŒã€éãããæ®»ã®èããã³ã»ããã§ç©ããã«åãé€ããéãå 端ã«ç©Žã圢æãããå èãæå·ããã«ããã®äžžãç©ŽãçŽåŸïŒãïŒïœïœã»ã©ã«å€§ããããããšãã§ããããã£ãããæ®»ã«ç©Žãåµããšå åŽã®æ®»ã®èïŒåµã®å 容ç©ãæ ŒçŽããïŒãç©ããã«å¥ããããã³ã»ããã§åãé€ããã絚æ¯å°¿èïŒïŒ£ïŒ¡ïŒïŒïŒé»èº«ãæ ŒçŽãããã¯ããªèãçºçãããŠããïŒãæå·ããªãããã«æ³šæããããšã
ãã¯ããªã®å粟åµãå°æ¹ã®åµåå Žããå ¥æããïŒæ¥ãšåæ¥ãèªåå転åŒã®ïŒïŒâã®ã€ã³ãã¥ããŒã¿ã«å ¥ãããåµã®å°ã£ãå 端ãïŒãïŒïŒåéäžã«åããŠå èããåµã®å 容ç©ãå¥é¢ããããã«åµãæåã§å転ããããïŒïŒïŒ åã³ãã ã¯ã€ããçšããŠåµå šäœãã¬ãããåµã®å€åŽãæž æœäžã€è¡ççã«ä¿ã€ãå±€æµããŒãã®äžã§ãéãæ¹ãäžã«ããŠåµãä¿æãããã³ã»ããã®å 端ã§æ éã«æ®»ãå²ãããšã«ãã£ãŠåµã®éãå 端ã«ç©ŽãïŒã€éãããæ®»ã®èããã³ã»ããã§ç©ããã«åãé€ããéãå 端ã«ç©Žã圢æãããå èãæå·ããã«ããã®äžžãç©ŽãçŽåŸïŒãïŒïœïœã»ã©ã«å€§ããããããšãã§ããããã£ãããæ®»ã«ç©Žãåµããšå åŽã®æ®»ã®èïŒåµã®å 容ç©ãæ ŒçŽããïŒãç©ããã«å¥ããããã³ã»ããã§åãé€ããã絚æ¯å°¿èïŒïŒ£ïŒ¡ïŒïŒïŒé»èº«ãæ ŒçŽãããã¯ããªèãçºçãããŠããïŒãæå·ããªãããã«æ³šæããããšã
次ãã§ããã©ãã£ã³ãç©ããã«åŒã䌞ã°ããç©Žã®åšãã«çœ®ãããšã«ãã£ãŠãæ»
èãããã©ãã£ã³ã¯ãã¯ã¹çŽã®ã·ãŒãã§ç©ŽãèŠãã次ãã§ãåµãã€ã³ãã¥ããŒã¿ïŒïŒïŒâïŒã®åµæ£ã«çœ®ããå転ãé²ããããªæ¹æ³ã§äœçœ®åãããããïŒæ¥åŸãåµãïŒã€ãã€ã€ã³ãã¥ããŒã¿ïŒéãæ¹ãäžïŒããåãåºããèã®åŸè
žã«èµ·æºãæã€ïŒ£ïŒ¡ïŒãçŽæ¥è©äŸ¡ããããã«ãçªãèŠããã©ãã£ã³ãå€ããâïŒé»å®³å€ïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®éã§è² è·ïŒãå«æããããªããŒãã¬ãããïŒã®å¢æ®ããŠããæ¯çŽ°è¡ç®¡åºã®äžã«èŒãããåµå
容ç©ãåã³ãã©ãã£ã³ã·ãŒãã§å¯å°ããåµãïŒïŒâã®ã€ã³ãã¥ããŒã¿ã«æ»ããããã«ïŒæ¥åŸãïŒã®è管æ§é ã®åæãèšé²ããïŒè¬å€ãïŒã®æ¯çŽ°è¡ç®¡åºã®èŒããŠïŒïŒæéåŸïŒãè¬å€ã®å¹æãïŒãïŒãïŒåã¯ïŒã«ççŽåããç¡è¡ç®¡ã®å°ºåºŠãçšããŠïŒ£ïŒ¡ïŒã«å¯Ÿããè¬å€ã®å¹æãã©ã³ã¯åããããç¡è¡ç®¡å°ºåºŠã®å€ã¯ä»¥äžã®ãšããã§ããã
ïŒ æè¡ç®¡åœ¢æ掻æ§ãªã
ïŒ åŸ®çŽ°ãªè¡ç®¡ã®æžå°
ïŒ è¬å€ãã¬ããïŒçŽåŸïŒïœïœïŒã®ãµã€ãºã«çžåœããå°ããªç¡è¡ç®¡å
ïŒ çŽåŸïŒãïŒïœïœã®ç¡è¡ç®¡å
ïŒ æè¡ç®¡åœ¢æ掻æ§ãªã
ïŒ åŸ®çŽ°ãªè¡ç®¡ã®æžå°
ïŒ è¬å€ãã¬ããïŒçŽåŸïŒïœïœïŒã®ãµã€ãºã«çžåœããå°ããªç¡è¡ç®¡å
ïŒ çŽåŸïŒãïŒïœïœã®ç¡è¡ç®¡å
âïŒé»å®³å€ãè² è·ãããã¬ããã®ååšã¯ãïŒã¢ãã»ã€ã«ãããŠè¡ç®¡åœ¢æã劚害ããåã¯äœäžããããã®ããšã¯ãâïŒé»å®³å€ã®æè¡ç®¡åœ¢æ掻æ§ãæããã«ããé»å®³å€ã®ããªããŒåŸæŸæ§è£œå€ã¯ãé床ã®æ¯æ§ãèªçºããããšãªããæ²»çäžæå¹ãªæ¿åºŠã®è¬å€ãæŸåºããæå¹ãªæ¹æ³ã§ããããšã瀺ããŠããã
掻æ§åå
ç®çŽ°èã«ãããâïŒçºçŸã«å¯ŸããâïŒé»å®³å€ïŒç¹ç°çãªïŒ¡ïŒ³ïŒ¯ããªãã¶ã€ã åã¯ïœïŒ²ïŒ®ïŒ¡é»å®³å€ïŒã®æå¹æ§
ããè垯å ç®çŽ°èïŒïŒšïŒµïŒ¶ïŒ¥ïŒ£ïŒãåé¢ããïŒïŒïŒ ãïŒïŒ ã®ããŒã«ããããè¡æž ãïŒïŒïœïœïŒïœïŒ¬ã®å ç®çŽ°èå¢æ®å åãïŒïŒïŒµïŒïœïŒ¬ã®ãããªã³åã³æçç©è³ªãå«æããïŒïŒïŒïŒå¹å°ïŒã·ã°ãâã¢ã«ããªããïŒã§äžæ¬¡å¹é€ãæš¹ç«ããç¶ä»£ããããµã€ãã«ã€ã³æ·»å ã®ïŒæ¥åã«ããã£ãããã¯ãã³ãã³ãŒããããã¬ãŒãã«çŽ°èãäºåã«æãã次ãã§ãâïŒé»å®³å€ã®ååšäžã§ïŒŽïŒ®ïŒŠâαïŒïŒïŒïœïœïŒïœïŒ¬ãïŒïŒ€ã·ã¹ãã ãºïŒãè£å®ããå¹é€å¹å°ã§ïŒïŒæéåºæ¿ããã
ããè垯å ç®çŽ°èïŒïŒšïŒµïŒ¶ïŒ¥ïŒ£ïŒãåé¢ããïŒïŒïŒ ãïŒïŒ ã®ããŒã«ããããè¡æž ãïŒïŒïœïœïŒïœïŒ¬ã®å ç®çŽ°èå¢æ®å åãïŒïŒïŒµïŒïœïŒ¬ã®ãããªã³åã³æçç©è³ªãå«æããïŒïŒïŒïŒå¹å°ïŒã·ã°ãâã¢ã«ããªããïŒã§äžæ¬¡å¹é€ãæš¹ç«ããç¶ä»£ããããµã€ãã«ã€ã³æ·»å ã®ïŒæ¥åã«ããã£ãããã¯ãã³ãã³ãŒããããã¬ãŒãã«çŽ°èãäºåã«æãã次ãã§ãâïŒé»å®³å€ã®ååšäžã§ïŒŽïŒ®ïŒŠâαïŒïŒïŒïœïœïŒïœïŒ¬ãïŒïŒ€ã·ã¹ãã ãºïŒãè£å®ããå¹é€å¹å°ã§ïŒïŒæéåºæ¿ããã
âïŒé»å®³å€ã®ååšäžã§ã®ãµã€ãã«ã€ã³ã®åºæ¿ã«ç¶ããŠã现èãååãã溶解ããåžè²©ã®ïœïŒ²ïŒ®ïŒ¡ç²Ÿè£œãããïŒãã¢ã²ã³ïŒãçšããŠïœïŒ²ïŒ®ïŒ¡ãæœåºããåžè²©ã®ããããçšããŠãé転ååŠçœ®ãè¡ããããªã¡ã©ãŒãŒéåå¿ïŒïŒ°ïŒ£ïŒ²ïŒãçšããŠãåŸããããå¢å¹
ãããªã¢ã«ã¿ã€ã æ©(ã©ã€ããµã€ã¯ã©ãŒããã€ãªã©ããïŒã«ãããŠå®éããã
âïŒã®çºçŸãé»å®³ããããã«ç¹ç°çãªãªãã¶ã€ã åã¯é»å®³çïœïŒ²ïŒ®ïŒ¡é åãå ããå¹é€ã®å ŽåãâïŒç£çã¯ãåžè²©ã®ïŒ³ïŒ€ïŒŠâïŒã®ïŒ¥ïŒ¬ïŒ©ïŒ³ïŒ¡ãããïŒïŒ²ïŒïŒ€ã·ã¹ãã ãºïŒãçšããŠå®éãããâïŒé»å®³å€ã®æäžã¯ãâαã§åºæ¿ããå¹é€ã«ããããã®ã±ã¢ã«ã€ã³ã®çºçŸã劚ããã
âïŒã®çºçŸãé»å®³ããããã«ç¹ç°çãªãªãã¶ã€ã åã¯é»å®³çïœïŒ²ïŒ®ïŒ¡é åãå ããå¹é€ã®å ŽåãâïŒç£çã¯ãåžè²©ã®ïŒ³ïŒ€ïŒŠâïŒã®ïŒ¥ïŒ¬ïŒ©ïŒ³ïŒ¡ãããïŒïŒ²ïŒïŒ€ã·ã¹ãã ãºïŒãçšããŠå®éãããâïŒé»å®³å€ã®æäžã¯ãâαã§åºæ¿ããå¹é€ã«ããããã®ã±ã¢ã«ã€ã³ã®çºçŸã劚ããã
ãããµã³ãã£ã«ã ã«ãããâïŒé»å®³å€ïŒç¹ç°çã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããããªãã¶ã€ã ãïœïŒ²ïŒ®ïŒ¡é»å®³å€åã¯äžåæäœïŒã®å
å
âïŒé»å®³å€ãïŒïŒïŒïœïŒ¬ã®ãžã¡ãã«ã¹ã«ããã·ãã«æº¶è§£ããïŒïŒ ïœïŒïœã®é ¢é žäžïŒïŒïŒïŒ ïœïŒïœã®ãããµã³ïŒãã«ã«ãµã€ãšã³ãã£ãã£ãã¯ãäœååéïŒïŒïœïŒ¬ã«ããããã§å ¥ããããã®æ··åç©ãã¹ããŒãã«ã§æ¹æããæ²æ®¿ããè¬å€ããããµã³æº¶æ¶²ã«å質ã«æžæ¿ããã次ãã§ããã®ç²æ§æ··åç©ïŒïœïŒ¬ãïŒïŒïŒïœïœã®ãããªç¿ã«æ³šããïŒïŒâã«ãŠäžæ©ä¹Ÿç¥ããããããµã³ã¯ããããªç¿ããå€ãããèããã£ã«ã ã«ä¹Ÿç¥ããããããã®ãã£ã«ã ã¯ãäžçšåºŠã«æè»æ§ããããçŽïŒïŒïœïœã®åãã§ãé»å®³å€ã¯ãïŒïŒïŒ ïŒãããµã³ã«å¯ŸããŠïœïŒïœïŒã®æ¿åºŠã§ãããµã³ãããªã¯ã¹ã«åäžã«æžæ¿ãããŠãããããããããµã³ãã£ã«ã ããã®è¬å€ã®æŸåºã枬å®ããã«ã¯ãïŒïŒïœïŒ¬ã®ïŒ°ïŒ¢ïŒ³ïŒïœïŒšïŒïŒïŒïŒã«ïŒïŒïœïœå ¥ãã管ã«èãããŠç¹å®ã®æéãïŒïŒâã«ãŠè»¢åãããããã£ã«ã ããã«æŸåºãããé»å®³å€ã®éãïŒïŒïŒïœïœã®åžåã«ãã£ãŠæž¬å®ãããè¬å€ã®æŸåºã¯ãæåã®çªçºã«ç¶ãç·©æ ¢ãªåŸæŸãç¹åŸŽãšãããé»å®³å€ã®ãã®æäžåœ¢æ ã¯ãå¶åŸ¡ãããæ¹åŒã§è¬å€ãæŸåºãããâïŒé»å®³å€ã®çäœé©åæ§ã®ãç²èä»çæ§ã®è£œå€ãè¡šãã
âïŒé»å®³å€ãïŒïŒïŒïœïŒ¬ã®ãžã¡ãã«ã¹ã«ããã·ãã«æº¶è§£ããïŒïŒ ïœïŒïœã®é ¢é žäžïŒïŒïŒïŒ ïœïŒïœã®ãããµã³ïŒãã«ã«ãµã€ãšã³ãã£ãã£ãã¯ãäœååéïŒïŒïœïŒ¬ã«ããããã§å ¥ããããã®æ··åç©ãã¹ããŒãã«ã§æ¹æããæ²æ®¿ããè¬å€ããããµã³æº¶æ¶²ã«å質ã«æžæ¿ããã次ãã§ããã®ç²æ§æ··åç©ïŒïœïŒ¬ãïŒïŒïŒïœïœã®ãããªç¿ã«æ³šããïŒïŒâã«ãŠäžæ©ä¹Ÿç¥ããããããµã³ã¯ããããªç¿ããå€ãããèããã£ã«ã ã«ä¹Ÿç¥ããããããã®ãã£ã«ã ã¯ãäžçšåºŠã«æè»æ§ããããçŽïŒïŒïœïœã®åãã§ãé»å®³å€ã¯ãïŒïŒïŒ ïŒãããµã³ã«å¯ŸããŠïœïŒïœïŒã®æ¿åºŠã§ãããµã³ãããªã¯ã¹ã«åäžã«æžæ¿ãããŠãããããããããµã³ãã£ã«ã ããã®è¬å€ã®æŸåºã枬å®ããã«ã¯ãïŒïŒïœïŒ¬ã®ïŒ°ïŒ¢ïŒ³ïŒïœïŒšïŒïŒïŒïŒã«ïŒïŒïœïœå ¥ãã管ã«èãããŠç¹å®ã®æéãïŒïŒâã«ãŠè»¢åãããããã£ã«ã ããã«æŸåºãããé»å®³å€ã®éãïŒïŒïŒïœïœã®åžåã«ãã£ãŠæž¬å®ãããè¬å€ã®æŸåºã¯ãæåã®çªçºã«ç¶ãç·©æ ¢ãªåŸæŸãç¹åŸŽãšãããé»å®³å€ã®ãã®æäžåœ¢æ ã¯ãå¶åŸ¡ãããæ¹åŒã§è¬å€ãæŸåºãããâïŒé»å®³å€ã®çäœé©åæ§ã®ãç²èä»çæ§ã®è£œå€ãè¡šãã
ããªã«ããã©ã¯ãã³ããŒã¹ãã«ãããã©ããã€ã·ã³ã®è£œé åã³ããªã«ããã©ã¯ãã³ããŒã¹ãããã®ãã®å¶åŸ¡ãããæŸåº
ïŒïŒïŒ ïŒïœïŒïœïŒã®æ¿åºŠã«ãŠïŒïŒâã«ãŠã¹ããŒãã«ã§ãã朰ãããšã«ããã©ããã€ã·ã³ãããªã«ããã©ã¯ãã³ïŒïŒ°ïŒ£ïŒ¬ãããŒãã³ã¬ã ããªããŒãºãååéïŒïŒïŒ«ïŒãšæ··åããã次ãã§ããã®æ··åç©ãïŒïœïŒ¬ã®ãã©ã¹ããã¯è£œæ³šå°åšã«è£ å¡«ããå·åŽããããã®è£œå€ãïŒïŒã²ãŒãžã®éãä»ããŠïŒïŒâã«ãŠæ³šå°ããããšãã§ããã
ïŒïŒïŒ ïŒïœïŒïœïŒã®æ¿åºŠã«ãŠïŒïŒâã«ãŠã¹ããŒãã«ã§ãã朰ãããšã«ããã©ããã€ã·ã³ãããªã«ããã©ã¯ãã³ïŒïŒ°ïŒ£ïŒ¬ãããŒãã³ã¬ã ããªããŒãºãååéïŒïŒïŒ«ïŒãšæ··åããã次ãã§ããã®æ··åç©ãïŒïœïŒ¬ã®ãã©ã¹ããã¯è£œæ³šå°åšã«è£ å¡«ããå·åŽããããã®è£œå€ãïŒïŒã²ãŒãžã®éãä»ããŠïŒïŒâã«ãŠæ³šå°ããããšãã§ããã
ããŒã¹ãããã®è¬å€ã®æŸåºã枬å®ããã«ã¯ãïŒïŒïœïœã®è解ããããŒã¹ããïŒïŒïœïŒ¬ã®ã¬ã©ã¹ç®¡ã®åºã«æ³šå
¥ããå·åŽãåºãããïŒïŒïœïŒ¬ã®ãªã³é
žç·©è¡ççé£å¡©æ°ŽïŒïŒ°ïŒ¢ïŒ³ïŒã管ã«å ãã管ã«èãããŠãïŒïŒâã®ãªãŒãã³ã«ãŠç«¯ãã端ã«è»¢åããããç¹å®ã®æéã«ã管ãåãåºããæŸåºãããè¬å€ã®éãåžååå
å
床èšã«ãã£ãŠåæãããã©ããã€ã·ã³ã®æŸåºã¯ãè¬å€æŸåºã®æåã®çªçºããã®åŸã®ç·©æ
¢ãªåŸæŸãç¹åŸŽãšãããã©ããã€ã·ã³ã®ãã®æäžåœ¢æ
ã¯ãå¶åŸ¡ãããæ¹åŒã§è¬å€ãæŸåºãããé»å®³å€ã®çäœé©åæ§ã®ãçå解æ§ã®æ³šå°å¯èœãªè£œå€ãè¡šãã
ãã¯ããªèã®çµšæ¯å°¿èã«ãããè¡ç®¡åœ¢æã«å¯Ÿããã©ããã€ã·ã³ãè² è·ãããã¬ããã®å¹æïŒïŒ£ïŒ¡ïŒã¢ãã»ã€ïŒ
ãã¯ããªã®å粟åµãå°æ¹ã®åµåå Žããå ¥æããïŒæ¥ãšåæ¥ãèªåå転åŒã®ïŒïŒâã®ã€ã³ãã¥ããŒã¿ã«å ¥ãããåµã®å°ã£ãå 端ãïŒãïŒïŒåéäžã«åããŠå èããåµã®å 容ç©ãå¥é¢ããããã«åµãæåã§å転ããããïŒïŒïŒ åã³ãã ã¯ã€ããçšããŠåµå šäœãã¬ãããåµã®å€åŽãæž æœäžã€è¡ççã«ä¿ã€ãå±€æµããŒãã®äžã§ãéãæ¹ãäžã«ããŠåµãä¿æãããã³ã»ããã®å 端ã§æ éã«æ®»ãå²ãããšã«ãã£ãŠåµã®éãå 端ã«ç©ŽãïŒã€éãããæ®»ã®èããã³ã»ããã§ç©ããã«åãé€ããéãå 端ã«ç©Žã圢æãããå èãæå·ããã«ããã®äžžãç©ŽãçŽåŸïŒãïŒïœïœã»ã©ã«å€§ããããããšãã§ããããã£ãããæ®»ã«ç©Žãåµããšå åŽã®æ®»ã®èïŒåµã®å 容ç©ãæ ŒçŽããïŒãç©ããã«å¥ããããã³ã»ããã§åãé€ããã絚æ¯å°¿èïŒïŒ£ïŒ¡ïŒïŒïŒé»èº«ãæ ŒçŽãããã¯ããªèãçºçãããŠããïŒãæå·ããªãããã«æ³šæããããšã
ãã¯ããªã®å粟åµãå°æ¹ã®åµåå Žããå ¥æããïŒæ¥ãšåæ¥ãèªåå転åŒã®ïŒïŒâã®ã€ã³ãã¥ããŒã¿ã«å ¥ãããåµã®å°ã£ãå 端ãïŒãïŒïŒåéäžã«åããŠå èããåµã®å 容ç©ãå¥é¢ããããã«åµãæåã§å転ããããïŒïŒïŒ åã³ãã ã¯ã€ããçšããŠåµå šäœãã¬ãããåµã®å€åŽãæž æœäžã€è¡ççã«ä¿ã€ãå±€æµããŒãã®äžã§ãéãæ¹ãäžã«ããŠåµãä¿æãããã³ã»ããã®å 端ã§æ éã«æ®»ãå²ãããšã«ãã£ãŠåµã®éãå 端ã«ç©ŽãïŒã€éãããæ®»ã®èããã³ã»ããã§ç©ããã«åãé€ããéãå 端ã«ç©Žã圢æãããå èãæå·ããã«ããã®äžžãç©ŽãçŽåŸïŒãïŒïœïœã»ã©ã«å€§ããããããšãã§ããããã£ãããæ®»ã«ç©Žãåµããšå åŽã®æ®»ã®èïŒåµã®å 容ç©ãæ ŒçŽããïŒãç©ããã«å¥ããããã³ã»ããã§åãé€ããã絚æ¯å°¿èïŒïŒ£ïŒ¡ïŒïŒïŒé»èº«ãæ ŒçŽãããã¯ããªèãçºçãããŠããïŒãæå·ããªãããã«æ³šæããããšã
次ãã§ããã©ãã£ã³ãç©ããã«åŒã䌞ã°ããç©Žã®åšãã«çœ®ãããšã«ãã£ãŠãæ»
èãããã©ãã£ã³ã¯ãã¯ã¹çŽã®ã·ãŒãã§ç©ŽãèŠãã次ãã§ãåµãã€ã³ãã¥ããŒã¿ïŒïŒïŒâïŒã®åµæ£ã«çœ®ããå転ãé²ããããªæ¹æ³ã§äœçœ®åãããããïŒæ¥åŸãåµãïŒã€ãã€ã€ã³ãã¥ããŒã¿ïŒéãæ¹ãäžïŒããåãåºããèã®åŸè
žã«èµ·æºãæã€ïŒ£ïŒ¡ïŒãçŽæ¥è©äŸ¡ããããã«ãçªãèŠããã©ãã£ã³ãå€ããã©ããã€ã·ã³ïŒïŒïŒ
ãïŒïŒïŒ
ïœïŒïœã®éã§è² è·ïŒãå«æããããªããŒãã¬ãããïŒã®å¢æ®ããŠããæ¯çŽ°è¡ç®¡åºã®äžã«èŒãããåµå
容ç©ãåã³ãã©ãã£ã³ã·ãŒãã§å¯å°ããåµãïŒïŒâã®ã€ã³ãã¥ããŒã¿ã«æ»ããããã«ïŒæ¥åŸãïŒã®è管æ§é ã®åæãèšé²ããïŒè¬å€ãïŒã®æ¯çŽ°è¡ç®¡åºã®èŒããŠïŒïŒæéåŸïŒãè¬å€ã®å¹æãïŒãïŒãïŒåã¯ïŒã«ççŽåããç¡è¡ç®¡ã®å°ºåºŠãçšããŠïŒ£ïŒ¡ïŒã«å¯Ÿããè¬å€ã®å¹æãã©ã³ã¯åããããç¡è¡ç®¡å°ºåºŠã®å€ã¯ä»¥äžã®ãšããã§ãã
ïŒ æè¡ç®¡åœ¢æ掻æ§ãªã
ïŒ åŸ®çŽ°ãªè¡ç®¡ã®æžå°
ïŒ è¬å€ãã¬ããïŒçŽåŸïŒïœïœïŒã®ãµã€ãºã«çžåœããå°ããªç¡è¡ç®¡å
ïŒ çŽåŸïŒãïŒïœïœã®ç¡è¡ç®¡å
ïŒ æè¡ç®¡åœ¢æ掻æ§ãªã
ïŒ åŸ®çŽ°ãªè¡ç®¡ã®æžå°
ïŒ è¬å€ãã¬ããïŒçŽåŸïŒïœïœïŒã®ãµã€ãºã«çžåœããå°ããªç¡è¡ç®¡å
ïŒ çŽåŸïŒãïŒïœïœã®ç¡è¡ç®¡å
âïŒé»å®³å€ãè² è·ãããã¬ããã®ååšã¯ãïŒã¢ãã»ã€ã«ãããŠè¡ç®¡åœ¢æã劚害ããåã¯äœäžããããã®ããšã¯ãã©ããã€ã·ã³ã®æè¡ç®¡åœ¢æ掻æ§ãæããã«ããã©ããã€ã·ã³ã®ããªããŒã®åŸæŸæ§è£œå€ã¯ãé床ã®æ¯æ§ãèªçºããããšãªããæ²»çäžæå¹ãªæ¿åºŠã®è¬å€ãæŸåºããæå¹ãªæ¹æ³ã§ããããšã瀺ããŠããã
ãããµã³ãã£ã«ã ã«ãããã©ããã€ã·ã³ã®å
å
ã©ããã€ã·ã³ãïŒïŒïŒïœïŒ¬ã®ãžã¡ãã«ã¹ã«ããã·ãã«æº¶è§£ãã次ãã§ïŒïŒ ïœïŒïœã®é ¢é žäžïŒïŒïŒïŒ ïœïŒïœã®ãããµã³ïŒãã«ã«ãµã€ãšã³ãã£ãã£ãã¯ãäœååéïŒïŒïœïŒ¬ã«ããããã§å ¥ããããã®æ··åç©ãã¹ããŒãã«ã§æ¹æããæ²æ®¿ããè¬å€ããããµã³æº¶æ¶²ã«å質ã«æžæ¿ããã次ãã§ããã®ç²æ§æ··åç©ïŒïœïŒ¬ãïŒïŒïŒïœïœã®ãããªç¿ã«æ³šããïŒïŒâã«ãŠäžæ©ä¹Ÿç¥ããããããµã³ã¯ããããªç¿ããå€ãããèããã£ã«ã ã«ä¹Ÿç¥ããããããã®ãã£ã«ã ã¯ãäžçšåºŠã«æè»æ§ããããçŽïŒïŒïœïœã®åãã§ãé»å®³å€ã¯ãïŒïŒïŒ ïŒãããµã³ã«å¯ŸããŠïœïŒïœïŒã®æ¿åºŠã§ãããµã³ãããªã¯ã¹ã«åäžã«æžæ¿ãããŠãããããããããµã³ãã£ã«ã ããã®è¬å€ã®æŸåºã枬å®ããã«ã¯ãïŒïŒïœïŒ¬ã®ïŒ°ïŒ¢ïŒ³ïŒïœïŒšïŒïŒïŒïŒã«ïŒïŒïœïœå ¥ãã管ã«èãããŠç¹å®ã®æéãïŒïŒâã«ãŠè»¢åãããããã£ã«ã ããã«æŸåºãããã©ããã€ã·ã³ã®éãïŒïŒïŒïœïœã®åžåã«ãã£ãŠæž¬å®ãããè¬å€ã®æŸåºã¯ãæåã®çªçºã«ç¶ãç·©æ ¢ãªåŸæŸãç¹åŸŽãšãããã©ããã€ã·ã³ã®ãã®æäžåœ¢æ ã¯ãå¶åŸ¡ãããæ¹åŒã§è¬å€ãæŸåºãããè¬å€ã®çäœé©åæ§ã®ãç²èä»çæ§ã®è£œå€ãè¡šãã
ã©ããã€ã·ã³ãïŒïŒïŒïœïŒ¬ã®ãžã¡ãã«ã¹ã«ããã·ãã«æº¶è§£ãã次ãã§ïŒïŒ ïœïŒïœã®é ¢é žäžïŒïŒïŒïŒ ïœïŒïœã®ãããµã³ïŒãã«ã«ãµã€ãšã³ãã£ãã£ãã¯ãäœååéïŒïŒïœïŒ¬ã«ããããã§å ¥ããããã®æ··åç©ãã¹ããŒãã«ã§æ¹æããæ²æ®¿ããè¬å€ããããµã³æº¶æ¶²ã«å質ã«æžæ¿ããã次ãã§ããã®ç²æ§æ··åç©ïŒïœïŒ¬ãïŒïŒïŒïœïœã®ãããªç¿ã«æ³šããïŒïŒâã«ãŠäžæ©ä¹Ÿç¥ããããããµã³ã¯ããããªç¿ããå€ãããèããã£ã«ã ã«ä¹Ÿç¥ããããããã®ãã£ã«ã ã¯ãäžçšåºŠã«æè»æ§ããããçŽïŒïŒïœïœã®åãã§ãé»å®³å€ã¯ãïŒïŒïŒ ïŒãããµã³ã«å¯ŸããŠïœïŒïœïŒã®æ¿åºŠã§ãããµã³ãããªã¯ã¹ã«åäžã«æžæ¿ãããŠãããããããããµã³ãã£ã«ã ããã®è¬å€ã®æŸåºã枬å®ããã«ã¯ãïŒïŒïœïŒ¬ã®ïŒ°ïŒ¢ïŒ³ïŒïœïŒšïŒïŒïŒïŒã«ïŒïŒïœïœå ¥ãã管ã«èãããŠç¹å®ã®æéãïŒïŒâã«ãŠè»¢åãããããã£ã«ã ããã«æŸåºãããã©ããã€ã·ã³ã®éãïŒïŒïŒïœïœã®åžåã«ãã£ãŠæž¬å®ãããè¬å€ã®æŸåºã¯ãæåã®çªçºã«ç¶ãç·©æ ¢ãªåŸæŸãç¹åŸŽãšãããã©ããã€ã·ã³ã®ãã®æäžåœ¢æ ã¯ãå¶åŸ¡ãããæ¹åŒã§è¬å€ãæŸåºãããè¬å€ã®çäœé©åæ§ã®ãç²èä»çæ§ã®è£œå€ãè¡šãã
ãŠãµã®ã®åå®®è§æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã«å¯Ÿãããã³ã€ãã³ãè² è·ãã(
ïŒïŒïŒ ïœïŒïœ)ãã¢ã«ãã³é žãã£ã«ã åã³ä¹³é žå ãªã³ã¬ãŒæ¶²äžãã³ã€ãã³ç¹æ»Žçšå€ïŒïŒïŒ
ïœïŒïœ)ã®æå¹æ§
èžçæ°Žäžã«ã°ãªã»ããŒã«ãšå ±ã«ãã¢ã«ãã³é žïŒïŒšïŒ¡ïŒã溶解ããããšã«ãã£ãŠïŒïŒïŒ ãã³ã€ãã³ã®ãã£ã«ã ã補å€åãããïŒïŒâã®ãªãŒãã³ã§éãã«å転ããããšã«ãã£ãŠïŒšïŒ¡ã®æº¶è§£ã¯ïŒæé以å ã«çãããæ··åããªããïŒã°ãªã»ããŒã«ã®æº¶æ¶²ã«ãã³ã€ãã³ïŒã·ã°ãã±ãã«ã«ãºïŒãå ãããæ¿ããæ··åããªããããæ¶æ©å€ã補å€ã«å ããããã®æº¶æ¶²ããããªç¿ã«æ³šå ¥ãããããïŒïŒâã®ãªãŒãã³ã«äžæ©å ¥ãã補å€ã也ç¥ãããŠãã£ã«ã ã«ããã次ãã§ãåŸããããã£ã«ã ïŒïŒïŒïŒ ãã³ã€ãã³ïœïŒïœïŒããã³ã»ããã§ãããªç¿ããå€ããé©åœãªå€§ããã«åæããã
ïŒïŒïŒ ïœïŒïœ)ãã¢ã«ãã³é žãã£ã«ã åã³ä¹³é žå ãªã³ã¬ãŒæ¶²äžãã³ã€ãã³ç¹æ»Žçšå€ïŒïŒïŒ
ïœïŒïœ)ã®æå¹æ§
èžçæ°Žäžã«ã°ãªã»ããŒã«ãšå ±ã«ãã¢ã«ãã³é žïŒïŒšïŒ¡ïŒã溶解ããããšã«ãã£ãŠïŒïŒïŒ ãã³ã€ãã³ã®ãã£ã«ã ã補å€åãããïŒïŒâã®ãªãŒãã³ã§éãã«å転ããããšã«ãã£ãŠïŒšïŒ¡ã®æº¶è§£ã¯ïŒæé以å ã«çãããæ··åããªããïŒã°ãªã»ããŒã«ã®æº¶æ¶²ã«ãã³ã€ãã³ïŒã·ã°ãã±ãã«ã«ãºïŒãå ãããæ¿ããæ··åããªããããæ¶æ©å€ã補å€ã«å ããããã®æº¶æ¶²ããããªç¿ã«æ³šå ¥ãããããïŒïŒâã®ãªãŒãã³ã«äžæ©å ¥ãã補å€ã也ç¥ãããŠãã£ã«ã ã«ããã次ãã§ãåŸããããã£ã«ã ïŒïŒïŒïŒ ãã³ã€ãã³ïœïŒïœïŒããã³ã»ããã§ãããªç¿ããå€ããé©åœãªå€§ããã«åæããã
ïŒïŒ
ïœïŒïœã®ãã³ã€ãã³ç¹æ»Žçšå€ã補å€åããã枬å®ããéã®ãã³ã€ãã³ãä¹³é
žå ãªã³ã¬ãŒæ¶²ã«å ããïŒïŒ
ïœïŒïœã®ç¹æ»Žçšå€ã圢æããã
ãŠãµã®ã®åå®®è§æè¡ççã¢ãã«ãçšããïŒçš®é¡ã®è£œå€ã調ã¹ããç°¡åã«èšãã°ããŠãµã®ã®è
¹éšã«åéãäœã£ããåå®®è§ãèŠã€ããè§ã®åºéšãæå®ãã(åã³äžè²«ãã)æéãã€ããããšã«ãã£ãŠå·ã€ãããå€ç§çšã¡ã¹ã§ãããããšã«ãã£ãŠç¹å®ã®é åã§ãŠãµã®ã®è
¹èã®åŽå£ãå·ã€ãããè
¹èã®åŽå£ã®ããã£ãé åã«èŒãããããªæ¹æ³ã§åå®®è§ã眮ããè§ã®å
端ãçž«ãåããããçž«ãåããã¯ãåŽå£ã®ããã£ãé åã®å€ã«ãã£ãããåå®®è§ãããã£ãé åããå€ããã®ãé²ãã ã
ããã£ãé åã®äžïŒè§ãšåŽå£ã®éïŒã«çŽæ¥çœ®ãããšã«ãã£ãŠãã³ã€ãã³ãã£ã«ã 補å€ã®æå¹æ§ãè©äŸ¡ãããè§ã¯åŽå£ã«ãã€ãä¿æãããªãã£ãã®ã§ãå·ã€ããåŽå£ã«çœ®ãããã£ã«ã ã¯ç²èä»çæ§ã§ãããããèªäœã®ç©æ§ã«ãã£ãŠãã®å Žæã«ãšã©ãŸã£ããŸãŸã§ãã£ãããšã«æ³šæã
æè¡åŠçœ®ãå®äºããåã«ããŠãµã®ã®è
¹éšã«è£œå€ãïŒïŒïœïŒ¬ç¹æ»Žããããšã«ãã£ãŠãã³ã€ãã³ç¹æ»Žçšå€è£œå€ã®æå¹æ§ãè©äŸ¡ããã
æè¡åŠçœ®ãå®äºããåã«ããŠãµã®ã®è
¹éšã«ïŒïŒïœïŒ¬ã®ä¹³é
žå ãªã³ã¬ãŒæ³šå°æ¶²ïŒµïŒ³ïŒ°ãç¹æ»Žããããšã«ãã£ãŠèª¿ã¹ããã察ç
§çŸ€ãšããããã®è£œå€ãæ¯èŒããã
åŠçœ®ã®ïŒïŒæ¥åŸããŠãµã®ãå®æ¥œæ»ãããŠçç圢æã®çšåºŠãè©äŸ¡ãããè©äŸ¡è
ã¯ãã©ã®çŸ€ãè©äŸ¡ãããã®ãã«ã€ããŠç²æ€ãããççã«èŠãããé¢ç©ãšåœ¢æããççã®åŒ·åºŠã®ç©ãšããŠãããã®ççãã©ã³ã¯åããããççã«èŠãããé¢ç©ã¯ïŒç¹ã®å°ºåºŠã§ã©ã³ã¯åãããççã®åŒ·åºŠã¯ãïŒãïŒã®å°ºåºŠã§ã©ã³ã¯åãããã以äžã®å°ºåºŠãçšããã
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
次ãã§ãé¢ç©ã¹ã³ã¢ãç·ç¶æ§ççã®åŒ·åºŠã¹ã³ã¢ã«ä¹ããããšã«ãã£ãŠåãŠãµã®ã«ã€ããŠã®ççã¹ã³ã¢ãåŸããããåè©ŠéšçŸ€ã«ã€ããŠã®ççã¹ã³ã¢ã®çµæãå³ïŒã«ç€ºããããŒã¿ã¯ïŒå¹ã®åç©ã®å¹³åççã¹ã³ã¢ïŒÂ±ïŒïŒ³ïŒãè¡šãã
ãããã®ããŒã¿ã¯ããã³ã€ãã³è£œå€ãåæ¹å
±ã«å¯Ÿç
§ãšæ¯ã¹ããšã矀ã«ããããŠãµã®ã®å¹³åççã¹ã³ã¢ãäœäžãããã®ã§ãæè¡ççã®æ²»çã«ãããŠæå¹ã§ããããšãæããã«ããŠããããŸãç¹æ»Žçšå€ã¯ããã£ã«ã ãããããã«æå¹ã§ãããšæãããããšãæããã«ããŠããã
ã©ããã®ç²è
žåŽå£ã®æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã«å¯Ÿãããã³ã€ãã³ã²ã«ã®æå¹æ§
äžé£ã®ã²ã«ããã®å®éšã®ããã«è£œå€åãããïŒ
ïŒïŒïŒïŒïŒïŒ ïœïŒïœãã¢ã«ãã³é žã²ã«äžã®ïŒïŒ ïœïŒïœãã³ã€ãã³
ïŒïŒïŒïŒïŒïŒ ïœïŒïœãã¢ã«ãã³é žã²ã«äžã®ïŒïŒïŒïŒ ïœïŒïœãã³ã€ãã³
ïŒïŒïŒïŒïŒïŒ ïœïŒïœãã¢ã«ãã³é žã²ã«äžã®ïŒïŒ ïœïŒïœãã³ã€ãã³
ïŒïŒïŒïŒïŒïŒ ïœïŒïœãã¢ã«ãã³é žã²ã«äžã®ïŒïŒ ïœïŒïœãã³ã€ãã³
ã©ããã®ç²è žåŽå£ã®æè¡ççã¢ãã«ãçšããããã®ã²ã«ãè©äŸ¡ããŠæè¡ççã®é²æ¢ã«å¯Ÿããæå¹æ§ã決å®ããã
äžé£ã®ã²ã«ããã®å®éšã®ããã«è£œå€åãããïŒ
ïŒïŒïŒïŒïŒïŒ ïœïŒïœãã¢ã«ãã³é žã²ã«äžã®ïŒïŒ ïœïŒïœãã³ã€ãã³
ïŒïŒïŒïŒïŒïŒ ïœïŒïœãã¢ã«ãã³é žã²ã«äžã®ïŒïŒïŒïŒ ïœïŒïœãã³ã€ãã³
ïŒïŒïŒïŒïŒïŒ ïœïŒïœãã¢ã«ãã³é žã²ã«äžã®ïŒïŒ ïœïŒïœãã³ã€ãã³
ïŒïŒïŒïŒïŒïŒ ïœïŒïœãã¢ã«ãã³é žã²ã«äžã®ïŒïŒ ïœïŒïœãã³ã€ãã³
ã©ããã®ç²è žåŽå£ã®æè¡ççã¢ãã«ãçšããããã®ã²ã«ãè©äŸ¡ããŠæè¡ççã®é²æ¢ã«å¯Ÿããæå¹æ§ã決å®ããã
ç°¡åã«èšãã°ãã©ããã®è
¹éšã«æ²¿ã£ãŠåéããç²è
žãèŠã€ããŠåŒãåºãããå€ç§çšã¡ã¹ã®åã§ç²è
žãäžã«ïŒïŒåãäžã«ïŒïŒåã次ãã§äžã«ïŒïŒåããã£ããè
¹èå£ãç®èããåé¢ãããã®å£ã®å°ããªåè§ã¯ãäžã®èãæããçèçµç¹ã®ç·ç¶å±€ãïŒã€é€ããã次ãã§ãæå®ã®äœçœ®ã§åè§ãèŠãããã«ç²è
žãçž«ãåããããçž«ãåããã¯ãç²è
žã®ïŒã€ã®äžã®è§ã§éå§ããããå®äºãããªãã£ãã®ã§ãç²è
žã¯ãå·ã€ããè
¹èå£ã«çµæãããªãã£ãã次ãã§ãç¹å®ã®ã²ã«ãç²è
žãšè
¹èå£ã®éã«çœ®ããŠãåŠæ¹ãããåŠçãé©çšããã察ç
§çŸ€ã®å Žåã¯ãåŠç補å€ãé©çšããªãã£ããçž«ãåãããå®æãããç²è
žã®è§ãå£ã«çµæãããã
åŠçœ®ã®ïŒæ¥åŸãã©ãããå®æ¥œæ»ãããŠãç²è
žãšåŽå£ãšã®éã§ãçç圢æã®çšåºŠãè©äŸ¡ãããè©äŸ¡è
ã¯ã©ã®çŸ€ãè©äŸ¡ãããŠããã®ãã«ã€ããŠç²æ€ãããççã«èŠãããé¢ç©ãšåœ¢æããççã®åŒ·åºŠã®ç©ãšããŠãããã®ççãã©ã³ã¯åããããççã«èŠãããé¢ç©ã¯ïŒç¹ã®å°ºåºŠã§ã©ã³ã¯åãããççã®åŒ·åºŠã¯ãïŒãïŒã®å°ºåºŠã§ã©ã³ã¯åãããã以äžã®å°ºåºŠãçšããã
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
次ãã§ãé¢ç©ã¹ã³ã¢ãç·ç¶æ§ççã®åŒ·åºŠã¹ã³ã¢ã«ä¹ããããšã«ãã£ãŠåã©ããã«ã€ããŠã®å
šäœçççã¹ã³ã¢ãåŸããããåè©ŠéšçŸ€ã«ã€ããŠã®ççã¹ã³ã¢ã®çµæãå³ïŒã«ç€ºãããããã®çµæã¯ãåŠç矀ïŒãã³ã€ãã³ã²ã«çŸ€ïŒã«ãããåç©ã®å¹³åã®å
šäœçççã¹ã³ã¢ãã察ç
§çŸ€ã®ãããããææã«äœãããšã瀺ããŠããããã®ããšã¯ããã³ã€ãã³ã²ã«è£œå€ãç·ç¶æ§ççã®åœ¢æãäºé²ããã®ã«æå¹ã§ããããšãæããã«ããŠããã
ã©ããã®åå®®è§ã®æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã«å¯Ÿãããã³ã€ãã³ç¹æ»Žçšå€è£œå€ã®æå¹æ§
é©åœéã®ãã³ã€ãã³ãä¹³é žå ãªã³ã¬ãŒæ¶²ã«æº¶è§£ãæå®ã®æ¿åºŠãéæããããšã«ãã£ãŠïŒïŒïŒïŒïŒïŒ ãïŒïŒïŒïŒïŒïŒ åã³ïŒïŒïŒïŒïŒ ïœïŒïœã®ãã³ã€ãã³ç¹æ»Žçšå€ã®æº¶æ¶²ã補é ããããã³ã€ãã³ã¯ãè€è²æµ·æŽè»é¡ãïœïœïœïœ ïœïœ ïœïœïœïœïœïœïœïœïœããã®æœåºç©ã§ãããã·ã°ãã±ãã«ã«ãºããå ¥æãããå¯Ÿç §ãšããŠä¹³é žå ãªã³ã¬ãŒæ¶²æ³šå°æ¶²ïŒµïŒ³ïŒ°ãçšããã©ããã®åå®®è§ã®æè¡ççã¢ãã«ãçšããŠãã©ããã§ã®æè¡ççã®äºé²ã«ãããæå¹æ§ã«ã€ããŠãããã®è£œå€ãè©äŸ¡ããã
é©åœéã®ãã³ã€ãã³ãä¹³é žå ãªã³ã¬ãŒæ¶²ã«æº¶è§£ãæå®ã®æ¿åºŠãéæããããšã«ãã£ãŠïŒïŒïŒïŒïŒïŒ ãïŒïŒïŒïŒïŒïŒ åã³ïŒïŒïŒïŒïŒ ïœïŒïœã®ãã³ã€ãã³ç¹æ»Žçšå€ã®æº¶æ¶²ã補é ããããã³ã€ãã³ã¯ãè€è²æµ·æŽè»é¡ãïœïœïœïœ ïœïœ ïœïœïœïœïœïœïœïœïœããã®æœåºç©ã§ãããã·ã°ãã±ãã«ã«ãºããå ¥æãããå¯Ÿç §ãšããŠä¹³é žå ãªã³ã¬ãŒæ¶²æ³šå°æ¶²ïŒµïŒ³ïŒ°ãçšããã©ããã®åå®®è§ã®æè¡ççã¢ãã«ãçšããŠãã©ããã§ã®æè¡ççã®äºé²ã«ãããæå¹æ§ã«ã€ããŠãããã®è£œå€ãè©äŸ¡ããã
ã©ããã®åå®®è§ã¢ãã«ã®æé ã¯ä»¥äžã®ãšããã§ãããåã©ããã麻é
ããæçç©è³ªãäžããã次ãã§ãè
¹éšã®æ£äžåã³è
¹å£ã®çœç·ã«æ²¿ã£ãŠïŒãïŒïœïœã®åéãäœã£ããåå®®è§ã®äžæ¹ãèŠã€ããè§ãæ¢è¡ããè
žéèããåãåã£ããå€ç§çšã¡ã¹ã§ãããäžã«ïŒïŒåãäžã«ïŒïŒåã次ãã§äžã«ïŒïŒåããã£ããããã¯ç¹ç¶åºè¡ãçããåãåŠçãå察åŽã®è§ã§ç¹°ãè¿ãããè
¹èå£ãç®èããåé¢ããå転ãããŠå£ã®å
åŽãããããè
¹èå£ã®å°ããªé åïŒïŒïŒïŒïœïŒïŒïŒïœïœïŒãåãåã£ãã次ãã§åå®®è§ãåŽå£ã®ãã®å·ã®äžã«çœ®ãããããçž«åãããåãåŠçœ®ãå察åŽã®åŽå£ã§è¡ã£ããè
¹èåŽå£ã«ã€ããŠïŒâïŒã®çž«å糞ã§åéãéãããæåŸã®çž«ãåãããçµã¶çŽåã«ã調ã¹ãã¹ãç¹æ»Žçšå€ïŒïœïŒ¬ãäºåã«è² è·ããæ»
è泚å°åšãçšããŠè
¹è
ã«å
¥ãããæè¡å®äºã®ããã«ãïŒâïŒã®çž«å糞ãç®èã«çšããã
ïŒæ¥åŸãã©ãããå®æ¥œæ»ããããã®ççã調ã¹ããè
¹èå£ãå転ããåå®®è§ãšåŽå£ãšã®éã®ççã調ã¹ãã
çç匷床åã³ççã«ãã£ãŠèŠãããæšå®é¢ç©ã«åºã¥ããŠççãã¹ã³ã¢åããã以äžã®å°ºåºŠãçšããŠåãã©ã¡ãŒã¿ã«ã€ããŠã¹ã³ã¢åããã
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
ççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
次ãã§ãççã«ãã£ãŠèŠãããé¢ç©ã¹ã³ã¢ãççã®åŒ·åºŠã¹ã³ã¢ã«ä¹ããããšã«ãã£ãŠåã©ããã«ã€ããŠã®å
šäœçãªççã¹ã³ã¢ãåŸããååŠç矀ã«ã€ããŠïŒå¹ã®åç©ãè©äŸ¡ãã察ç
§çŸ€ã§ã¯ïŒå¹ã®ã©ããã ã£ããå矀ã«ã€ããŠã®å¹³åã®å
šäœçãªççã¹ã³ã¢ã®ã°ã©ããå³ïŒã«æäŸããããããã®ããŒã¿ã¯ã調ã¹ããã¹ãŠã®æ¿åºŠã«ãŠç¹æ»Žçšå€äžã®ãã³ã€ãã³ã®ååšã«ãã£ãŠå
šäœçãªççã¹ã³ã¢ãææã«äœäžããããšã瀺ããŠããããã³ã€ãã³ãç·ç¶æ§ççã®åœ¢æãäºé²ããã®ã«æå¹ã§ããããšãæããã«ããŠããã
ãŠãµã®ã®åå®®è§ã®æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã«å¯Ÿãããã³ã€ãã³ç¹æ»Žçšå€è£œå€ã®æå¹æ§
ãŠãµã®ã§è¡ãããæå¹æ§è©Šéšã¯ããŠãµã®ã«ãããæè¡ççç æ ã®åå®®è§ã¢ãã«ãå©çšããããã¥ãŒãžãŒã©ã³ããã¯ã€ãçš®ã®ãŠãµã®ãå ¥æããåŠçã®å°ãªããšãïŒæ¥åã«å容ããããŠãµã®ã¯ãŠãµã®çšã®é€åã³æ°Žã«èªç±ã«ã¢ã¯ã»ã¹ããããæé ã¯ä»¥äžã®ãšããã§ãã£ãã
ãŠãµã®ã§è¡ãããæå¹æ§è©Šéšã¯ããŠãµã®ã«ãããæè¡ççç æ ã®åå®®è§ã¢ãã«ãå©çšããããã¥ãŒãžãŒã©ã³ããã¯ã€ãçš®ã®ãŠãµã®ãå ¥æããåŠçã®å°ãªããšãïŒæ¥åã«å容ããããŠãµã®ã¯ãŠãµã®çšã®é€åã³æ°Žã«èªç±ã«ã¢ã¯ã»ã¹ããããæé ã¯ä»¥äžã®ãšããã§ãã£ãã
ãŠãµã®ã®äœéã枬å®ãã次ãã§ãåŸè¢ã®åŽé¢ã®çèå
ã«ïŒïŒïŒïŒïœïœïŒïœïœã®ã±ã¿ãã³åã³ïŒïŒïŒïœïœïŒïœïœã®ãã·ã©ãžã³ãæäžããããšã«ããåæè¬ã«ãã£ãŠæè¡ã®æºåããããïŒïŒ
ã€ãœãã«ã©ã³åã³é
žçŽ åžå
¥ã«ããããŒãºã³ãŒã³ã麻é
èªå°ã«çšããã次ãã§ããŠãµã®ãã€ã³ãã¥ããŒãããæ®ãã®åŠçœ®ã®ããã«åç©ãã€ã¹ãã«ã©ã³ã§ç¶æãããçŒã也ãã®ãé²ãããã«åçŒçŒã®äžã«ãã¥ã©ãã£ã¢ãå ããã
次ãã§ããŠãµã®ã®è
¹éšåã³èã®éšåãåæ¯ããåç©ãæè¡å®€ã®æè¡å°ã«ç§»ãããè
¹éšãæž
æµããæ»
èã¿ãªã«ããããæ£äžè
¹éšåéãä»ããŠå
¥ã£ããäžæ¹ã®åå®®è§ãèŠã€ããŠåæãããé»æ°çŒçŒåšãçšããŠçŽïŒïœïœã®åå®®è§ãæ¢è¡ãããè§ã®æ¢è¡ããéšåãåºãåå®®é垯ããåæããççé£å¡©æ°Žã§æ¹¿ãããæ»
èã¬ãŒãŒã®äžã«çœ®ãããè
¹å£ãçž®ããè£è¿ããŠæ®éåå®®ãçŽãŸã£ãŠããäœçœ®ã«æãè¿ãè
¹èã®äžéšããããããè
¹èåã³çèïŒè
¹éšã暪åãïŒã®è¡šå±€ãïŒïŒïŒïœïŒïœïœ2ã®é¢ç©ã«ããã£ãŠåæãããåæã¯ã第ïŒã®å±€ããèåŸã®
ç¡å·ã®äžéšåã³è£ãããç·ç¶ã®äžéšãæ®ããŠãå è ¹æçãå«ãã ã埮å°ã®å±æã®åºè¡ã«ã¯æ¢ãŸããŸã§ã¿ã³ãã³ãå ¥ããããã£ã«ã 補å€ã§åŠçãããåç©ã§ã¯ããã£ã«ã ãçŽæ¥ãããã£ãè ¹èïŒè§ãšåŽå£ãšã®éïŒã®äžã«çœ®ãããåå®®è§ã®æ¢è¡éšåãåŽå£ã®å·ã®äžã«çœ®ããããã£ãéšäœã®äžäžã®çžããå°ãªããšãïŒïœïœé¢ããå°ç¹ã§åäžã®çž«ãç®ã§çž«åãããå察åŽã®åå®®è§åã³åŽå£ã§æé ãç¹°ãè¿ããã
ç¡å·ã®äžéšåã³è£ãããç·ç¶ã®äžéšãæ®ããŠãå è ¹æçãå«ãã ã埮å°ã®å±æã®åºè¡ã«ã¯æ¢ãŸããŸã§ã¿ã³ãã³ãå ¥ããããã£ã«ã 補å€ã§åŠçãããåç©ã§ã¯ããã£ã«ã ãçŽæ¥ãããã£ãè ¹èïŒè§ãšåŽå£ãšã®éïŒã®äžã«çœ®ãããåå®®è§ã®æ¢è¡éšåãåŽå£ã®å·ã®äžã«çœ®ããããã£ãéšäœã®äžäžã®çžããå°ãªããšãïŒïœïœé¢ããå°ç¹ã§åäžã®çž«ãç®ã§çž«åãããå察åŽã®åå®®è§åã³åŽå£ã§æé ãç¹°ãè¿ããã
æè¡æé ã«ç¶ããŠãïŒâïŒã®çµ¹ã®çž«å糞ã§è
¹å£ãéããã次ãã§ïŒâïŒã®çµ¹ã®çž«å糞ã§ç®èãéãããæåŸã®çž«ãç®ãçµã¶åã«åŠçããããŠãµã®ã®è
¹éšã«ïŒïŒïœïŒ¬ã®ç¹æ»Žçšå€æº¶æ¶²ãæäžãããåç©ã®è
¹è
ããç¹æ»Žçšå€ãæŒããŠããªãããšã«æ³šæããŠã次ãã§æåŸã®çž«ãç®ãçµãã ãå ç±ã©ã³ãã®ããšã§ã®æž
æœãªå¯åºã«ãŠãµã®ã眮ããå埩ããéãã¿ãªã«ããããŠäœæž©ãç¶æããã
åŠçœ®ã®ïŒïŒæ¥åŸããŠãµã®ãå®æ¥œæ»ãããå·ã€ããåå®®è§ãšè
¹èã®éã§çç圢æã®çšåºŠãè©äŸ¡ããã圢æãããè
¹éšã®ççãèšé²ãããè©äŸ¡è
ã¯ã©ã®è£œå€ãè©äŸ¡ãããŠããã®ãã«ã€ããŠç²æ€ãããåå®®è§ã®ççã¯ã以äžã®å°ºåºŠãçšããŠççã«ããèŠãããé¢ç©ãšåœ¢æãããççã®åŒ·åºŠã®ç©ãšããŠèšç®ãããã
çç匷床ã®ã©ã³ã¯åã尺床
ïŒãïŒïŒïŒ ã»ãšãã©ççããªã
ïŒïŒïŒãïŒïŒïŒ éãå¥é¢ã§åŒãé¢ãå¯èœ
ïŒïŒïŒãïŒ åäžé åã§å®¹æã«ã¯åé¢ã§ããªã
ïŒãïŒ éãå¥é¢ãå¿ èŠãšãã
ïŒ ç©¿ååã¯åŒãè£ããåé¿ã§ããªã
ççé¢ç©ã®å°ºåºŠ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
çç匷床ã®ã©ã³ã¯åã尺床
ïŒãïŒïŒïŒ ã»ãšãã©ççããªã
ïŒïŒïŒãïŒïŒïŒ éãå¥é¢ã§åŒãé¢ãå¯èœ
ïŒïŒïŒãïŒ åäžé åã§å®¹æã«ã¯åé¢ã§ããªã
ïŒãïŒ éãå¥é¢ãå¿ èŠãšãã
ïŒ ç©¿ååã¯åŒãè£ããåé¿ã§ããªã
ççé¢ç©ã®å°ºåºŠ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
æå®ã®æ²»çã«å¯Ÿããåèšã®ççã¹ã³ã¢ã¯ã匷床ã¹ã³ã¢ãšççé¢ç©ã¹ã³ã¢ã®ç©ãšããŠå ±åãããããã®å°ºåºŠãçšããççã®æé«ã¹ã³ã¢ã¯ïŒïŒã§ããã
æå¹æ§ã®å®éš
ãã®å®éšã«ã¯åèšïŒïŒå¹ã®ãŠãµã®ã䜿çšããããŠãµã®ã¯ãã¹ãŠäžè¿°ã®åå®®è§åŠçœ®ã®å¯Ÿè±¡ãšããããŠãµã®ãïŒçŸ€ã«åããïŒå¹ã®åç©ã¯ç¡åŠçã§ãããïŒå¹ã«ã¯ïŒïŒïœïŒ¬ã®ïŒïŒïŒïŒ ïœïŒïœã®ãã³ã€ãã³ç¹æ»Žçšå€ãäžãïŒïŒïŒïœïœã®ãã³ã€ãã³çšéïŒãïŒå¹ã®åç©ã«ã¯ãïŒïŒïœïŒ¬ã®ïŒïŒ ïœïŒïœã®ãã³ã€ãã³ç¹æ»Žçšå€ãäžããïŒïŒïŒïŒïœïœã®ãã³ã€ãã³çšéïŒãè¡åŸïŒïŒæ¥ç®ã«ååç©ã®ççã¹ã³ã¢ãè©äŸ¡ããå³ïŒã«ããããããã
ãã®å®éšã«ã¯åèšïŒïŒå¹ã®ãŠãµã®ã䜿çšããããŠãµã®ã¯ãã¹ãŠäžè¿°ã®åå®®è§åŠçœ®ã®å¯Ÿè±¡ãšããããŠãµã®ãïŒçŸ€ã«åããïŒå¹ã®åç©ã¯ç¡åŠçã§ãããïŒå¹ã«ã¯ïŒïŒïœïŒ¬ã®ïŒïŒïŒïŒ ïœïŒïœã®ãã³ã€ãã³ç¹æ»Žçšå€ãäžãïŒïŒïŒïœïœã®ãã³ã€ãã³çšéïŒãïŒå¹ã®åç©ã«ã¯ãïŒïŒïœïŒ¬ã®ïŒïŒ ïœïŒïœã®ãã³ã€ãã³ç¹æ»Žçšå€ãäžããïŒïŒïŒïŒïœïœã®ãã³ã€ãã³çšéïŒãè¡åŸïŒïŒæ¥ç®ã«ååç©ã®ççã¹ã³ã¢ãè©äŸ¡ããå³ïŒã«ããããããã
ããŒã¿ã¯ããã³ã€ãã³ç¹æ»Žçšå€ã«ããæ²»çããç¡åŠçã®å¯Ÿç
§çŸ€ã«æ¯ã¹ãŠãå
šäœçãªççã¹ã³ã¢ã§åçãªäœäžãçããããšã瀺ãããããã®ããŒã¿ã¯ãæè¡ççãæå¶ããåã¯äºé²ããã®ã«ãã³ã€ãã³ãæå¹ã§ããããšã瀺ãã
ã©ããã®åå®®è§ã®æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã®ããã®ïŒŠïœïœïœïœ ïœïœ
ïœïœïœïœïœïœïœïœïœåã³ïŒ¬ïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïŒã³ã³ãïŒã«ç±æ¥ãããã³ã€ãã³ã®äœ¿çš
ã©ããã®åå®®è§ã®æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã«ãããæå¹æ§ã«ã€ããŠïŒŠïœïœïœïœ ïœïœ ïœïœïœïœïœïœïœïœïœåã³ïŒ¬ïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïŒã³ã³ãïŒã«ç±æ¥ãããã³ã€ãã³ãè©äŸ¡ãããïŒïŒïŒïŒïŒïŒ ïœïŒïœã®æ¿åºŠã§ãã³ã€ãã³ã®åèµ·æºãä¹³é žå ãªã³ã¬ãŒæ³šå°æ¶²ïŒµïŒ³ïŒ°ã«æº¶è§£ãããåå®®è§ã®æè¡ççã¢ãã«ãçšããæè¡ã«ç¶ããŠããããïŒïœïŒ¬ã®çšéã§è ¹è å ã§ã©ããã«æäžãããããã補å€ã®æå¹æ§ãä¹³é žå ãªã³ã¬ãŒæ³šå°æ¶²ïŒµïŒ³ïŒ°ã®å¯Ÿç §ïŒã©ããåœããïŒïœïŒ¬ïŒãšæ¯èŒããã
ã©ããã®åå®®è§ã®æè¡ççã¢ãã«ãçšããæè¡ççã®äºé²ã«ãããæå¹æ§ã«ã€ããŠïŒŠïœïœïœïœ ïœïœ ïœïœïœïœïœïœïœïœïœåã³ïŒ¬ïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïŒã³ã³ãïŒã«ç±æ¥ãããã³ã€ãã³ãè©äŸ¡ãããïŒïŒïŒïŒïŒïŒ ïœïŒïœã®æ¿åºŠã§ãã³ã€ãã³ã®åèµ·æºãä¹³é žå ãªã³ã¬ãŒæ³šå°æ¶²ïŒµïŒ³ïŒ°ã«æº¶è§£ãããåå®®è§ã®æè¡ççã¢ãã«ãçšããæè¡ã«ç¶ããŠããããïŒïœïŒ¬ã®çšéã§è ¹è å ã§ã©ããã«æäžãããããã補å€ã®æå¹æ§ãä¹³é žå ãªã³ã¬ãŒæ³šå°æ¶²ïŒµïŒ³ïŒ°ã®å¯Ÿç §ïŒã©ããåœããïŒïœïŒ¬ïŒãšæ¯èŒããã
å
ããã©ããã麻é
ããæçç©è³ªãäžããã次ãã§ãè
¹éšã®æ£äžåã³è
¹èå£ã®çœç·ã«æ²¿ã£ãŠïŒãïŒïœïœã®åéãäœã£ããåå®®è§ã®äžæ¹ãèŠã€ããè§ãæ¢è¡ããè
žéèããåãåã£ããå€ç§çšã¡ã¹ã§ãããäžã«ïŒïŒåãäžã«ïŒïŒåã次ãã§äžã«ïŒïŒåããã£ããããã¯ç¹ç¶åºè¡ãçããåãåŠçãå察åŽã®è§ã§ç¹°ãè¿ãããè
¹èå£ãç®èããåé¢ããå転ãããŠå£ã®å
åŽãããããè
¹å£ã®å°ããªé åïŒïŒïŒïŒïœïŒïŒïŒïœïœïŒãåãåã£ãã次ãã§åå®®è§ãåŽå£ã®å·ã®äžã«çœ®ããå·ãè² ã£ãè
¹èåŽå£ã®å·ã®äžåŽã®çž«ãç®ïŒã€ãšå°ŸåŽã®çž«ãç®ïŒã€ã§ãããçž«åãããåãåŠçœ®ãå察åŽã®åŽå£ã§è¡ã£ãã
è
¹èåŽå£ã«ã€ããŠïŒâïŒã®çž«å糞ã§å€ç§åéãéãããæåŸã®çž«ãåãããçµã¶çŽåã«ã調ã¹ãã¹ãç¹æ»Žçšå€ãè
¹è
ã«å
¥ããã次ãã§æåŸã®çž«ãç®ãçµãã ãç®èåéã®ééã¯ãïŒâïŒã®çž«å糞ãçšããŠè¡ã£ãã
ïŒæ¥åŸãã©ãããå®æ¥œæ»ããããã®ççã調ã¹ããè
¹å£ãå転ããåå®®è§ãšåŽå£ãšã®éã®ççã調ã¹ãã
çç匷床åã³ççãååšããççããåŽå£ã®é¢ç©ã«åºã¥ããŠççãã¹ã³ã¢åããã以äžã®å°ºåºŠãçšããŠãççããé åå
ã®ççã®åŒ·åºŠåã³ççã§èŠãããé¢ç©ãã¹ã³ã¢åãããççã®åŒ·åºŠã®å°ºåºŠ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
ïŒ ççããªã
ïŒ éãå¥é¢ã§åŒãé¢ãå¯èœãªçç
ïŒ å®¹æã«ã¯åé¢ã§ããªãçç
ïŒ ççã®éãå¥é¢ãå¿ èŠãšããïŒå£åã¯è§ãåŒãè£ãïŒ
ççã«ãã£ãŠèŠãããé¢ç©ã®å°ºåºŠïŒ
ïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒ ïŒ
ïŒïŒãïŒïŒïŒïŒ ïŒ
次ãã§ãççã®åŒ·åºŠã«é¢ããã¹ã³ã¢ãççã«ãã£ãŠèŠãããé¢ç©ã«é¢ããã¹ã³ã¢ã«ä¹ããããšã«ãã£ãŠåã©ããã«ã€ããŠã®ççã¹ã³ã¢ãåŸãããã®åŠçœ®ãåããã©ãããïŒã€ã®åŠç矀ïŒçŸ€åœããïœïŒïŒïŒã«åããïœïœïœïœ ïœïœ
ïœïœïœïœïœïœïœïœïœã«ç±æ¥ããïŒïŒïŒïŒïŒïŒ
ïœïŒïœã®ç¹æ»Žçšå€ãã³ã€ãã³ïŒïœïŒ¬ãïœïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïŒã³ã³ãïŒã«ç±æ¥ããïŒïŒïŒïŒïŒïŒ
ïœïŒïœã®ç¹æ»Žçšå€ãã³ã€ãã³ïŒïœïŒ¬ãåã¯ä¹³é
žå ãªã³ã¬ãŒæ³šå°æ¶²ïŒµïŒ³ïŒ°ïŒå¯Ÿç
§ïŒãäžããããããïŒçŸ€ã®å¹³åããççã¹ã³ã¢ã«å¯Ÿããå¹æãå³ïŒïŒã«æäŸããããããã®ããŒã¿ã¯ã察ç
§ã«æ¯ã¹ãŠè©ŠéšçŸ€ã§ã®ææã«äœãççã¹ã³ã¢ã«ãã£ãŠããããã®èµ·æºããã®ãã³ã€ãã³ãæè¡ççã®äºé²ã«æå¹ã§ããããšãæããã«ããŠããã
Claims (27)
- ç·ç¶æ§ççãæå¶ããäœçšå€ãéžæããããšåã³ç·ç¶æ§ççãæããããšãçãããéšäœã«æ²»çäžæå¹éã®è©²äœçšå€ãæäžããããšãå«ã¿ã該äœçšå€ãâïŒé»å®³å€ãå«ããåç©ã«ãããŠç¹ç¶æ§ççãæå¶ããæ¹æ³ã
- 該âïŒé»å®³å€ããæâïŒã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããïŒïŒ¡ïŒ³ïŒ¯ïŒã§ããè«æ±é ïŒã®æ¹æ³ã
- 該âïŒé»å®³å€ããæâïŒå°ååã§ããè«æ±é ïŒã®æ¹æ³ã
- 該âïŒé»å®³å€ããæâïŒïœïœïŒ²ïŒ®ïŒ¡ã§ããè«æ±é ïŒã®æ¹æ³ã
- 該âïŒé»å®³å€ããæâïŒãªãã¶ã€ã ã§ããè«æ±é ïŒã®æ¹æ³ã
- 該âïŒé»å®³å€ããâïŒã®å°ååé»å®³å€ã§ããè«æ±é ïŒã®æ¹æ³ã
- 該âïŒé»å®³å€ããæâïŒæäœåã¯æâïŒã¢ãã¿ããŒã§ããè«æ±é ïŒã®æ¹æ³ã
- 該âïŒé»å®³å€ããæïœïŒ³ïŒ€ïŒŠâïŒïŒïŒ°ïŒ¢ïŒ³ïŒŠã§ããè«æ±é ïŒã®æ¹æ³ã
- éšäœãå€ç§çéšäœã§ããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- éšäœã骚ç€å ççæ§çŸæ£éšäœãç©ççå€å·éšäœãæŸå°ç·è¢«æéšäœããŸãã¯ç°ç©æ§çŸæ£éšäœã§ããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- éšäœãåç©ã®è ¹éšãåè¢ãèæ€ãèžè ãããã¯é éšã®å éšã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- éšäœãåç©ã®çæ®åšå®ãèè žãèºåšå®ç³»ãå¿èãŸãã¯è¡ç®¡ç³»ãããã¯æ³å°¿åšç³»ã®å éšã§ããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- è¬å€ããããªããŒã®æäžåœ¢æ ããã®å¶åŸ¡æŸåºãä»ããŠå®è³ªçã«é£ç¶ããŠç å€éšäœã«æäžãããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- è¬å€ãã溶液åã¯æžæ¿æ¶²ãšããŠç å€éšäœã«å®è³ªçã«ééãããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- äœçšå€ããã«ã³ãšã®äœµçšã§æäžãããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- ãã«ã³ããã³ã€ãã³ã§ããè«æ±é ïŒïŒã®æ¹æ³ã
- ãã«ã³ãç¹æ»Žçšå€ã®åœ¢æ ã§ããè«æ±é ïŒïŒåã¯ïŒïŒã®æ¹æ³ã
- äœçšå€ããåèšè«æ±é ã®ããããïŒé ã®ç¬¬ïŒã®äœçšå€ãšã®äœµçšã§æäžãããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- äœçšå€ããæ²»çäžèš±å®¹å¯èœãªéã®ãã®ã»ãã®æ²»çå€ãšã®äœµçšã§æäžãããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- åç©ã人éã§ããããšãç¹åŸŽãšããè«æ±é ïŒèšèŒã®æ¹æ³ã
- ç·ç¶æ§ççãæå¶ããããšã決å®ããããšãåã³ç·ç¶æ§ççãæããããšãçãããéšäœã«ãæ²»çäžæå¹éã®ãã«ã³åã³ãã€ãªã³ãã¬ãŒãå€ãããªãšã³ãã¯ãã©ã€ãæçç©è³ªãïŒâããããã·âïŒâã¡ãã«ã°ã«ããªã«âïœïŒ¡ãéå é µçŽ é»å®³å€ãã¬ããã€ããæè¡æ å€ãæååºå€ããã©ã¹ãããŒã²ã³æŽ»æ§åå€ããµã€ãã«ã€ã³ããããªã¯ã¹ã¡ã¿ããããã€ããŒãŒé»å®³å€ãããã©ãµã€ã¯ãªã³ãé»å®³å€ãããã¹ãã©ã³ç³ãåã¯ã«ã©ã®ãŒãã³ã®å°ãªããšãïŒçš®ãæäžããããšãå«ãåç©ã§ç·ç¶æ§ççãæå¶ããæ¹æ³ã
- ç·ç¶æ§ççãæå¶ããããšã決å®ããããšãåã³ç·ç¶æ§ççãæããããšãçãããéšäœã«ãæ²»çäžæå¹éã®ãã«ã³åã³ãããã§ãããµãã³ã¡ã·ã¬ãŒããã·ã ãã¹ã¿ãã³ãã¬ããã€ã³é žããããªã³ããã³ããã·ãã£ãªã³ãã¹ãã¬ãããããŒãŒãâβãïŒïŒ°âïŒãã©ããã€ã·ã³ãããã©ãµã€ã¯ãªã³ããããµã€ã¯ãªã³ãã«ããããªã«ãããã·ãµã€ã¯ãªã³ããšãã©ããªã«ãããã¹ãã©ã³ç¡«é žãããã¹ãããŒã¹ãããã¹ãã©ã³ïŒŽïŒïŒãã³ãã¯é žãã³ã©ãŒã²ã³ããã³ãã³ãã±ã«ã»ãã³äºæ°Žåç©ãã«ãã§ã€ã³ãã©ã ãâã«ã©ã®ãŒãã³ãã€ãªã¿âã«ã©ã®ãŒãã³ãããããã·ãããã«ã»ã«ããŒã¹ãã¹ã¿ããªãŒã¹ãã³ã³ããã€ãã³ç¡«é žïŒ¡åã¯ã¬ãã«ãããã®å°ãªããšãïŒçš®ãæäžããããšãå«ãåç©ã§ç·ç¶æ§ççãæå¶ããæ¹æ³ã
- ç·ç¶æ§ççãæå¶ããããšã決å®ããããšãåã³ç·ç¶æ§ççãæããããšãçãããéšäœã«ãæ²»çäžæå¹éã®ãã«ã³åã³å°ãªããšãïŒçš®ã®æè «çå€ãæäžããããšãå«ãåç©ã§ç·ç¶æ§ççãæå¶ããæ¹æ³ã
- æè «çå€ããã¢ã«ãã«åå€ã代è¬æå¶å€ããªããã¯ã¬ãªããéå é µçŽ é»å®³å€ã现èå·å®³æ§æçç©è³ªãã¿ããµã³ããã³ã«ã¢ã«ã«ãã€ãåã¯ãããã¢ãŒãŒé»å®³å€ã®å°ãªããšãïŒçš®ãå«ãè«æ±é ïŒïŒã®æ¹æ³ã
- ç·ç¶æ§ççãæå¶ããããšã決å®ããããšãåã³ç·ç¶æ§ççãæããããšãçãããéšäœã«ãæ²»çäžæå¹éã®ãã«ã³åã³ããã¹ã«ãã¡ã³ãã·ã¯ããã¹ãã¡ããããšã¹ãã©ã ã¹ãã³ãã·ã¹ãã©ãã³ããã«ã«ããžã³ãããããã·ãŠã¬ã¢ãããã¿ã³ããã»ã¿ãã»ã«ãç¡«é žãã³ãã©ã¹ãã³åã¯ïŒïŒ§ïŒïŒïŒã®å°ãªããšãïŒçš®ãæäžããããšãå«ãåç©ã§ç·ç¶æ§ççãæå¶ããæ¹æ³ã
- ç·ç¶æ§ççãæå¶ããããšã決å®ããããšãåã³ç·ç¶æ§ççãæããããšãçãããéšäœã«ãæ²»çäžæå¹éã®ãã«ã³åã³å°ãªããšãïŒçš®ã®æççå€ãæäžããããšãå«ãåç©ã§ç·ç¶æ§ççãæå¶ããæ¹æ³ã
- æççå€ããâïŒé»å®³å€ããã§ãã¡ãŒãããªãã·ã«ã ãã¢ã»ãã«é žèªå°äœããµãªãã«é žèªå°äœåã¯ã³ã«ãã³ã¹ããã€ãã®å°ãªããšãïŒçš®ãå«ãè«æ±é ïŒïŒã®æ¹æ³ã
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47490703P | 2003-05-30 | 2003-05-30 | |
US47765403P | 2003-06-10 | 2003-06-10 | |
US50525803P | 2003-09-22 | 2003-09-22 | |
US50525703P | 2003-09-22 | 2003-09-22 | |
US52080803P | 2003-11-17 | 2003-11-17 | |
US52057403P | 2003-11-17 | 2003-11-17 | |
US52080403P | 2003-11-17 | 2003-11-17 | |
US52913603P | 2003-12-11 | 2003-12-11 | |
US53366903P | 2003-12-31 | 2003-12-31 | |
PCT/CA2004/000800 WO2004105737A2 (en) | 2003-05-30 | 2004-05-28 | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007504273A JP2007504273A (ja) | 2007-03-01 |
JP2007504273A5 true JP2007504273A5 (ja) | 2007-07-19 |
Family
ID=33494425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006529506A Withdrawn JP2007504273A (ja) | 2003-05-30 | 2004-05-28 | çš®ã ã®äœçšå€ãçšãããç·ç¶æ§ççã®æå¶ã«é¢ããå»è¬çµæç©åã³æ¹æ³ |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1631265A2 (ja) |
JP (1) | JP2007504273A (ja) |
KR (1) | KR20060034227A (ja) |
AU (1) | AU2004243513A1 (ja) |
BR (1) | BRPI0418384A (ja) |
CA (1) | CA2527429A1 (ja) |
TW (1) | TW200509949A (ja) |
WO (1) | WO2004105737A2 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1809303B1 (en) * | 2004-09-23 | 2019-03-06 | ARC Medical Devices, Inc. | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
CA2606081C (en) * | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
WO2006121887A2 (en) * | 2005-05-05 | 2006-11-16 | Cook Biotech Incorporated | Implantable materials and methods for inhibiting tissue adhesion formation |
DE102005023170A1 (de) * | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung fÃŒr mRNA |
US8426381B2 (en) | 2005-09-09 | 2013-04-23 | Lucas Meyer Cosmetics Canada Inc. | Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation |
DE102008005172A1 (de) * | 2008-01-19 | 2009-07-23 | Mike Ehrlich | Pharmazeutische Zusammensetzung zur Verhinderung von post-operativen AdhÀsionen |
US8865668B2 (en) | 2008-02-20 | 2014-10-21 | Devgen N.V. | Methods and compositions for increasing RNA interference |
CN105816498A (zh) | 2009-04-27 | 2016-08-03 | ç«ç³å¯æéå ¬åž | æ€ç©æ§æç€ç®å¶å |
JO3676B1 (ar) * | 2009-07-27 | 2020-08-27 | Arc Medical Devices Inc | ٠رÙؚات صÙدÙاÙÙØ© تض٠ÙÙÙاÙات ٠عدÙØ© Ùطر٠تتعÙÙ ØšÙا |
MY167224A (en) | 2010-05-03 | 2018-08-14 | Teikoku Pharma Usa Inc | Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same |
TWI382841B (zh) | 2010-10-29 | 2013-01-21 | Univ China Medical | çšæŒæå¶çŒçä¹é«è¥çµåç© |
US8936635B2 (en) | 2011-03-23 | 2015-01-20 | Palmetto Pharmaceuticals Llc | Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents |
US20130095160A1 (en) * | 2011-09-12 | 2013-04-18 | Gautam S. GHATNEKAR | Resorbable polystatin biomaterials |
DE202012013018U1 (de) | 2011-12-19 | 2014-08-20 | Mary Kay Inc. | Kombination von Pflanzenextrakten zur Verbesserung des Hauttons |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صÙغ اÙت؎تÙت اÙجسÙÙ Ù ÙÙتاÙسÙ٠غÙر اÙ٠ا؊٠Ùطر٠استخدا٠Ùا |
US9707323B2 (en) | 2012-11-12 | 2017-07-18 | Warsaw Orthopedic, Inc. | Devices and methods for inhibiting adhesion formation |
US9421221B2 (en) | 2012-11-12 | 2016-08-23 | Warsaw Orthopedic, Inc. | Compositions and methods for inhibiting adhesion formation |
US9474767B2 (en) | 2012-11-12 | 2016-10-25 | Warsaw Orthopedic, Inc. | Compositions and methods for inhibiting bone growth |
ITTO20130317A1 (it) * | 2013-04-19 | 2014-10-20 | Idea Medical Devices S R L | Dispositivo medico comprendente una struttura di supporto a base di chitosano |
CN103267842B (zh) * | 2013-05-15 | 2016-03-02 | éæ°æ | æ£æµäžæè¯è¿æ³æ·»å åæ°¯è¬é žçå ç«è¶äœéæ¹æ³ |
US9901662B2 (en) | 2013-05-29 | 2018-02-27 | Otsuka Pharmaceutical Factory, Inc. | Adhesion preventing material |
US9566296B2 (en) | 2013-11-08 | 2017-02-14 | Warsaw Orthopedic, Inc. | Multi-layered anti-adhesion device |
KR102323049B1 (ko) | 2014-03-10 | 2021-11-05 | ë§ëŠ¬ ìŒìŽ ìžìœí¬ë ìŽí°ë | íŒë¶ ëŒìŽížë ì¡°ì±ë¬Œ |
US11642368B2 (en) | 2018-07-27 | 2023-05-09 | ARC Medical Inc. | Highly purified and/or modified fucan compositions for the treatment of fibrous adhesions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57167919A (en) * | 1981-04-07 | 1982-10-16 | Hirozo Ohira | Preventing agent for intraperitoneal adhesion |
US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
US5266326A (en) * | 1992-06-30 | 1993-11-30 | Pfizer Hospital Products Group, Inc. | In situ modification of alginate |
US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
KR20010010151A (ko) * | 1999-07-16 | 2001-02-05 | ê¹ì€ | ìì©ì± ìꞎì°ìŒê³Œ 칎륎복ìë©íž ì 룰ë¡ì€ì€ë¥Œ 죌ì±ë¶ìŒë¡ íë ì ì°©ë°©ì§ì ë° ê·žì ì ì¡°ë°©ë² |
KR20010107067A (ko) * | 2000-05-25 | 2001-12-07 | ê¹ì ì | ì ì°©ë°©ì§ì |
US6812220B2 (en) * | 2001-08-29 | 2004-11-02 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
KR100523953B1 (ko) * | 2002-08-27 | 2005-10-25 | 죌ìíì¬ ìì§ìëª ê³Œí | ì²ì°ë€ë¹ë¥ì íìë£šë¡ ì°ì ë§ìŽí¬ë¡ë¹ë ë° ìŽì ì ì¡° ë°©ë² |
-
2004
- 2004-05-28 AU AU2004243513A patent/AU2004243513A1/en not_active Abandoned
- 2004-05-28 KR KR1020057022983A patent/KR20060034227A/ko not_active Application Discontinuation
- 2004-05-28 CA CA002527429A patent/CA2527429A1/en not_active Abandoned
- 2004-05-28 EP EP04735180A patent/EP1631265A2/en not_active Withdrawn
- 2004-05-28 WO PCT/CA2004/000800 patent/WO2004105737A2/en active Application Filing
- 2004-05-28 JP JP2006529506A patent/JP2007504273A/ja not_active Withdrawn
- 2004-05-28 BR BRPI0418384-3A patent/BRPI0418384A/pt not_active IP Right Cessation
- 2004-05-31 TW TW093115497A patent/TW200509949A/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200338114A1 (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans | |
JP2007504273A5 (ja) | ||
JP2007504273A (ja) | çš®ã ã®äœçšå€ãçšãããç·ç¶æ§ççã®æå¶ã«é¢ããå»è¬çµæç©åã³æ¹æ³ | |
AU2002325113B2 (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis | |
AU2002325113A1 (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis | |
US20070238697A1 (en) | Pharmaceutical compositions and methods relating to fucans | |
JP2019142896A (ja) | ç·ç¶æ§ççåã³ä»ã®çŸæ£ã®æ²»çã«çšããå€æ§ãã«ã³ãå«ãå»è¬çµæç© | |
JP2003525243A (ja) | ççæ§çŸæ£ã®æ²»çã®ããã®çµæç©åã³æ¹æ³ | |
US20170252367A1 (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans | |
EP1870105A1 (en) | Use of fucans in the treatment of psoriasis |